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3Abstract
Disorders of Coenzyme Q10 (CoQ10) biosynthesis represent the most treatable
subgroup of mitochondrial diseases. Neurological involvement is frequently
observed in CoQ10 deficiency, typically presenting as cerebellar ataxia and/or
seizures. The aetiology of the neurological presentation of CoQ10 deficiency has
yet to be fully elucidated and therefore in order to investigate these phenomena
we have established a neuronal cell model of CoQ10 deficiency by treatment of
the neuronal SH-SY5Y cell line with Para-AminoBenzoic Acid (PABA). This
neuronal cell model provides insights into the effects of CoQ10 deficiency on
neuronal mitochondrial function and oxidative stress. A marginal decrease in
CoQ10 status (76% residual CoQ10) appears to be sufficient to impair Electron
Transport Chain (ETC) function and increase mitochondrial oxidative stress,
highlighting the vulnerability of neurons to a small deficit in CoQ10 status. In
contrast to CoQ10 deficient fibroblasts, a CoQ10 deficiency (46% residual CoQ10)
in neuronal cells appears to result in reversal of Complex V activity. This
phenomenon has not been reported in previous studies of CoQ10 deficiency and
may be a unique characteristic of neuronal cells.
This neuronal cell model was subsequently utilised in the evaluation of
candidate therapies for neurological conditions associated with CoQ10
deficiency. The efficacy of CoQ10 supplementation and methylene blue (MB)
treatment were evaluated. CoQ10 supplementation proved effective at
preventing mitochondrial oxidative stress and partially restoring neuronal
mitochondrial function. However ETC complex activities were still compromised,
suggesting an explanation for the refractory nature of neurological CoQ10
deficiency to treatment.
Muscle is considered the “gold standard” for CoQ10 quantification; however
neurological CoQ10 deficiency does not always present with a significant
decrease in muscle CoQ10 status, despite a genetic diagnosis of CoQ10
deficiency. Cerebrospinal Fluid (CSF) CoQ10 quantification offers a more direct
measurement of cerebellar CoQ10 levels. A tandem mass spectrometry
(MS/MS) method capable of quantifying nanomolar (nM) levels of CoQ10 was
therefore developed.
4In conclusion this PhD thesis has been successful in expanding our
understanding of the pathophysiology of neuronal CoQ10 deficiency and
subsequently suggesting why neurological CoQ10 deficiency might be refractory
to CoQ10 treatment. This thesis has also led to the development of a new
technique for quantification of CSF CoQ10 concentration, opening up many
possibilities for future studies and applications. This project is funded by Ataxia
UK (www.ataxiauk.org.uk).
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Chapter 1
Introduction
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1.1. Coenzyme Q10 Structure
Coenzyme Qs (CoQs), also known as ubiquinones are a group of homologous
quinones that are widely distributed in animals, plants and microorganisms.
CoQ was first characterised by Morton and associates in Liverpool in 1955
(Festenstein et al. 1955). It was initially described as the “275 mµ substance”,
due to the sizable absorbance at 275 nm. Wolf et al then determined the
complex structure of CoQ via NMR in 1958 (Wolf et al. 1958; Figure 1.1). As the
new compound was a quinone and due to its ubiquitous nature the official name
was established as ubiquinone (Braunstein et al. 1975). CoQ is known
chemically as 2,3-dimethoxy, 5-methyl, 6-polyisoprene parabenzoquinone. The
polyisoprenoid chain can vary in length between 6 and 10 isoprene units
between different species. In humans the main species of ubiquinone is CoQ10,
with small amounts of CoQ9 (2-7%; Turunen et al. 2004). The distribution of
CoQ10 is variable between tissue types, ranging from 8µg/g in lung to 114µg/g in
heart (Turunen et al. 2004; Table 1.1). Such extensive variation is likely to
reflect differences in tissue energy requirements. Variation in CoQ10 content is
also observed in the brain (Table 1.2). Forebrain regions, particularly the
striatum have high CoQ10 content. The cerebellum also has a relatively high
level of CoQ10. The white matter has the lowest CoQ10 content. It is
hypothesised that the distribution of CoQ10 in the brain may reflect the variation
in energy requirements.
Figure 1.1 The Chemical Structure of Coenzyme Q10 (CoQ10)
The oxidised structure of CoQ10; consisting of an isopreniod tail attached to a benzene ring. The
isopreniod tail is species specific and can vary from 6-10 isopreniod units. The most common
form in humans is the 10 isoprenoid form CoQ10.
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Tissue
Human CoQ10 content (µg/g
tissue)
Heart 114
Kidney 67
Liver 55
Muscle 40
Brain 13
Pancreas 33
Spleen 25
Lung 8
Thyroid 25
Testis 11
Intestine 12
Colon 11
Ventricle 12
Table 1.1 CoQ10 Content in Human Tissues
Brain Region
Human CoQ10 content
(µg/g tissue)
Striatum 25
Cerebellum 16
Parietal cortex 15
Temporal cortex 10
Hippocampus 6
Medulla oblongata 5
White matter 3
Table 1.2 CoQ10 Content in Brain Regions of Humans
Data for both tables taken from Turunen et al. 2004. CoQ10 was quantified in tissue using a
HPLC method with UV detection. The data in this paper was taken from Aberg et al. 1992 and
Runquist et al. 1995.
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1.2. Coenzyme Q10 Function
1.2.1. The Mitochondrial Electron Transport Chain (ETC)
The main function of CoQ10 is in the mitochondrial electron transport chain
(ETC). First proposed by Crane and colleagues in 1957, interest grew
throughout the 1960’s where this proposed role of CoQ10 was further elucidated
(Ernster et al. 1969). Dr Peter Mitchell revolutionised the field by introducing the
concept of oxidative phosphorylation, where the presence of a proton gradient
across the mitochondrial inner membrane leads to the production of ATP
(Mitchell 1961; Mitchell 1966). Mitchell later described this phenomenon as the
protonmotive Q cycle (Mitchell 1975). In humans CoQ10 is well recognised as a
fundamental component of the mitochondrial ETC where it acts as an electron
carrier. CoQ10 accepts electrons derived from Complex I (NADH ubiquinone
oxidoreductase; EC 1.6.5.3) and Complex II (succinate ubiquinone reductase;
EC 1.3.5.1) and transporting them to Complex III (ubiquinol cytochrome c
reductase; EC 1.10.2.2) (Ernster & Dallner 1995). The electrons are then
transported via cytochrome c to their terminal electron acceptor Complex IV
(cytochrome c oxidase; EC 1.9.3.1). The energy from the proton gradient
produced by the ETC is then utilised in the production of ATP by Complex V
(ATP synthase; EC 3.6.3.14).
An often forgotten esoteric component of the ETC is Electron Transfer
Flavoprotein Quinone Oxidoreductase (ETF-QO; also called Electron Transfer
Flavoprotein Dehydrogenase; EC 1.5.5.1). The ETF/ ETF-QO system serves as
a short electron transfer pathway forming part of the mitochondrial ETC;
catalysing the reduction of CoQ by ETF, linking fatty acid (and amino acid)
metabolism to the ETC (Figure 1.2).
Historically, the ETC and ATP synthase were thought to be arranged in a fluid
mosaic composition, whereby integral protein complexes of the mitochondrial
inner membrane are randomly dispersed in the phospholipid bilayers (Green &
Tzagoloff 1966). In this model electron transfer would occur via random collision
(Hackenbrock et al. 1986). In 1973, the two-enzyme oxidation and reduction of
CoQ was quantified in beef heart submitochondrial particles suggesting CoQ
pool behaviour (Kröger & Klingenberg 1973). Thus CoQ would behave
kinetically as a freely diffusing pool; shuttling electrons between Complexes I/II
and Complex III.
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The use of mild detergents in Blue Native Poly-Acrylamide Gel Electrophoresis
(BN-PAGE) experiments allow the structural and functional integrity of the multi-
complex units to be preserved (Schägger & Pfeiffer 2000). Thus numerous
super-complexes or respirasomes have been described in yeast and
mammalian mitochondria. Complexes I, III and IV all appear to form super-
complexes with each other in varying stoichiometric ratios. 70% of Complex I is
associated with super-complexes (7%: I1III2, 54%: I1III2IV1, 9%: I1III2IV2). The
super-complex would allow direct transfer of electrons via the electron carriers
(CoQ and cytochrome c) i.e. channelling (Schägger & Pfeiffer 2000).
Consequently the ETC would behave a single enzyme unit, and inhibition of any
of the enzymes components would result in a global influence (flux control;
Kholodenko et al. 1994).
Although there is evidence of association between Complexes II and III (Tisdale
1961) this study used bile acids in enzyme preparation which may have led to
protein aggregation (Schägger & Pfeiffer 2000). There is extensive evidence
that Complex II exhibits pool behaviour (Kröger & Klingenberg 1973) and thus
does not form part of a super-complex (Schägger & Pfeiffer 2000).
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Figure 1.2 The Mitochondrial Electron Transport Chain (ETC) + Complex V (ATP Synthase)
Coenzyme Q10 (denoted as Q) transports electrons from Complex I and Complex II to Complex III. Cytochrome c (denoted as
Cyt c) then transports electrons from Complex III to Complex IV. The proton gradient created in this process facilitates the
phosphorylation of ADP to ATP by Complex V (ATP synthase)
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Acylcarnitine
Carnitine palmitoyltransferase CoASH
Acyl-CoA
Acyl-CoA dehydrogenase
2-Enoyl-CoA
Trifunctional protein
Acyl-CoA
Acyl-CoA dehydrogenase (MCAD) FAD FADH
2-Enoyl-CoA
2-Enoyl hydratase
3-Hyoxyacyl-CoA
3-Hyoxyacyl-CoA dehydrogenases NAD NADH
3-Ketoacyl-CoA
3-Ketoacyl-CoA thiolases CoASH Acyl-CoA
Acetyl-CoA
Figure 1.3 Fatty acid oxidation pathway and the ETF/ETF-QO System
Ocyl-CoA is oxidised to enoyl-CoA by medium-chain acyl-CoA dehydrogenase (MCAD). This is a step in the fatty acid
oxidation pathway. MCAD (specifically the FADH2) is re-oxidised by two electron-transfer flavoproteins (ETF). The
semiquinone is then re-oxidised by ETF-quinone oxidase (QO) which in turn transfers electrons to ubiquinone.
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1.2.1.1. Complex I
Complex I is the largest enzyme in the ETC; containing 45 subunits with a
molecular mass of 980kDa. The L-shaped structure of Complex I was initially
revealed by electron microscopy; further detail was subsequently provided by x-
ray crystallography studies of the enzyme in the bacterium Thermus
thermophilus and the fungus Yarrowia lipolytica (Fassone & Rahman 2012).
Complex I catalyses the two-electron oxidation of NADH, and the consequent
reduction of CoQ, facilitating proton pumping across the inner mitochondrial
membrane (reviewed in Hirst 2010). The potential energy from three sequential
steps of rapid electron transfer, from a flavin mononucleotide along a series of
iron-sulphur clusters, is utilised to produce a protonmotive force (Δp) enabling
ATP synthesis via Complex V (Dutton et al. 1998). NADH is produced
predominantly by the Krebs cycle and by the β-oxidation of fatty acids. Complex
I oxidises NADH, thus replenishing the NAD+ pool in the mitochondrial matrix.
The 2 electrons produced by this process are then utilised to reduce CoQ to
CoQH2 in the inner mitochondrial membrane. CoQH2 is then re-oxidised by
Complex III further adding to the Δp (Hirst 2010).
Complex I is well recognised as a major contributor to Reactive Oxygen
Species (ROS) generation within the cell (Murphy 2009). Complex I ROS
production was first demonstrated through the uncoupler sensitive H2O2
production by submitochondrial particles following CoQ reduction (Hinkle et al.
1967) and subsequently through the production of O2●- by isolated Complex I in
the presence of NADH. O2●- production is increased after addition of rotenone, a
Complex I non-competitive inhibitor (Cadenas et al. 1977). ROS production in
this instance occurs when the NADH/NAD+ ratio is high and ATP production is
low. ROS is also produced by Complex I in reverse electron transfer. This
occurs when the Δp and the CoQH2/CoQ ratio are high and ATP production is
low (Chance & Hollunger 1961).
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Figure 1.4 The Krebs cycle
The Krebs cycle begins with the transfer of a two-carbon acetyl group from acetyl-CoA to the
oxaloacetate (OAA) to form citrate; a six-carbon compound. The citrate then goes through a
series of chemical transformations, losing two carboxyl groups as CO2. Most of the energy
made available by the oxidative steps of the cycle is transferred as energy-rich electrons to
NAD+, forming NADH. For each acetyl group that enters the citric acid cycle, three molecules of
NADH are produced. The conversion of succinate to fumarate is catalysed by succinate
dehydrogenase/ubiquinone reductase (Complex II) consequently reducing FAD to FADH2. At
the end of each cycle OAA has been regenerated and the cycle continues.
Taken from: http://themedicalbiochemistrypage.org/tca-cycle.php
30
1.2.1.2. Complex II
Complex II is the only enzyme that participates in both the Krebs cycle (Figure
1.4) and the ETC. The oxidation of succinate to fumarate in the Krebs cycle is
catalysed by Complex II. CoQ is subsequently reduced to CoQH2 replenishing
the CoQH2 pool.
A flavoprotein (SDHA) and an iron-sulfur protein (SDHB) form a hydrophilic
domain that projects out into the matrix and two hydrophobic transmembrane
subunits (SDHC and SDHD) anchor the complex to the membrane (Ackrell
2000). The transmembrane subunits are composed of a cytochrome b, haem b
group and a CoQ binding site. These subunits also contain two phospholipid
molecules; cardiolipin and phosphatidylethanolamine (Ackrell 2000). The
flavoprotein domain contains a FAD cofactor and a succinate binding site.
Interestingly, in humans and in the majority of eukaryotes Complex II is the only
complex that is completely nuclear encoded (Hirawake et al. 1999; Bourgeron
et al. 1995).
During succinate oxidation the covalently bonded FAD cofactor accepts a
hydride group forming FADH2. Electrons from the FADH2 are then transferred
along the iron-sulphur clusters [2Fe-2S],[4Fe-4S] to the terminal [3Fe-4S]. An
awaiting CoQ molecule is then reduced within the active site. This two electron
reduction involves the intermediate production of semi-ubiquinone (Cecchini
2003). It has been suggested that the haem acts as an electron buffer to
prevent ROS production (Yankovskaya et al. 2003), however further
investigation is needed.
1.2.1.3. Complex III
Complex III, sometimes called the cytochrome bc1 complex is the third complex
in the ETC. Complex III is synthesised by both the mitochondria (cytochrome b)
and the nucleus (all other subunits). It contains 11 subunits, 3 respiratory
subunits (cytochrome b, cytochrome c1, Rieske protein), 2 core proteins and 6
low-molecular weight proteins (Crofts 2004). Ubiquinol cytochrome-c reductase
catalyses the chemical reaction:
QH2 + 2 Fe3+-cytochrome c +2H+in↔Q + 2 Fe2+-cytochrome c + 4H+out
The above reaction is a modified version of the Q cycle, first proposed by
Mitchell (1975). The Q cycle involves the release of four protons into the inter
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membrane space, whilst only two protons are utilised from the matrix; resulting
in a proton gradient across the membrane. The overall reaction facilitates the
oxidation of two ubiquinols to ubiquinones, the reduction of a ubiquinone to a
ubiquinol. Subsequently two electrons are transferred from ubiquinol to
ubiquinone, via two cytochrome c intermediates (Figure 1.5)
Proton transfer is dependent on the simultaneous movement of electrons (from
ubiquinol) via two routes. The [2Fe-2S] cluster of the Rieske iron sulfur protein
(ISP) is the first electron acceptor. The electrons are subsequently passed via
the bound cytochrome c1 onto the mobile cytochrome c2. The electrons then
flow onto Complex IV (Crofts 2004).
The second path for the flow of electrons is via cytochrome bL and cytochrome
bH to the Qi-site (Crofts 2004). The Qi-site catalyses the reduction of one CoQ to
CoQH2 through a two electron gate. The two electrons required are supplied by
the oxidation of two ubiquinol molecules at the Qo-site, thus releasing four H+,
delivering two electrons to each chain.
The Qo-site of Complex III is an important site for superoxide production
(Turrens et al. 1985). This is largely attributable to the production of
semiubiquinone when the second electron path (described above) is blocked.
Superoxide production occurs when the transfer of electrons from the
intermediate semiubiquinone to cytochrome bL becomes limited.
Under physiological conditions a low mitochondrial membrane potential and a
low ∆p lead to superoxide production; maximal superoxide production occurs at
~2% of normal turnover (Crofts 2004). Although Complex III superoxide
production can be significantly increased by the addition of antimycin, a
Complex III inhibitor, under physiological conditions production is far lower
compared to Complex I superoxide production (Chance & Hollunger 1961).
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Figure 1.5 Complex III/ Q cycle
The modified Q cycle in Complex III: Ubiquinone (Q) binds the Qi site of complex III.
Ubiquinol (QH2) binds to the Qo site of complex III and is oxidised in a two step process
(Ubiqionol-semiubiquinone-ubiquinone). Ubiquinol is then oxidized (gives up one
electron each) to the Rieske iron-sulfur '(FeS) protein' and to the bL heme. This
oxidation reaction produces a transient semiquinone before complete oxidation to
ubiquinone, which then leaves the Qo site of complex III. The 'FeS protein' then
donates an electron to Cytochrome c1.
Image taken from: http://en.wikipedia.org/wiki/File:Complex_III.png
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1.2.1.4. Complex IV
Complex IV is the last enzyme in the mitochondrial ETC located in the
mitochondrial membrane. The enzyme is composed of several metal prosthetic
sites and 14 protein subunits. 11 subunits are synthesised by the nucleus and 3
originate from the mitochondria. The metal prosthetic sites include two haems,
cytochrome a and a3, and two copper centres (CuA and CuB; Brzezinski and
Gennis 2008).
Complex IV receives four electrons from the intermembrane space via four
cytochrome c molecules. Protons are utilised from the mitochondrial matrix to
convert one oxygen molecule to two water molecules. The haem-copper active
site (cytochrome aa3) of the enzyme is located deep within the protein, thus
oxygen enters via a channel into the hydrophobic core of the membrane. The
reaction displayed below illustrates the 4 electron reduction of water catalysed
by cytochrome c oxidase (Brzezinski & Gennis 2008).
4 Fe2+-cytochrome c + 8 H+in + O2↔4 Fe3+-cytochrome c + 2 H2O + 4 H+out
Complex IV is the only true proton pump in the ETC. The existence of a proton
pump in Complex IV was first established by Wikstrom in 1977 (Wikstrom
1977). The protonmotive force in the mitochondria is driven by the mitochondrial
membrane potential (∆Ψm). The Complex IV is very efficient at converting
chemical energy into the ∆p. As demonstrated in the above reaction two
charges cross the membrane for every electron that passes through the
enzyme complex. The ∆Ψm is then utilised by ATP synthase (Complex V) to
synthesise ATP.
1.2.1.5. Complex V
Complex V (F1 Fo ATP synthase; EC 3.6.3.14) consists of 2 regions; F1 and Fo
(Figure 1.6). The F1 region is water soluble and catalyses the synthesis (or
hydrolysis in the reverse mode) of ATP. The F0 lies within the membrane that
catalyses the ion translocation across the membrane (von Ballmoos et al.
2008).
The mechanism of action of Complex V was first proposed by Paul Boyer in
1997 (Boyer 1997); for which he won the Nobel Prize alongside John Walker.
Boyer proposed a binding change model whereby the internal rotation of the γ
subunit leads to a binding change in the catalytic β subunits. Crystallography
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studies of the F1 region revealed alternating alpha and beta subunits (3 of
each), arranged around a central gamma subunit (α3β3γδε). The ∆p across the
inner mitochondrial membrane drives the flow of protons through the Fo region
of ATP synthase. The Fo region is composed of a ring of c subunits (c-ring). As
a proton passes through the ring, via an arginine controlled mechanism, rotation
of the c- ring ensues. The c-ring is tightly attached to the asymmetric central
stalk, consisting primarily of the γ subunit of the F1 region. The γ subunit rotates
within the α3β3 subunits of F1 region initiating a series of conformational
changes at the three catalytic nucleotide binding sites (von Ballmoos et al.
2008). Further rotation in line with the central stalk is prevented by a peripheral
stalk that joins the α3β3 subunits to the non-rotating portion of Fo (Wang & Oster
1998).
Under certain physiological conditions Complex V can work in the reverse
mode, thus hydrolysing ATP and pumping protons against the proton gradient.
Work by Boyer showed that when the ∆Ψm is reduced by the addition of an
uncoupler in the presence of ATP, ATP hydrolysis occurs (Boyer 2002).
1.2.1.6. Electron Transfer Flavoprotein Quinone Oxidoreductase
β-oxidation of long chain fatty acids is an essential process for energy provision;
particularly in cardiac and skeletal muscle. The products of β-oxidation can be
utilised in the formation of ketone bodies, that in turn can be used for energy
(Bartlett & Eaton 2004). During the β-oxidation process the two carbon units are
removed from long-chain acyl-CoA esters by repeated cycles of oxidation,
hydration, oxidation and thiolysis by chain length specific acyl-CoA
dehydrogenases. Medium-chain acyl-CoA dehydrogenase (MCAD) oxidises
acyl-CoA to enoyl-CoA. MCAD (specifically the FADH2 component) is re-
oxidised by two ETF. The ETF flavin semiquinone is in turn re-oxidised by ETF-
QO which catalyses the transfer of the electrons to the mitochondrial CoQ pool
(Figure 1.3; Watmough & Frerman 2010).
The ETF/ETF-QO system serves as a short electron transfer pathway
connecting fatty acid β-oxidation and amino acid catabolism to the CoQ pool of
the main respiratory chain.
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Figure 1.6 The Structure of Complex V (ATP Synthase)
consists of F1 and Fo Regions
Complex V (F1 Fo ATP synthase; EC 3.6.3.14) consists of 2 regions; F1 and Fo. The F1 region is
water soluble and catalyses the synthesis (or hydrolysis in the reverse mode) of ATP. The F0
lies within the membrane that catalyses the ion translocation across the membrane.
Taken from: http://www.pnas.org/content/98/9/4966/F1
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1.2.2. Mitochondrial Oxidative Stress and the Antioxidant Role of
Coenzyme Q10
1.2.2.1. Mitochondrial Oxidative Stress
Approximately 90% of normal mammalian oxygen consumption is
mitochondrial, the majority of which is coupled to ATP synthesis. However ~1-
2% is uncoupled by mitochondrial proton leak (Rolfe & Brown 1997). In line with
the proportion of proton leakage ROS production accounts for 1–2% of the
oxygen consumed by mitochondria. Mitochondria are considered to be the
major source of O2●- free radicals and H2O2 production in the cell (Papa &
Skulachev 1997; Skulachev 1998). The mitochondrial ETC is very efficient at
producing ATP; however the alternating one-electron oxidation-reduction
reactions predispose the mitochondria to elevated ROS production. There is a
5–10 fold higher concentration of O2●- free radicals in the mitochondrial matrix
than in other subcellular compartments (Enrique Cadenas & Davies 2000).
The formation of mitochondrial ROS is dependent on the state of respiration.
The 5 states of respiration were first proposed by Chance & Williams (1956).
Resting or state 4 of respiration is characterised by a slow rate of respiration, a
high mitochondrial membrane potential, no availability of ADP and a relatively
high rate of O2●- and H2O2 production. Conversely, active or state 3 has a high
rate of respiration, a lower mitochondrial membrane potential, high levels of
ADP and a slow rate of O2●- and H2O2 production, most likely due to the
oxidized state of the components of the respiratory chain. Finally, in anoxic
state 5 respiration a limited supply of O2 supply and a lack of ADP leads to only
a partial reduction of O2 leading to ROS production.
Nitric oxide (NO) also plays an important role in ROS production through
various mechanisms including; reversible binding to Complex IV, inhibition of
electron transfer at the bc1 segment (Complex III), partial oxidation of
mitochondrial ubiquinol to ubisemiquinone and generation of superoxide. NO is
produced by endothelial nitric oxide synthase or by the mitochondrial isozyme
(Poderoso et al. 1999; Poderoso et al. 1998; Cadenas & Davies 2000).
Free radicals are capable of causing substantial cellular damage to lipids,
proteins and DNA, or oxidative stress. Lipid peroxidation is by far the most
studied process resulting from oxidative stress. It is the process in which free
radicals remove electrons from the lipids in cellular membranes (Niki 1987).
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Phospholipids found in cellular membranes are highly vulnerable to lipid
peroxidation. Polyunsaturated side chains e.g. arachidionic acid are particularly
susceptible to free radical attack, forming lipid hydroperoxides and leading to
changes in membrane permeability and fluidity and altered lipid-protein
interactions. Initiation of lipid peroxidation occurs when a free radical of
sufficient reactivity (for examples see Table 1.3) extracts a hydrogen atom from
the methylene group of an unsaturated fatty acid. The initiating species then
undergoes conjugated diene bond rearrangement. The lipid radical formed
reacts with oxygen forming a peroxyl radical (Table 1.3). These peroxyl radicals
can react with each, other forming detergents capable of damaging cellular
membranes. These unstable molecules can also react with macromolecules
and thus further contribute to the damage caused. A single initiation event can
be amplified many times as long as oxygen and subsequent un-oxidised fatty
acids are available (Rice-Evans & Burdon 1993).
During protein oxidation certain amino acids are more prone to oxidation than
others. However it is the protein-bound transition metals that are the greatest
risk factor. They react with ROS and form hydroxyl radicals at the metal-binding
site (Stadtman & Berlett 1991; Stadtman 1990). Oxidised proteins are digested
to amino acids by specific proteases, making replacement via synthesis of
proteins the only repair mechanism (Grune et al. 1997; Ullrich et al. 1999). DNA
oxidation by ROS is also believed to be dependent on transition metals
(Halliwell & Aruom 1991). Due to the relatively high concentration of ROS in
mitochondria, and because of the lack of protective histones and limited repair
mechanisms, mitochondrial DNA is exposed to 10-fold higher oxidative damage
than nuclear DNA (Ozawa 1997). Once damaged oxidized DNA may be
repaired by either replacement or removal of the affected nucleic acids (Wood
1996).
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Superoxide radical O2●-
Hydroxyl radical ●OH
Peroxyl radical ROO●
Perhydroxyl radical HOO●
Alkoxyl radical RO●
Nitric oxide NO●
Hydrogen peroxide H2O2
Table 1.3 Examples of Reactive Oxygen Species (ROS)
ROS has the potential to alter the normal functioning of the cell. To protect the
cell from further damage there are a number of defense mechanisms in place,
which include antioxidants and non-enzymatic agents. Antioxidant enzymes
include superoxide dismutase and various peroxidases such as glutathione
peroxidase, catalase, thioredoxin reductase and peroxiredoxin (Holmgren &
Bjornstedt, 1995; Wood, Poole, & Karplus, 2003). Nonenzymatic agents include
vitamins C and E, carotenoids, glutathione, α-lipoic acid, flavinoids and CoQ.
Glutathione (GSH) is a ubiquitous tripeptide that, like CoQ, is known to
participate in a number of important cellular processes. The thiol group present
in reduced GSH acts as a reducing agent where it can directly neutralise free
radicals and reactive oxygen compounds as well as maintaining exogenous
antioxidants such as vitamins C and E in their reduced (active) forms (Meister &
Anderson 1983). After donating an electron GSH is very reactive. It is able to
react with other GSH compounds to form its dimeric oxidised form glutathione
disulphide (GSSG). GSH can then be regenerated in a NADPH dependant
process. The ratio of reduced glutathione to oxidized glutathione within cells is
often used as a measure of cellular toxicity (Anderson 1985).
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Figure 1.7 Redox States of CoQ10
Ubiquinone, Ubisemiquinone and Ubiquinol: the fully oxidized ubiquinone form (CoQ10); the
radical semiquinone intermediate (CoQ10H·), and the fully reduced ubiquinol form (CoQ10H2).
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1.2.2.2. Antioxidant Function of Coenzyme Q10
CoQ is located in all cellular lipid membranes at an abundance approximately 3-
30 times greater than that of vitamin E. Consequently, due to its close proximity
to unsaturated lipids which are prone to lipid peroxidation, CoQ is the primary
scavenger of free radicals. In its reduced form, ubiquinol, CoQ is a potent
antioxidant and is considered more efficient than vitamin E (Frei et al. 1990). It
has been suggested that ubiquinol acts earlier in the prevention of lipid
peroxidation than vitamin E (Ernster & Forsmark-Andree 1993) and ubiquinol is
also able to regenerate vitamin E from the α-tocopheroxyl radical. Ubiquinol is
able to inhibit lipid peroxidation in most subcellular membranes (Ernster et al.
1992; Ernster & Dallner 1995) and plays an important role as an antioxidant in
the circulation (Romagnoli et al. 1994; Alleva et al. 1995). Reductive
regeneration of ubiquinol is vital to maintain its antioxidative function. The ETC
ensures that mitochondrial ubiquinol is kept in a highly reduced state (Aberg et
al. 1992). In the plasma and endomembranes there are at least three enzymes
that are known to maintain CoQ in its reduced state. These enzymes are NADH
cytochrome b5 reductase, NADH/NADPH oxidoreductase and NADPH
coenzyme Q reductase (Villalba & Navas 2000; Takahashi et al. 1996). NADH
cytochrome b5 reductase and NADPH coenzyme Q reductase are able to
facilitate a one electron transfer and are important in the neutralisation of
semiubiquinone to ubiquinol. DT diaphorase is able to reduce CoQ via a 2
electron transfer, consequently eliminating the intermediate production of
ubisemiquinone (Figure 1.7). Interestingly under conditions of oxidative stress
(such as lack of selenium and vitamin E) the CoQ content in membranes is
increased in conjunction with the amount of DT diaphorase (Navarro et al.
1999).
The potency of CoQ as an antioxidant can be demonstrated using CoQ
deficient yeast models (Poon et al. 1997) and patient fibroblasts (Quinzii et al.
2010). Yeast mutants deficient in CoQ show more lipid peroxide formation than
normal yeast (Poon et al. 1997). In patient fibroblasts middle range CoQ10
deficiency (30-50% of normal) was associated with increased ROS, including an
increase in lipid peroxidation (Quinzii et al. 2010).
Ubiquinol is also able to reduce vitamin E back its active form (Arroyo et al.
2000). Regeneration of vitamin E is also evident in low density lipoproteins.
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Here a relatively small amount of CoQ is capable of direct reduction of vitamin
E back to its reduced active form (Schneider & Elstner 2000; Thomas et al.
1999). Vitamin C is regenerated by glutathione within the cell, however there is
evidence that electron transport (via CoQ) in the plasma membrane can be
used to regenerate vitamin C (Crane 2001).
1.2.3. The Plasma Membrane Redox System
As in the mitochondrial ETC, CoQ is also able to facilitate electron transport
across the plasma membrane. The plasma membrane of eukaryotic cells
contains an NADH oxidase (NOX) that is implicated in the transfer of electrons
across the membrane. The NOX protein is located on the external surface of
the plasma membrane. Hormones and growth factors are both able to stimulate
activity of the NOX (Brightman et al. 1992). A quinone reductase is bound to the
internal cytosolic surface of the plasma membrane. This catalyses the reduction
of CoQ in the presence of NADH (Kishi et al. 1999), thus enabling the
regeneration of the cellular reduced CoQ pool. There are several proposed
functions of NOX including control of cell growth and differentiation and
regenerating extracellular reduced ascorbate (Crane et al. 1985; Burón et al.
1993).
It is also possible that NOX is involved in the regulation of the cytosolic
NAD+/NADH ratio (Gómez-Díaz et al. 1997). Larm et al (1994) demonstrated
that in the absence of mitochondrial DNA the cell is able to regenerate NADH
via the plasma membrane. Crane et al. (1994) proposed that the CoQ10 plasma
membrane electron transfer system may function as a signaling molecule. It
was discovered that in Escherichia coli the redox state of CoQ acts as a control
of tyrosine kinase activity (Iuchi & Lin 1991). Semiquinone may also play a role;
oxidation of semiquinone in the plasma membrane could generate peroxide,
activation of peroxide generation induces tyrosine kinase and gene expression
(Shibanuma et al. 1990; Stirpe 1991).
1.2.4. Lysosomal Electron Transfer
It was also suggested that lysosomes contain an NADH-dependent CoQ
reductase involved in translocation of protons into the lysosomal lumen (Gille &
Nohl 2000), thus allowing the regulation of lysosomal pH. It is thought that the
reduction of CoQ occurs in two subsequent one-electron transfer steps
involving FAD and cytochrome b5 with molecular oxygen as the terminal
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electron acceptor. Though intriguing, further research will be necessary to
define the function of this CoQ-dependent lysosomal reductase.
1.2.5. The Mitochondrial Permeability Transition Pore (PTP)
The mitochondrial inner membrane has an extremely low permeability to ions
and solutes. To facilitate trans-membrane transport, the inner membrane
contains numerous macromolecule transporters and ion channels. However
during in vitro Ca2+ accumulation the mitochondrial inner membrane undergoes
permeabilisation, known as permeability transition, via the PTP. This causes
interruption of the ETC, disruption of ionic status, and hydrolysis of ATP
(Fontaine & Bernardi 1999).
The PTP is effectively a voltage-dependent channel, favoring a closed
conformation at high membrane potentials and an open conformation at low
membrane potentials. Permeability transition is thought to be regulated by many
factors including the mitochondrial membrane potential, the matrix pH,
cyclosporin A, phosphate, oxidized glutathione and pyrimidine nucleotides
derived from oxidative stress. It has been suggested that the permeability
transition is a key event in apoptosis (Green & Reed 1998). Several analogues
of CoQ have been shown to affect the PTP (E Fontaine et al. 1998; Walter et al.
2000; Walter et al. 2002). It has been suggested that the quinones’
benzoquinone rings share a common binding site, acting as either inhibitors or
inducers of PTP. CoQ10 seems to prevent PTP opening (Papucci et al. 2003).
This mechanism may go some way to explain the relationship between
apoptosis and CoQ10 (López-Lluch et al., 1999). However, the PTP opening and
the mechanism of action by CoQ10 were not investigated in this study.
1.2.6. Uncoupling Proteins (UCPs)
UCPs are able to transport H+ from the outside to the inside of the mitochondrial
inner membrane, thus counteracting the proton gradient built by the ETC
(Nicholls & Locke 1984). UCPs are ubiquitous throughout animal and plant
cells. Five UCPs (1–5 in humans) are known and they form a subfamily of the
mitochondrial carrier family. UCP3 is the most common subtype in human
skeletal muscle (Pecqueur et al. 2001). UCPs are important in thermogenesis
but may also be involved in suppression of oxygen radicals. Echtay et al (2000;
2001) showed that CoQ is a vital cofactor in UCP function in bacterial liposomes
which is inhibited by the addition of ATP. It has been suggested that CoQ
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interact with UCP within the hydrophobic bilayer given that short chain CoQs
were ineffective in activating UCPs (Echtay et al. 2001).
1.2.7. Cofactor in Pyrimidine Biosynthesis
The pyrimidine derivatives: cytosine, thymine, and uracil are components of
nucleic acids (DNA and RNA). Pyrimidines are therefore important for protein
synthesis and cell growth. CoQ10 is a cofactor in the conversion of
dihydroorotate (DHO) to orotic acid (OA) (Malmquist et al. 2008).
Dihydroorotate dehydrogenase (DHODH) is a flavin containing protein that
catalyses this conversion in the de novo synthesis of pyrimidine. DHODH is
classified into two families. Most eukaryotes, including humans, have family 2
enzymes. Family 2 enzymes are bound to the inner membrane of the
mitochondria and transfer electrons to CoQ10, chemically coupling pyrimidine to
the respiratory chain. Human DHODH appears to have two distinct CoQ-
substrate binding sites on either side of the flavin mononucleotide (FMN)
(Malmquist et al. 2008).
De novo pyrimidine synthesis has been studied in CoQ10 deficient patient
fibroblasts (López-Martín et al. 2007). The fibroblasts showed slow growth rates
compared to control fibroblasts. Growth was increased after incubation with
uridine, indicating that a defect in pyrimidine biosynthesis and not a defect in
ETC function is responsible for the slow growth rates.
1.2.8. Regulation of Cellular Membranes
All organelles isolated through subfractionation of the liver contain varying
amounts of CoQ. CoQ is a major component as expected, in both the outer and
inner membranes of the mitochondria. It is also found in high concentrations in
the lysosome and in the Golgi vesicles (Löw et al. 1992; Zhang 1996; Ericsson
& Dallner 1993). The distribution of CoQ, as well as that of other mevalonate
lipids, is able to considerably alter membrane properties. It is the structural
organisation of these lipids that may explain the differences between organelle
membrane type and possibly perturbation during disease. CoQ, dolichol and
dolichyl-P have long isoprenoid chains that would remain in the hydrophobic
region between the bilayer. This is likely to increase membrane thickness and
could de-stabilise the membrane, thereby increasing fluidity and permeability.
Cholesterol acts in a converse manner. Due to cholesterols short chain length it
does not protrude into the intermembrane space and therefore stabilises the
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membrane leading to decreased fluidity and permeability (Van Dijck et al.
1976). From this we can come to two conclusions: firstly that for optimal
function of subcellular membranes the distribution of mevalonate lipids must be
appropriate to that membrane and secondly if this balance fluctuates in any way
the effect may be deleterious to organelle function.
1.3. CoQ Biosynthesis
CoQ biosynthesis has been comprehensively investigated in bacteria and yeast
but little is known about the pathway in mammals. CoQ biosynthesis begins with
acetyl-coenzyme A (acetyl-CoA) which enters the mevalonate pathway
producing farnesyl pyrophosphate (FPP; Figure 1.8). FPP is then condensed to
the tyrosine derived 4-hydroxybenzoate. The terminal stages of CoQ
biosynthesis involve a series of ring modifications to the benzoquinone core of
the molecule (Figure 1.9). The terminal portion of bacterial and yeast CoQ
biosynthesis differ in the order of synthetic events in the terminal portion of the
pathway, i.e. in prokaryotes (yeast) the ring modifications occur in the order of
decarboxylation, hydroxylation and methylation, whereas in eukaryotes
(bacteria) decarboxylation precedes hydroxylation and methylation. COQ
biosynthetic genes isolated from yeast (coq1–8) have a putative mitochondrial
targeting signal (Belogrudov et al. 2001), however CoQ is found in all
subcellular compartments. This suggests that there must be a transport
mechanism from the mitochondria to other subcellular membranes. Interestingly
it appears that in yeast, CoQ synthesizing enzymes (Coq3-9) are organised in a
multi-subunit complex (Hsu et al. 2000; Hsieh et al. 2007), and thus accumulate
3-hexaprenyl-4-hydroxybenzoic acid (product regulated by the Coq2 gene)
regardless of the gene defect.
1.3.1. The Mevalonate Pathway
The mevalonate pathway encompasses the formation of FPP from acetyl-CoA
to FPP (Figure 1.8). FPP is a common substrate for the biosynthesis of CoQ, as
well as cholesterol, dolichol and isoprenylated proteins (Grünler et al. 1994;
Brown & Goldstein 1986), making the mevalonate pathway universal to all end-
products. Interestingly the mevalonate pathway lipids are synthesised in
exceptionally different concentrations. The most likely point of regulation is at
the FPP branch point. The initial stages of the mevalonate pathway involve the
condensation of three acetyl-CoA to 3-hydroxy-3-methylglutaryl- coenzyme A
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(HMG-CoA). This is mediated by two enzymes, acetoacetyl-CoA thiolase and
HMG-CoA synthase. HMG-CoA reductase then converts HMG-CoA to
mevalonate. This enzyme is considered to be the central regulatory enzyme in
cholesterol biosynthesis and consequently CoQ biosynthesis.
Mevalonate is consequently phosphorylated by two enzymes, mevalonate
kinase and phosphomevalonate kinase. Mevalonate pyrophosphate then
undergoes decarboxylation producing isopentenyl pyrophosphate (IPP). IPP is
a precursor of FPP and the main component of dolichol. Isomerisation of IPP
gives dimethylallyl pyrophosphate which participates in the synthesis of
isopentenyl tRNA at the position six of an adenosine (Warner et al. 2000). FPP
synthase catalyses the fusion of IPP and its isomer dimethylallyl pyrophosphate
to FPP forming an intermediate product, geranyl pyrophosphate (GPP) (Rilling
1985). FPP is then converted into cholesterol, dolichol, CoQ or isoprenylated
proteins by one of 4 enzymes: squalene synthase, cis-prenyltransferase, trans-
prenyltransferase and farnesyl-protein transferase. These are considered to be
the rate limiting enzymes in the terminal part of the lipids biosynthetic pathway.
1.3.2. CoQ Biosynthesis
The biosynthesis of CoQ has been studied extensively in Escherichia coli and
Saccharomyces cerevisiae and Schizosaccharomyces pombe (Tran & Clarke
2007; Kawamukai 2009). The polyprenyl tail of CoQ is produced in a species
specific manner by trans-prenyl-transferase (TPT; also called decaprenyl
transferase; encoded for by coq1). The number of isoprenoid units varies
between species. Saccharomyces species predominantly produce CoQ6, mice
and rats predominantly produce CoQ9 and humans predominantly produce
CoQ10. In humans, TPT is encoded by the PDSS1 and PDSS2 genes.
The ring precursor in coenzyme Q biosynthesis is 4-hydroxy benzoate (4HB).
Bacteria can produce 4HB via de novo synthesis (Siebert et al. 1994) however
animals rely on a dietary source of essential amino acids. Thus tyrosine and
phenylalanine are used to generate 4HB (Tran & Clarke 2007).
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Figure 1.8 The Mevalonate Pathway-illustrating the synthesis of CoQ10
Acetyl CoA is converted via a complex pathway into Coenzyme Q10 (CoQ10), cholesterol,
dolichol (and Dolichol-P), t-RNA and Isoprenylated proteins via the mevalonate pathway. 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMG CoA reductase) is the main rate controlling
enzyme of the mevalonate pathway. The Farnesyl diphosphate (FPP) branch point enzymes
also appear to regulate the synthesis of these compounds. IPP: isopentenyl diphosphate; GPP:
geranyl diphosphate; FPP: farnesyl diphosphate
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Human homologues of the yeast genes have been shown to restore CoQ
biosynthesis in yeast mutants (reviewed in Tran & Clarke 2007). In yeast, coq
polypeptides (enzymes responsible for CoQ biosynthesis) are located on the
matrix side of the inner mitochondrial membrane (Tran & Clarke 2007). Many
lines of evidence suggest that the coq polypeptides are conjoined in one or
more multi-subunit complexes, similar to the ETC complexes (explained in
Section 1.2.1).
Yeast mutants with deletions in coq3, coq4, coq5, coq6, coq7, coq8, or coq9
genes accumulate only the first CoQ-intermediate, 3-hexaprenyl-4- hydroxy-
benzoic acid (Poon et al. 1995; Poon et al. 1997; Johnson et al. 2005).
Subsequently, levels of the Coq polypeptides are substantially decreased in
yeast mutants with deletions in any of the COQ biosynthetic genes (Hsieh et al.
2007; Gin & Clarke 2005). This is hypothesised to be caused by the
destabilisation of the CoQ multisubunit complex. Further publications add to
these lines of evidence, suggesting a direct interaction of the complexes. Gel
filtration and BN-PAGE analysis of yeast digitonin extracts revealed that several
of the coq polypeptides co-migrate at a high molecular mass (Hsieh et al. 2007;
Marbois et al. 2005; Tran et al. 2006). It was also noted that demethoxy-CoQ,
the penultimate intermediate in Q biosynthesis, co-migrates with the Coq
polypeptide complex suggesting that it is still attached to the complex post-
synthesis (Marbois et al. 2005).
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Table 1.4 Table Illustrating the Phenotypes Associated with CoQ10 Deficiency
Data taken from (Emmanuele et al, 2012)
Phenotype
No. of
cases
Clinical features (responsible gene) CoQ10 level
Encephalomyopathy 4
Juvenile-onset mitochondrial myopathy, recurrent myoglobinuria,
encephalopathy (No known gene)
3.7%-39% of normal in muscle,
normal in fibroblasts in 1 patient
Isolated myopathy 18
Juvenile- or adult-onset muscle weakness, myoglobinuria, exercise
intolerance, cramps, myalgias, elevated creatine kinase level (ETFDH)
12.4%-49% of normal in muscle,
normal in fibroblasts in 1 patient
Nephropathy 11
Infantile- or early childhood-onset steroid-resistant nephrotic syndrome
(COQ2); Infantile- or juvenile-onset steroid-resistant nephrotic
syndrome typically with congenital sensorineural deafness (COQ6)
38% of normal in muscle in 1
patient, 17% of normal in
fibroblasts in 1 patient
Infantile
multisystemic
disease
18
Infantile-onset psychomotor regression, encephalopathy, optic atrophy,
retinopathy, hearing loss, renal dysfunction (mainly nephrotic
syndrome) (COQ2, PDSS2, COQ9, PDSS1, COQ6)
2.5%-37% of normal in muscle,
reduced in fibroblasts: 10/11
patients
Cerebellar ataxia 117
Typically juvenile-onset cerebellar ataxia, additional manifestations
may occur (ADCK3, APTX)
4%-66% of normal in muscle,
reduced in fibroblasts: 18/30
patients
49
1.4. Human CoQ10 Deficiency
CoQ10 deficiency was first reported by Ogasahara in 1989 in siblings with
progressive muscle weakness, fatigability and central nervous system
dysfunction (Ogasahara et al. 1989). Primary CoQ10 deficiency is usually
inherited in an autosomal recessive manner, with recessive mutations reported
in 7 CoQ10 biosynthetic genes (6 biosynthetic enzymes) to date: PDSS1 (Mollet
et al. 2007) and PDSS2 (Rötig et al. 2000; López et al. 2006), ADCK3 (Mollet et
al. 2008; Lagier-Tourenne et al. 2008), COQ9 (Duncan et al. 2009), COQ6
(Heeringa et al. 2011), COQ4 (Salviati et al. 2012) and COQ2 (Mollet et al.
2007; Quinzii et al. 2006; Diomedi-Camassei et al. 2007). CoQ10 deficiency can
be broadly divided into five major phenotypes: 1) Encephalomyopathy; 2)
infantile multisystemic disease; 3) isolated cerebellar ataxia; 4) a pure
myopathic form; and 5) nephropathy (Table 1.4). Leigh syndrome has been
reported in 3 patients and can be considered a separate phenotype (Van
Maldergem et al. 2002; López et al. 2006).
Numerous genes have been associated with these phenotypes (Table 1.4). The
encephalomyopathic and the multisystemic phenotypes demonstrated the most
severe defect in CoQ10 level (Encephalomyopathy: 3.7%-39% of normal in
muscle; Infantile multisystemic: 2.5%-37% of normal in muscle). The 4 cases of
the encephalomyopathic phenotype are not associated with any particular gene
defect. However the Infantile multisystemic phenotype (18 reported cases) is
associated with defects in 5 different genes: COQ2, PDSS2, COQ9, PDSS1,
COQ6 (Emmanuele et al, 2012).
There are 18 reported cases of the isolated myopathic phenotype which is
associated with defects in the ETFDH gene. CoQ10 levels are 12.4%-49% of
normal in the muscle of these patients. Defects in the ADCK3 and the APTX
gene are associated with the cerebellar phenotype. There are currently 117
cases that report varying effects on CoQ10 biosynthesis (4%-66% of normal
CoQ10 in muscle). However in fibroblasts only 60% of patients have CoQ10
levels lower than normal.
The nephritic phenotype is associated with defects in two genes: COQ2 and
COQ6. Patients with a defect in the COQ2 gene present with an earlier onset
(inflantile or early childhood) steroid resistant nephrotic disease; whereas
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patient with a defect in the COQ6 gene present later and also have
sensorineural hearing loss. CoQ10 was not quantified in the majority of these
patients however 1 patient had a CoQ10 level that was 38% of normal in muscle.
1.4.1. COQ2 (encoding PHB-polyprenyl transferase)
In 2006 Quinzii and colleagues discovered a homozygous missense mutation in
the COQ2 gene in two siblings with infantile steroid resistant nephropathy, and
subsequent encephalomyopathy in the eldest child (Quinzii et al. 2006). Both
patients had CoQ10 deficiency in muscle and fibroblasts, with a consequent
decrease in Complex I/III (nicotinamide adenine dinucleotide–cytochrome c
oxidoreduc- tase) and II/III (succinate–cytochrome c oxidoreductase) activity.
The other ETC complexes had normal activity. In 2007, Mollet and colleagues
reported a homozygous base pair deletion in exon 7 of the COQ2 gene. This
patient presented with neonatal neurological distress, liver failure, nephrotic
syndrome, diabetes mellitus, pancytopenia, seizures, lactatemia and died at 12
days of multisystem failure. CoQ10 quantification revealed a decrease in
fibroblasts and enzymological studies of liver homogenate revealed a decrease
in Complex I/III and Complex II/III activities. Combined Complex I/III and II/III
activities are dependent upon CoQ10 thus we would expect the activities to be
low in a CoQ10 deficient patient. Diomedi-Camassei et al (2007) reported a
COQ2 mutation in two patients with early onset glomerular lesions. The first had
steroid resistant nephrotic syndrome, with no extra-renal symptoms. The
second patient presented with olioguria which rapidly developed into end stage
renal disease and died at 6 months of epileptic encephalopathy complications.
Both patients had decreased levels of CoQ10 and Complex II/III activity in
muscle (Complex I/III not measured). Complex I activity was also decreased
and Complex II, III and IV were at the lower limit of the reference range. Thus to
date six patients have been identified as having COQ2 gene mutations.
The COQ2 gene encodes a protein called 4HB-polyprenyl transferase. This
enzyme catalyses a polyprenyl transfer reaction whereby the tyrosine (or
phenylanaline) derived 4-HB is condensed with the mevalonate pathway
derived FPP (Figure 1.9).
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1.4.2. PDSS1 and 2 (encoding transprenyl transferase)
The PDSS2 gene encodes a subunit of the TPT enzyme. This heterotetramer is
composed of two different subunits; PDSS1 and PDSS2. TPT catalyses the
formation of CoQ10’s decaprenyl side chain. In 2006 Lopez et al described a
male infant with compound heterozygous mutations in the PDSS2 subunit gene
(López et al. 2006). The patient had severe Leigh syndrome, nephrotic
syndrome and epilepsy. ETC activity determination revealed decreased ETC
Complex II/III activity and Complex I activity in fibroblasts. Complex II, III and IV
activities were normal. CoQ10 content was severely reduced in muscle and
fibroblasts. A homozygous missense mutation in PDSS1 was discovered in a
single patient from a family with a history of consanguinity. The patient
presented with a multisystem disease with early-onset deafness,
encephaloneuropathy, obesity, livedo reticularis and valvulopathy. Assessment
of ETC complexes revealed low levels of Complex III and Complex II/III, as well
as CoQ10 deficiency in fibroblasts. Muscle analysis revealed ETC activities
within the normal range for all the complexes (Mollet et al. 2007).
Rotig and collegues (2000) performed a radio-labelling study whereby patient
fibroblasts were grown in the presence of 3H-Mevalonate. The CoQ10 deficient
patient was unable to convert 3H-Mevalonate into 3H-CoQ10. This patient was
later discovered to have a PDSS2 gene defect (Rahman et al. 2012 [personal
communication]).
1.4.3. ADCK3 (or CABC1)
ADCK3 (or CABC1) was originally isolated in yeast in 2002 by Iiizumi et al as a
protein found within the mitochondria that was able to reduce apoptotic
processes. The role of ADCK3 is unknown. ADCK proteins in general possess
conserved protein-kinase motifs for ATP binding and phosphotransfer. It has
been suggested that it may function in the distal portion of the biosynthetic
pathway, possibly through phosphorylation of the coq3 protein (Tauche et al.
2008).
In 2008 two studies identified patients with ADCK3 gene mutations (Mollet et al.
2008; Lagier-Tourenne et al. 2008). To date mutations in the ADCK3 gene have
been found in 22 patients from 15 different families (Emmanuele et al. 2012). All
of the patients in this literature review presented with childhood onset ataxia
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with slow progression. Two patients had concurrent epilepsy. Assessment of
ETC activities often showed a mild decrease in Complex I/III and Complex II/III
activities and CoQ10 deficiency in muscle. But in fact many of the patients had
CoQ10 and ETC complex activities within the normal range, especially in
fibroblasts. A paper published in 2012 described four patients with ADCK3 gene
mutations that presented with an adult onset cerebellar ataxia (Horvath et al.
2012). Similarly half of the patients had a muscle CoQ10 status and ETC
complex activities within the normal range. Consequently to date there are 26
patients from 17 different families with a confirmed ADCK3 gene mutation,
making this the most common form of CoQ10 deficiency.
1.4.4. COQ9
The mutation in the COQ9 gene was discovered in 2009 by Duncan and
colleagues (Duncan et al. 2009). The patient in question developed a multi-
systemic disease including intractable seizures, global developmental delay,
hypertrophic cardiomyopathy, and renal tubular dysfunction (Rahman et al.
2001). Assessment of skeletal muscle revealed a profound decrease in CoQ10.
ETC Complex II/III activity was undetectable and the other ETC complexes had
normal activities (Complex I/III was not measured). The exact function of the
protein that COQ9 encodes remains to be elucidated. Yeast studies of the coq9
protein indicate that it is localised in the inner mitochondrial membrane as part
of a multi-subunit complex with other peptides involved in the biosynthesis of
CoQ10 (Hsieh et al. 2007; Hsu et al. 2000). It is hypothesised that COQ9
protein acts distally to the prenylation step since yeast coq9 mutants are
capable of producing 3-hexaprenyl-4-hydroxybenzoic acid (Johnson et al.
2005). It is also interesting to note that Duncan and associates (2009) observed
an un-identified peak on HPLC analysis of CoQ10 possibly representing an
accumulating biosynthetic intermediate from the distal portion of the pathway in
COQ9 patient fibroblasts.
1.4.5. COQ6
Recently mutations in the COQ6 gene has been reported in 11 patients from
five families (Heeringa et al. 2011) making this the second most common
phenotype of primary CoQ10 deficiency. These patients presented with a
nephrotic syndrome associated with sensorineural hearing loss, similar to that
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observed in patients with PDSS1 and COQ2 gene mutations. The COQ6 gene
consists of 13.2 kb and 12 exons. The protein that the COQ6 gene encodes is
highly conserved throughout evolution and is required for one or more ring
hydroxylation steps in the biosythesis of CoQ10.
In four of these cases central nervous system involvement including seizures
and ataxia was reported. ∆Ψm was decreased in podocyte clones isolated from
patients, suggesting a defect in the ETC function (Heeringa et al. 2011).
However ETC activities were not measured in this study.
1.4.6. COQ4
COQ4 encodes a protein that organises the multienzyme complex for the
synthesis of CoQ10. The protein does not appear to possess a specific
enzymatic activity but plays rather a structural role (Marbois et al. 2009; Casarin
et al. 2008). A 3.9 Mb deletion of chromosome 9q34.13 was identified in a 3-
year-old boy with mental retardation, encephalomyopathy and dysmorphic
features. ETC Complex II/III activity and CoQ10 was reduced in fibroblasts
(Salviati et al. 2012). This deletion also leads to the deletion of 80 other
neighbouring genes; which may contribute the complexity of the clinical
phenotype seen here.
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Figure 1.9 CoQ Biosynthesis
Characterised in yeast, demonstrates the proposed biosynthetic pathway of CoQ. Adck3 is
thought to act as a kinase in the phosphorylation of coq3 (Tauche et al. 2008)
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1.4.7. Secondary CoQ10 Deficiency
Mutations in genes not directly associated with the CoQ10 biosynthetic pathway
have been detected in patients presenting with the cerebellar and myopathic
forms of CoQ10 deficiency. Musumeci et al (2008) reported six patients with
cerebellar ataxia, pyramidal signs and seizures, who were responsive to CoQ10
supplementation. Patients had a muscle CoQ10 deficiency with decreased
Complex I/III and II/III activities, and a marginal decrease in separate Complex I
and Complex II activities. Later studies revealed a homozygous mutation in the
APTX gene, encoding aprataxin, which is a known cause of ataxia-oculomotor-
apraxia 1 (AOA1; Moreira et al. 2001). In 2007, Le Ber et al. further established
AOA1 as a cause of secondary CoQ10 deficiency (Le Ber et al. 2007). These
authors noted decreased CoQ10 levels in five unrelated patients with genetically
confirmed AOA1 with a more severe deficiency in patients with a homozygous
W279X mutation. Again these patients improved after CoQ10 supplementation
(Quinzii et al. 2005). The W279X gene mutation leads to a truncated protein
and possibly to a complete loss of protein which may explain the greater
decrease in CoQ10 content versus other gene defects in the APTX gene. There
is no obvious link between aprataxin and CoQ10 biosynthesis. However it is
intriguing that to note that hypercholesterolaemia is a common feature of AOA1,
suggesting an interaction with the mevalonate pathway.
The myopathic phenotype is now associated with ETFDH (electron-transferring-
flavoprotein dehydrogenase) gene mutation (see Section 1.2.2 for details on the
biochemistry). Gempel and associates (2007) reported seven patients (five
families) with exercise intolerance, fatigue and proximal myopathy. All patients
had a severe CoQ10 deficiency, with a concurrent decrease in ETC Complex I
and II/III activities and showed dramatic improvement following CoQ10
supplementation (Gempel et al. 2007). CoQ10 is a direct acceptor of electrons
from the ETC/ETC-QO system and thus it is possible that an inhibitory feedback
mechanism may be responsible for the down-regulation of CoQ10 seen in these
patients.
CoQ10 deficiency has also been documented in Cardiofaciocutaneous
syndrome due to a BRAF mutation (Aeby et al. 2007). However the cause of the
CoQ10 deficiency associated with the BRAF mutation is yet to be elucidated.
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1.4.7.1. Pharmacological Inhibition of CoQ10
Statins are reversible inhibitors of the enzyme HMG CoA-reductase. They are
the most widely used and effective drugs used to reduce low density lipoprotein
(LDL) cholesterol, thus reducing the likelihood of cardiovascular events (Harper
& Jacobson 2010). Statin myopathy occurs in 10-15% of statin users (Harper &
Jacobson 2010). It is widely speculated that this is caused by a secondary
CoQ10 deficiency (Hargreaves & Heales 2002). HMG CoA-reductase is a major
regulatory enzyme in the mevalonate pathway, which is common to both CoQ10
and cholesterol (Alberts 1988). Thus a concurrent decrease in CoQ10 and
cholesterol is plausible following statin therapy.
The majority of studies investigating CoQ10 deficiency in relation to statin
therapy have been conducted on serum (Hargreaves et al. 2005). It has been
suggested that serum is not the ideal tissue for CoQ10 quantification.
Consequently the deficiencies highlighted may not be demonstrating a cellular
CoQ10 deficiency. Serum/plasma CoQ10 levels are subject to dietary intake and
hepatic synthesis; not de novo synthesis. Additionally CoQ10 levels are also
dependant on blood lipids thus quantification of serum CoQ10 could be improved
through standardising results against lipoprotein levels. However studies that
use muscle for quantification of CoQ10 levels also variably find a deficiency in
relation to statin therapy (Harper & Jacobson 2010). Subsequently CoQ10
supplementation also has variable efficacy in preventing myopathy when taken
in conjunction with statin therapy (Harper & Jacobson 2010).
1.4.7.2. Mitochondrial Disorders
Secondary CoQ10 deficiency has been reported in a number of patients with
mitochondrial diseases. In 1989, Zierz et al. reported a patient with Kearns-
Sayre syndrome who had CoQ10 deficiency in plasma and muscle (Zierz et al.
1989). Subsequently in 1991, Matsuoka et al. reported 25 patients with
mitochondrial encephalomyopathies that had low levels of CoQ10 in muscle
(Matsuoka et al. 1991). Additionally Montero and colleagues published two
papers outlining two patients, one with mtDNA (mitochondrial DNA) depletion
and the other with a confirmed mitochondrial disease, who both presented with
CoQ10 deficiency in muscle. Miles et al. investigated a large cohort of paediatric
patients with suspected mitochondrial myopathy. This study found that muscle
57
CoQ10 content correlated with a decrease in ETC activity in these patients
(Miles et al. 2008). A recent study of 76 patients with mitochondrial disorders of
a hetrogeneous nature found that 37% of patients had a CoQ10 lower than
normal (Sacconi et al. 2010). A possible explanation for the observed CoQ10
deficiency in patients with mitochondrial disorders could be an increase in
oxidative stress. Mitochondria are the primary site of ROS production (Cadenas
& Davies 2000) and thus mitochondrial dysfunction is commonly associated
with increased ROS production. Synthesis/consumption of cellular antioxidants,
such as CoQ10 may be perturbed during periods of high ROS production.
The observed CoQ10 deficiency appears to quantitatively be most severe in
mtDNA depletion syndromes (Sacconi et al. 2010). In view of the involvement of
CoQ10 in pyrimidine biosynthesis it is possible that a deficiency in CoQ10 further
contributes to the mtDNA depletion syndrome.
1.4.7.3. Metabolic Disorders
Secondary CoQ10 deficiency has been reported in Mevalonic Aciduria (MVA),
Methyl Malonic Acidaemia (MMA) and Phenylketonuria (PKU). In MVA a
decrease in mevalonate kinase activity, an enzyme common to both CoQ10 and
cholesterol synthesis, may lead to a decrease in CoQ10 production (Hargreaves
2007). Although decreased levels have been reported in plasma, Haas et al.
(2009) did not find a significant decrease in the CoQ10 status in MVA patient
fibroblasts.
However Haas et al did find CoQ10 deficiency in patients with MMA. MMA is
caused by an inherited deficiency of the mitochondrial enzyme methylmalonyl-
CoA mutase (EC 5.4.99.2) or by defects in the synthesis of 5-
deoxyadenosylcobalamin, the cofactor of methylmalonyl-CoA mutase, resulting
in an accumulation of MMA in tissues and body fluids. The authors suggest that
the CoQ10 deficiency observed in the MMA patients is due to an increase in
oxidative stress (Haas et al. 2009).
In PKU patients elevated phenylalanine levels have been reported to result in a
decrease in plasma CoQ10 levels. Decreased levels of CoQ10 in plasma in PKU
patients could possibly be due to phenylalanine inhibiting two enzymes required
for cholesterol and CoQ10 biosynthesis, 3-hydroxy-3-methylglutaryl-CoA
reductase and mevalonate-5-pyrophosphate decarboxylase (Hargreaves,
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2007). However studies performed in blood mononuclear cells did not show a
deficiency of CoQ10 (Hargreaves 2007).
1.4.7.4. Neurodegenerative Disorders
Mitochondrial dysfunction has long been implicated in the pathogenesis of
neurodegenerative diseases. This is particularly evident in Parkinson’s disease
(PD). PD has historically been associated with a decrease in mitochondrial
Complex I activity (Shults et al. 1997). Developments in genetics have led to the
discovery of several familial PD genes that are associated with the
mitochondria: PINK1, DJ-1, Omi/HtrA2 (Gandhi et al. 2009). Low levels of
CoQ10 have been reported in platelets (Shults et al. 1997), with concurrent
decreases in ETC Complex I and II/III activities, and in the brain cortex
(Hargreaves et al. 2008).
Patients with Friedreich’s Ataxia (FA) also have mitochondrial dysfunction.
Deficiencies in ETC Complex I, II and III have been described in cardiac and
skeletal muscle (Lodi et al. 2002). CoQ10 deficiency in plasma has been
associated with the efficacy of CoQ10 supplementation in FA patients.
Although mitochondrial dysfunction has also been implicated in other
neurodegenerative diseases, serum CoQ10 levels are not significantly different
from controls in Huntington Disease (HD), Amyotrophic lateral sclerosis (ALS)
and Alzheimer’s disease (AD) (Spindler et al. 2009).
1.5. CoQ10 Supplementation
Patients with primary and secondary CoQ10 deficiency showed variable
responses to CoQ10 treatment. There is currently no recommended dose for
CoQ10 supplementation. In fact the doses administered differ substantially; 30-
3000mg/day. However, in general a dose of 10-30mg/kg/day for children and
1200-3000 mg/day in adults appear to be effective in patients with COQ2
mutations (Rahman et al. 2012).
CoQ10 is available in many different forms with variable bioavailablity, including
powder, suspension, oil solution, solubilised forms (All-Q and Q-Gel), as well as
creams, tablets, wafers, and hard-shell or softgel capsules. Most recently a self-
emulsifying drug delivery system (SEDDS) composed of oil and surfactant
(Onoue et al. 2012) and a lipid-based formulation that self-assembles on
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contact with an aqueous phase into a colloid delivery system (VESIsorb,
colloidal-Q10) (Liu & Artmann 2009), have been developed in an effort to
increase bioavailability. Various formulations of ubiquinol are also available
(Hosoe et al. 2007).
1.5.1. Primary CoQ10 Deficiency
In patients with encephalomyopathy, muscle symptoms improved after therapy
(Ogasahara et al. 1989; Sobreira et al. 1997; Giovanni et al. 2001), however
one patient developed cerebellar ataxia (Sobreira et al. 1997).
Six patients with pure myopathy (Lalani et al. 2005; Horvath et al. 2012)
improved after CoQ10 supplementation. Riboflavin (vitamin B2) is the co-factor
shared by ETF, ETFDH and all acyl-CoA dehydrogenases. Two patients with
ETFDH mutations only improved after additional treatment with riboflavin, 100
mg daily (Gempel et al. 2007). Therapy with riboflavin, carnitine and low-fat,
low-protein diet is beneficial to patients with ETFDH mutations; however
addition of CoQ10 supplementation may also be beneficial to therapy.
In patients with the infantile multisystemic phenotype, CoQ10 supplementation
halted neurological disease progression and improved myopathy (Rötig et al.
2000). Another patient with a COQ2 gene mutation improved dramatically after
CoQ10 supplementation, particularly the neurological symptoms. Interestingly
this patient’s sister (who had isolated nephropathy) improved upon CoQ10
supplementation and did not go on to develop any neurological symptoms
(Quinzii et al. 2006). A patient with the COQ9 mutation who received CoQ10
supplementation had a reduction in blood lactate levels, but showed no sign of
clinical improvement and died at 2 years (Rahman et al. 2001). A patient with
the PDSS2 gene mutation also failed to respond to CoQ10 supplementation and
died at 8 months (López et al. 2006).
Two patients with the COQ6 gene mutation showed improved renal function
with decreased levels of proteinuria, however hearing loss did not improve
(Heeringa et al. 2011).
Response to CoQ10 supplementation in patients with the ataxic phenotype is
also variable. 46% of patients with the ADCK3 gene mutation showed
improvement of their ataxic symptoms (Lagier-Tourenne et al. 2008; Pineda et
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al. 2010), however many patients were refractory to treatment (Horvath et al.
2012; Mollet et al. 2008). One patient, despite improvement of muscle
symptoms, developed a tremor, myoclonic jerks, and cerebellar atrophy (Mollet
et al. 2008). A similar level of variability is found in patients with defects in the
APTX gene. Three siblings with the mutation demonstrated resolved ataxic and
epileptic symptoms (Quinzii et al. 2005). However another patient showed no
improvement upon CoQ10 supplementation (D’Arrigo et al. 2008). In cases
where no causative gene defect for the ataxia was identified response to CoQ10
supplementation was also variable. Two patients demonstrated an improvement
in muscle symptoms but not ataxic symptoms (Boitier et al. 1998; Musumeci et
al. 2001). Nine patients demonstrated a decrease in the International
Cooperative Ataxia Rating Scale (ICARS) (Pineda et al. 2010; Artuch et al.
2006; Gironi et al. 2004). Furthermore eleven patients with an undefined defect
were refractory to treatment (Lamperti et al. 2003; Terracciano et al. 2012).
Two patients with Leigh syndrome and one patient with cardiofaciocutaneous
syndrome improved after treatment (Aeby et al. 2007; Van Maldergem et al.
2002) and a patient with hypotonia and infantile spasms did not show any sign
of improvement (Huntsman et al. 2009).
1.5.2. Secondary CoQ10 Deficiency
Large scale clinical trials are not feasible for primary CoQ10 deficiency due to
the small number of patients, however many clinical trials have taken place in
relation to a number of neurogenerative diseases. Success has been seen in
the treatment of FA with CoQ10 in conjunction with vitamin E, whereby 49% of
patients demonstrated an improvement in the ICARS score (Cooper et al.
2008). However this study did not have a placebo/no treatment group for
comparison and this was only a small scale study (n=50). Interestingly despite
the initial success seen in CoQ10 supplementation for PD (Shults et al. 2002)
the recent Phase III trial was terminated after it was deemed unlikely to yield
significant results (Beale et al. 2011). Publication of further analysis is pending,
however this abstract did outline a trend towards a worse Universal Parkinson’s
Disease Rating Scale (UPDRS) score.
Owing to the increasing evidence of CoQ10 deficiency in mitochondrial diseases
a phase III clinical trial is also underway investigating CoQ10 supplementation in
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mitochondrial disease (Hassani et al. 2010). This is a randomized placebo-
controlled, double- blinded trial to assess the safety and efficacy of CoQ10 in
patients with mitochondrial disease.
1.6. Aims
The overall objective of this thesis was to investigate the pathogenesis of
neurological CoQ10 deficiency at a cellular, biochemical level and to utilise this
knowledge to understand why CoQ10 supplementation may not be successful in
treating neurological CoQ10 disease.
Another objective will be to develop an analytical method capable of quantifying
CoQ10 in CSF. The diagnosis of CoQ10 deficiency is currently unreliable.
Quantification of CoQ10 in fibroblasts and muscle does not always result in the
diagnosis of a CoQ10 deficiency, despite confirmation of an ADCK3 gene
mutation. Consequently a test for CSF CoQ10 quantification would not only be
useful diagnostically, but also in monitoring CoQ10 supplementation.
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Chapter 2
Materials and Methods
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2.1. Materials
The following were purchased from VWR International Ltd (Lutterworth, UK):
Potassium Phosphate (analar grade); Potassium dihydrogen phosphate (analar
grade); Magnesium Chloride Hexahydrate (analar grade); Potassium Cyanide
(analar grade); Ethanol (analar grade); EDTA K+ (analar grade); Perchloric acid
60% (Hipersolv for HPLC); Ethanol 96% (Hipersolv for HPLC); n-Hexane
(Hipersolv for HPLC); Methanol (Hipersolv for HPLC); Potassium hydroxide
pellets (analar grade); 85% Orthophosphoric acid (Hipersolv for HPLC)
The following were purchased from Sigma Aldrich (Poole, UK):
Triton X-100; SigmaUltra ≥ 99.5%; Sterile 0.4% Trypan blue; Dimethyl
sulphoxide; Coenzyme Q1~95%; β-Nicotinamide adenine dinucleotide, reduced
disodium salt hydrate ≥ 97%; Rotenone ≥ 95%; BSA (Bovine Serum Albumin) ≥
96%; Trizma-base (reagent garde); Cytochrome c from equine heart ≥ 95%;
Antimycin A from Steptomyces sp.; Sodium succinate dibasic hexhydrate
ReagentPlus®, ≥ 99%; 5,5'-Dithiobis(2-nitrobenzoic acid), ≥ 98%; Acetyl
coenzyme A sodium salt, ≥ 93%; Oxaloacetic acid, ≥ 97%; L-Ascorbic acid, cell
culture tested; Potassium hexacyanoferrate(III), ReagentPlus®, ~99%;
Coenzyme Q10, ≥ 98%; Sodium perchlorate, 98%; 1-Propanol, chromasolv® for
HPLC, ≥ 99.9%; Oligomycin from Streptomyces sp.; Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone, ≥ 98%;
Sterile cell culture products: Dulbecco’s modified eagles medium/Ham’s F-12
Nutrient Mixture (DMEM/F-12) (1:1) with No L-glutamine; L-glutamine; Fetal
bovine serum, heat inactivated (EU approved origin); 0.25% Trypsin-EDTA
were purchased from Invitrogen Ltd (Paisley, UK).
Microscopy probes were all purchased from Invitrogen Ltd (Paisley, UK).
Disposable PD-10 Desalting Columns were purchased from GE Healthcare
Lifesciences (Amersham, UK).
HPLC vials and caps were purchased from Chromacol (Welwyn Garden City,
UK).
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Techsphere ODS 5µ, 150 x 4.6mm and Techsphere ODS C18, 250 x 4.6mm
HPLC columns were purchased from HPLC technology (Welwyn Garden City,
UK).
DC total protein assay Reagent A and Reagent B were purchased from Bio-Rad
Laboratories Ltd (Hemel Hempstead, UK).
2.2. Tissue Culture
2.2.1. Cell Line
The SK-N-SH cell line was conceived from a bone-marrow biopsy of a four year
old female patient with a neuroblastoma of the chest (Biedler et al. 1973). This
line contained two distinct cell groups: a neuroblast-like cell and an epithelial-
like cell. The neuroblast-like cell group was three times sub-cloned as SH-SY,
SHSY5 and finally SH-SY5Y (Biedler et al. 1978). The SH-SY5Y cell line has a
neuroblast-like morphology (Figure 2.2) and the SK-N-SH cell line that it was
cloned has been shown to have various neurotransmitter activities:
dopaminergic, acetylcholinergic and adenosinergic (Biedler et al. 1978).
2.2.2. Cell Passage
SH-SY5Y cells were acquired from the European Collection of Cell Cultures
(Health Protection Agency, Salisbury, UK). Cells were seeded at a density of 1
x 104 cells/cm2 into 75cm2 tissue culture flasks and maintained in Dulbecco’s
modified Eagle’s medium/ Ham’s F-12 nutrient mixture (1:1; DMEM/F-12;
Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 2mM L-
Glutamine. Cells were grown at +37°C in 95% air and 5% CO2. The culture
medium was replaced the day after seeding. Cells were passaged at 80-90%
confluence, approximately every 5-6 days. Passaging was undertaken in sterile
conditions and involved washing once with 5mL Hank’s balanced salt solution
(HBSS) at +20°C. Cells were then lifted with 1mL/flask of 0.25% trypsin-EDTA
(Invitrogen) and incubated at +37°C for 3min. The cell surface of the flask was
then washed with 5 ml of HBSS and cells were collected by centrifugation at
500xg for 5min at +25˚C. The supernatant was removed and the cells were re-
suspended in DMEM/F-12+10% FBS. 100μL cell suspension was mixed 1:1
with 4g/L trypan blue and cells counted using a Neubauer improved
haemocytometer. Live cells (colourless and bright) were counted in the 4 corner
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squares (Figure 2.1) and an average was taken. The number of cells per ml
was then calculated (average number of cells in corner squares x dilution factor
x 104). To obtain reproducible results only cells of passage number 19 to 24
were used for experiments.
Figure 2.1 Haemocytometer
Used for counting cells as seen under a microscope
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2.2.3. Cell Storage and Recovery
Cells were stored in liquid nitrogen at a density of 1 x 106 cells/mL in 40% FBS,
10% dimethyl sulphoxide (DMSO) and 50% DMEM/F-12 as 1mL aliquots. Cells
were first frozen for 24hr in -80°C using an isopropanol freezing vessel and then
transferred to liquid nitrogen for long term storage. Cells were recovered from
liquid nitrogen and seeded at a density of 5 x 105 cells/cm2 in 75cm2 flasks.
2.2.4. Treatment of SH-SY5Y Cells
We set out to use a method previously described by González-Aragón et al in
2005. This study used 1mM Para-aminobenzoic acid (PABA) treatment over a 4
day time course on cultured HL-60 (Human promyelocytic leukemia cells) cells.
This method originally used in 1975 by Alam, Nambidiri and Rudney works
through competitively inhibiting the biosynthesis of CoQ10. More specifically
PABA competes with para-hydroxybenzoate for the active site of polyprenyl-4-
hydroxybenzoate transferase (Alam et al. 1975).
Cells were treated with various concentrations of PABA: 0mM (no PABA
treatment), 0.25mM, 0.5mM, 0.75mM and 1mM. Incubation of neuronal cells
with a PABA concentration greater than 1mM did not induce a further decrease
in cellular CoQ10 (see Section 3.4.1). Therefore 1mM PABA was selected as the
upper limit of treatment. The cells were grown in the presence of the listed
concentrations over a 5 day time course.
In Chapter 4 and Section 1.1.1 cells were subsequently treated with CoQ10
(Sigma) and methylene blue (MB; chapter 4; Sigma). Cells were treated with 2.5
and 5 µM CoQ10 for 5 days; as this is the approximate concentration reached in
the plasma of patients undergoing CoQ10 supplementation (López et al. 2010;
Miles 2007; Bhagavan & Chopra 2006).
Cells were also treated with MB in parallel with the CoQ10 supplementation.
Here we chose to use a concentration range of: 0.1, 0.5 and 1 µM for 5 days.
Cells treated with 2 µM MB and greater died after 24 hours.
As the CoQ10 formulation that we are using is suspended in ethanol and due to
the lipophilic nature of CoQ10 is can be challenging to get into aqueous solution
(this is discussed further in chapter 4). Thus, to ensure optimal absorption we
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incubated the media plus CoQ10 at +37°C for 15 minutes prior to addition of the
SH-SY-5Y cells.
2.2.5. SH-SY5Y Cell Harvesting for Biochemical Analysis
Cells were seeded at a density of 1 x 104 cells/cm2 into 175/75cm2 tissue
culture flasks or 6 wells plates for the ATP assay. Following a 5 day treatment
with various concentrations of PABA the cells were harvested for testing (see
Section 2.2.4). Cells were washed once with HBSS and lifted with trypsin-EDTA
at +37°C for 3 min. Trypsin was quenched by the addition of an equal volume of
DMEM/F-12. The cell surface of the flask was then washed with 5 ml of HBSS
and cells were collected by centrifugation at 500xg for 5min at +4˚C. The
supernatant was removed and the cells washed by resuspension in HBSS and
centrifugation at 500xg for 5min at +4˚C. The supernatant was removed and
cells were resuspended in HBSS. The cells were then aliquoted into seven
eppendorfs and stored at -80°C; one eppendorf to be used for the determination
of: ETC Complex I,II+III and IV, citrate synthase (CS), CoQ10, total GSH and
total protein. The samples for assessment of ATP in the 6 well plates were
assayed immediately.
2.2.6. SH-SY5Y Cell Harvesting for Microscopy
For live cell imaging microscopy analysis cells were required to be alive and
adherent to 22mm cover slips. The cover slips were sterilized with 100%
ethanol, left to dry for ~15 mins, then placed (one coverslip per well) into a 6
well plate. Cells were seeded at a density of 1 x 104 cells/cm2 and were treated
over a 5 day time-course (see Section 2.2.4).
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Figure 2.2 SH-SY5Y Neuroblastoma Cells stained with Bodipy 581/591, a
Lipid Peroxidation Marker
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Figure 2.3 A typical Bovine Serum Albumin (BSA) standard line
A 6 point concentration curve (0-1mg/ml). The BSA standard line is used to determine the
concentration of protein in a given solution. Absorbance values for a solution are read across to
the standard line to determine the concentration of protein (e.g. If absorbance= 0.1, then protein
concentrations=0.24mg/ml)
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2.3. Total Protein Determination
Total protein was determined by the Bio-Rad DC-protein assay (Bio-Rad
Laboratories Ltd, Hemel Hempstead, UK). This assay is a modified method
based on that of Lowry et al. (1951). The assay was performed as per
manufacturer’s instructions. Briefly all samples were diluted in HPLC grade
H2O. A 6-point standard line was prepared with BSA in distilled water from 0 to
1mg/mL. 5μL of each standard and sample were added to 3 wells of a 96 well
plate. 25μL reagent A (alkaline copper tartrate) and 200μL reagent B (Folin-
Ciocalteau phenol) was added to each sample. Samples were incubated for 15
min at +25˚C, in the dark. After incubation absorbance of samples was
measured at 750nm using a FLUOstar omega plate reader (BMG Labtech Ltd).
Total protein was determined from linear regression of sample absorbance units
against the BSA standard line (Figure 2.3).
2.4. Coenzyme Q10 Quantification
2.4.1. Equipment
PU-980 intelligent pump (Jasco); AS-950 intelligent autosampler (Jasco);
Techsphere ODS 5µ, 150 x 4.6mm column; TSPChromojet SP4400 series
integrator; PG-975-50 UV/VIS detector (Jasco).
2.4.2. Procedure
CoQ10 was measured using reversed-phase HPLC with Ultraviolet (UV)
detection using a modified method of that described by Boitier et al (1998). The
mobile phase was prepared by dissolving 7g of sodium perchlorate to Ethanol-
Methanol-60% (v/v) perchloric acid (700:300:1.2). The flow rate was 0.7mL/min
(see Figure 2.6 for HPLC schematic diagram).
To account for the loss of analyte during sample preparation an internal
standard (IS) was added before the CoQ10 was extracted from each sample.
Dipropoxy-CoQ10 was first proposed for use as an internal standard in 2005 by
Duncan et al. Previously naturally occurring ubiquinones have been used as
ISs, i.e. CoQ9, however, contamination with both dietary sources and
endogenous synthesis is possible. Dipropoxy-CoQ10 is advantageous because
it is a chemically synthesised compound with very similar characteristics to
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CoQ10. The IS (200 nM) was added to the cell sample prior to extraction.
Cellular membranes were disrupted by freeze thawing three times followed by
vigorous mixing using a vortex. Extraction of CoQ10 involves the addition of 5:2
(v/v) hexane/ethanol. Samples were centrifuged at 15,000 rpm for 3 min at
+25˚C and the top hexane layer was collected and stored on ice. The lower
aqueous layer is re-extracted a further two times. Samples were evaporated
using a rotary evaporator, resuspended in 300 µl ethanol and filtered (using a 4-
SF-02 (PV) filter) prior to injection.
A working standard (200nM CoQ10 and 200nM dipropoxy-CoQ10) was injected
for calibration (Figure 2.5). 50μL of each sample was injected and separated on
a C18 reversed phase Techsphere ODS 5µ, 150 x 4.6mm column (HPLC
Technology, Welwyn Garden City, UK), maintained at +25˚C. CoQ10 is detected
using an online UV detector (PG-975-50 UV/VIS detector) at a wavelength of
275nm (
Figure 2.4).
2.4.3. Data Analysis
CoQ10 was quantified using the following equation:
Conc CoQ10 (pmol/ml) =
(sample peak area /internal standard peak height) x internal standard conc. (μM)
Dilution factor:
Conc CoQ10 (pmol/ml) =
(Conc CoQ10 (pmol/ml) x resuspension volume) / volume of extracted sample
For intracellular determination of CoQ10 the concentration was divided by total
protein (mg/mL) and expressed as pmol/mg of protein (see Section 2.3).
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Figure 2.4 A Typical CoQ10 Chromatogram for a SH-SY5Y Cell Sample
Samples quantified using a UV detection method. CoQ10 elutes at ~9.5 minutes and I (Internal
standard [di-propoxyCoQ10]) elutes at ~13 minutes.
Figure 2.5 Concentration Curve for CoQ10 (HPLC-UV Detection Method)
The area (height x width) of the CoQ10 peak recorded on a using a HPLC with UV detection. 6
concentrations of CoQ10 (0-5uM) were used to determine the linearity of the method.
Time (min)
U
V
ab
so
rb
an
ce
at
27
5
nM
73
Figure 2.6 Schematic Diagram of a High Performance Liquid Chromatography (HPLC) System
The sample is delivered into the solvent via an injector and pumped around the HPLC system using a pump. The molecule of interest is then separated by the
column and the detector displays a visual read out called a chromatogram that can be interpreted to determine the separation of the molecule of interest.
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2.5. Reduced Glutathione (GSH) Quantification
2.5.1. Equipment
PU-1580 pump (Jasco); AS-2055 Plus autosampler (Jasco); Techsphere ODS
C18, 250 x 4.6mm column; Coulochem II electrochemical detector (ESA); 5010
analytical cell (ESA); Thermo Finnigan Chromjet integrator (Thermo Fisher
Scientific, Rockford, IL, USA); DG-980-50 inline degasser (Jasco).
2.5.2. Procedure
GSH was measured using reversed-phase high performance liquid
chromatography (HPLC) with coulometric electrochemical detection using the
method of Riederer et al (1989). The mobile phase consisted of 15mM
orthophosphoric acid in HPLC grade H2O. The flow rate was 0.5mL/min (see
Figure 2.6 for HPLC schematic diagram).
Samples were subjected to three cycles of freeze-thawing to disrupt cellular
membranes and subsequently diluted in 15mM orthophosphoric acid. They
were then centrifuged at 15,000rpm for 5 minutes +5oC, and the supernatant
was removed for analysis. 50μL of each sample was injected and separated on
a C18 reversed phase 250 x 4.6mm Techsphere ODS column (HPLC
Technology, Welwyn Garden City, UK), maintained at +25˚C. The screening
electrode (E1) was set to +50mV to oxidise analytes of low oxidation potential.
Optimum potential for the detector electrode (E2) was determined via a
voltamogram (Figure 2.7A). This involved monitoring the peak height of a 5μM
glutathione standard between a range of detector electrode potentials (+300mV
to +800mV). A maximum response was achieved with 750mV, and thus was
used for analysis. Samples were quantified against an external standard of 5μM
GSH diluted in 15mM orthophosphoric acid. A calibration curve confirmed
linearity between 0.1μM and 25μM (r2 = 0.995) (Figure 2.7B). Figure 2.8 shows
a typical GSH chromatogram.
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2.5.3. Data Analysis
GSH was identified using a Thermo Finnigan Chromjet integrator (Thermo
Fisher Scientific) and quantified using the following equation:
Conc. (μM) =
(sample peak height /external standard peak height) x external standard conc. (μM)
For intracellular determination of GSH the conc. (μM) was divided by total
protein (mg/mL) and expressed as nmol/mg of protein (see Section 2.3).
Figure 2.7 A Typical Reduced glutathione (GSH) Chromatogram for a SH-
SY5Y Cell Sample
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Figure 2.8 Reduced Glutathione (GSH) A) Voltamagram- utilised to find the
optimum electrochemical detector (EC) electrode voltage. A voltage on
the plateau of the voltamagram ensures detection of the entire compound
of interest, B) Calibration Curve- increasing concentrations of GSH
produce a proportional increase in chromatogram peak height,
demonstrating linearity of the EC detector method
A
B
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2.6. Enzyme Assays
2.6.1. Complex I Assay (NADH:ubiquinone reductase; EC 1.6.5.3)
This assay is based on that described by Reed & Ragan (1987). It measures
the oxidation of NADH by Complex I, as the decrease in absorbance at 340nm.
During this process electrons are transferred to exogenous ubiquinone (CoQ1)
forming ubiquinol. NADH oxidation also occurs in other cellular processes that
are mainly anabolic e.g. gluconeogenesis. Rotenone (a specific Complex I
inhibitor) is used to determine the level of Complex I independent NADH
oxidation. Rotenone acts on the matrix embedded long arm of the complex
arresting electron transfer from the Fe-S cluster to CoQ (Friedrich et al. 1994).
20μL of each sample was added to two analogous cuvettes containing at final
concentration 2.5mg/mL bovine serum albumin (BSA), 0.15mM β-NADH, 1mM
potassium cyanide (KCN) in a 20mM potassium phosphate buffer + 8mM
magnesium chloride (pH 7.2). The final volume in each cuvette was 1mL.
Samples were then gently mixed by double invertion and inserted into the
Uvikon 941 spectrophotometer (Northstar Scientific, Potton, UK). Duplicate
cuvettes were placed into either the reference or sample compartment. The
reaction was started by the addition of 10μL 5mM CoQ1 into the sample cuvette.
The reaction was monitored at an absorbance of 340nm at 30sec intervals for
5min at +30˚C. 20μL 1mM rotenone was added to each sample cuvette and
measurement was continued for 5min. Subtraction of the decrease before and
after rotenone addition will produce a specific value for Complex I NADH
oxidation. Absorbance was converted to molar concentration using the Beer-
Lambert law:
c = ΔA x l 
ε
Where ΔA is the specific change in absorbance; ε = extinction coefficient (6.81
x 103 M-1 cm-1); l = path length (1cm) and c = mole/min/ml.
Results are expressed as nmol/min/mg of protein (for protein determination
method see Section 2.3); then as a ratio of mitochondrial specific citrate
synthase activity (see Section 2.6.4), to control for mitochondrial
enrichment/depletion. Linearity of Complex I activity (R2=0.999) with total
protein was quantified to further validate the method Figure 2.9A.
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2.6.2. Complex II/III Assay (succinate cytochrome c reductase; EC 1.8.1.3)
Complex II/III was measured by a method described by (Bhuvaneswaran &
King 1967). Complex II (succinate dehydrogenase; EC 1.6.5.3) catalyses the
oxidation of succinate to fumarate and in the process reduces ubiquinone to
ubiquinol. Ubiquinol then acts as an electron donor facilitating the reduction of
cytochrome c by Complex III (Cytochrome bc1 complex; EC 1.10.2.2). This
assay measures the reduction of cytochrome c by measuring an absorbance
increase at 550nm. The Complex III inhibitor, antimycin A is used to discover
the level of cytochrome c oxidation which is not dependant on Complex II/III
activity. Antimycin A binds to the Qi site of cytochrome c reductase, thereby
inhibiting the oxidation of ubiquinol.
20μL of each sample was added to a two analogous cuvettes containing at final
concentration 0.3mM EDTA, 1mM KCN, 0.1mM cytochrome c in 100mM
potassium phosphate buffer (pH 7.4). The final volume in each cuvette was
1mL. Samples were then gently mixed by double invertion and inserted into the
Uvikon 941 spectrophotometer (Northstar Scientific, Potton, UK). Duplicate
cuvettes were placed into either the reference or sample compartment. The
reaction was started by the addition of 40µl of 0.5M succinate to the sample
cuvette. The reaction was measured at an absorbance of 550nm at 30sec
intervals for 5min at +30˚C. 10μL 1mM antimycin A was added to each sample
cuvette and measurement was continued for 5min. Subtraction of the increase
before and after antimycin A addition will produce a specific value for Complex
II/III cytochrome c reduction. Absorbance was converted to molar concentration
using the Beer-Lambert law as described earlier (see Section 2.6.1). The
extinction coefficient of cytochrome c is 19.2 x 103 M-1 cm-1 (path length 1 cm,
total volume 1mL). Results are expressed as nmol/min/mg of protein (see
Section 2.3) or as a ratio to citrate synthase activity (see Section 2.6.4).
Linearity of Complex II/III activity (R2=0.996) with total protein was quantified to
further validate the method Figure 2.9B.
2.6.3. Complex IV Assay (Cytochrome c oxidase; EC 1.9.3.1)
Complex IV was measured by the method of Tzagoloff & Wharton (1965). This
assay measures the oxidation of cytochrome c catalysed by Complex IV.
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0.8M oxidized cytochrome c is first reduced by the addition of a few crystals of
ascorbic acid. A PD10 desalting column equilibrated with 10mM potassium
phosphate buffer (pH 7.0) was used to remove ascorbate from the now reduced
cytochrome c. To quantify the concentration of reduced cytochrome c, 50μL
was added to 950μL H2O in a sample and a reference cuvette and the sample
cuvette was blanked against the reference at 550nm using a Uvikon 941
spectrophotometer (Northstar Scientific). Cytochrome c in the reference cuvette
was then oxidsed by the addition of 10μL100mM ferricyanide. The absorbance
was recorded after 1min and used to determine the concentration of reduced
cytochrome c using Beer-Lambert law (see Section 2.6.1). The extinction
coefficient for cytochrome c is 19.2 x 103 M-1 cm-1 (path length 1 cm, total
volume 1mL).
Reduced Cytochrome c to a final concentration of 50μM was then added to
sample and reference cuvettes containing 10mM potassium phosphate (pH 7.0)
to a final volume of 1mL. The sample cuvette was blanked against the reference
at 550nm using a Uvikon 941 spectrophotometer (Northstar Scientific).10μL
100mM ferricyanide was added to the reference cuvette. The reaction was
started by the addition of 20μL sample to the sample cuvette and the change in
absorbance at 550nm was recorded over 3min at +30˚C. The reaction of
Complex IV with cytochrome c follows first-order kinetics as it is dependent on
the concentration of cytochrome c. Activity is therefore expressed as a first
order rate constant (k). k is calculated by plotting the natural log of absorbance
against time and determining the slope. Results are expressed as k/min/mg of
protein (see Section 2.3) or as a ratio to citrate synthase activity (see Section
2.6.4). Linearity of Complex IV activity (R2=0.999) with total protein was
quantified to further validate the method Figure 2.9C.
2.6.4. Citrate Synthase Assay (CS; EC 4.1.3.7)
CS is an enzyme in the citric acid cycle which catalyses the condensation of
oxaloacetate and acetyl-coenzyme A to form citric acid and coenzyme A. It is
found within the mitochondrial matrix and is commonly used as a measure of
mitochondrial enrichment (Almeida et al. 1998; Hargreaves et al. 1999). The
assay used was described by Shepherd & Garland in 1969. The assay
measures the production of coenzyme A via a reaction with 5, 5’-dithio-bis (2-
nitrobenzoic acid) (DTNB).
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20μL of each sample was added to two analogous cuvettes containing at final
concentration 0.1mM acetyl-coenzyme A, 0.2mM DNTB in 100mM tris buffer
(pH 8.0) + 1g/L triton X-100. The final volume in each cuvette was 1mL.
Samples were then gently mixed by double invertion and inserted into the
Uvikon 941 spectrophotometer (Northstar Scientific, Potton, UK). Duplicate
cuvettes were placed into either the reference or sample compartment. The
reaction was started by the addition of 10μL 20mM oxaloacetate to the sample
cuvette. The reaction measured at 412nm for 5min at 30sec intervals for 5min
at +30˚C. Absorbance was converted to molar concentration was calculated
using Beer-Lambert law (see Section 2.6.1). The extinction coefficient of DTNB
is 13.6 x 103 M-1 cm-1 (path length 1 cm, total volume 1mL). Results are
expressed as nmol/min/mg of protein (see Section 2.3). Linearity of CS activity
(R2=0.999) with total protein was quantified to further validate the method
Figure 2.9D.
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Figure 2.9 Linearity of Mitochondrial Complex Activities versus SH-SY5Y protein- demonstrating an increase in the level of SH-
SY5Y protein produces a proportional increase in enzyme activity. A) Complex I: R2=0.999, B) Complex II/III: R2=0.996, C)
Complex IV: R2=0.999, D) Citrate Synthase: R2=0.999
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2.6.5. Complex V (EC 3.6.3.14) in Gel Assay
BN-PAGE can be used for one-step isolation of protein complexes from
biological membranes and total cell and tissue homogenates. It can also be
used to determine native protein masses and oligomeric states and to identify
physiological protein–protein interactions. BN-PAGE was developed for the
separation of mitochondrial membrane proteins and complexes in the mass
range of 10 kDa to 10 Mda (Witting et al. 2000).
Nonionic detergents are used for solubilisation of biological membranes. One of
the mildest detergents is digitonin Dodecylmaltoside may also be used and has
stronger delipidating properties compared to digitonin. The anionic dye
Coomassie blue G-250 is added to the supernatant. This dye binds to
membrane proteins because of its hydrophobic properties. The dye imposes a
charge shift on the proteins that causes even basic proteins to migrate to the
anode at pH 7.5. During BN-PAGE proteins are separated according to size in
acrylamide gradient gels.
Blue native gel electrophoresis was used to further examine the effect of CoQ10
deficiency on mitochondrial ETC protein levels, and on Complex V (ATP
synthase) activity. A mitochondrial fraction was initially obtained from the SHSY-
5Y cell pellet (7.5 x105 cells) using two low speed centrifugation steps (600g x
10min) at +4°C, separated by a homogenisation step (30 strokes). The
supernatant from each spin was combined and a higher spin (14,000g x 10 min)
was performed in order to eliminate nuclei and other subcellular membranes.
The mitochondrial membranes were then solubilised using a 750mM amino
hexanoic acid/50mM Bis Tris buffer + 4% n-dodecyl β-D maltoside detergent.
Samples were left on ice for 30 minutes and a further high spin (14,000g x 10
min) was used to pellet insoluble material.
Mitochondrial protein was quantified via a Bradford protein assay (Bradford
1976). An equal quantity of mitochondrial protein (30µg) was loaded for each
condition. The blue native gel was run using a 3-12% Bis-Tris gel (Invitrogen) to
ensure discrete separation of Complex V. Blue native gel electrophoresis was
performed according to an adaption of a previously reported method (Witting et
al 2006). The in-gel Complex V activity staining involved incubation at +25°C
overnight with the Complex V activity stain (34mM Tris, 270mM glycine, 14mM
magnesium chloride, 6mM Lead (II) nitrate and 8mM ATP). The stain measures
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Complex V activity in the reverse mode i.e. lysis of the ATP supplied. The
inorganic phosphate produced by this process results in the accumulation of
lead phosphate where the Complex V is present.
The complex protein levels and the Complex V activity bands were quantified by
scanning with a Biorad Chemidoc™ XRS 170-8070 system densitometer (Bio-
Rad Laboratories, UK). The Complex V activity reading was then divided by the
protein reading, as the protein readings obtained for each condition were
variable.
2.6.6. Adenosine Triphospate (ATP) Assay
ATP is a multifunctional coenzyme which is often referred to as the “molecular
unit of currency” in intracellular energy transfer. ATP is the end product of
respiration. In aerobic respiration the main source of ATP is from the ETC (8-
glycolysis, 30- electron transport chain; Rich, 2003). ATP can be used to assess
the functional integrity of living cells and to assess the functionality of the ETC.
The kit used, ViaLight® HS Kit (Lonza Rockland Inc, USA) is based upon the
bioluminescent measurement of ATP utilising the luciferase enzyme, which
catalyses the formation of light from ATP and luciferin according to the following
reaction (Holmsen et al. 1966):
Luciferase
ATP + Luciferin + O2 → Oxyluciferin + AMP + PPi + CO2 +LIGHT
Mg 2+
Initially all reagents are brought up to room temperature. The ATP monitoring
reagent (AMR) is then reconstituted in the tris buffer provided (10mL of tris/vial).
After 15 mins any surplus AMR not required for the current assay should be
stored at -20˚C (stable for 2 months). A 6 point ATP standard line was freshly
prepared for each experiment (diluted in distilled water) from 0-2µM (Figure
2.10). 300 μL of each sample is mixed with an equal volume of Nucleotide
Releasing Reagent (NRR) and left to stand for 5 mins at +20˚C. 180 μL per well
of each sample, in triplicate, should be transferred to the clear bottomed white
walled illuminescence plate. 20 μL of the previously prepared AMR is added.
The plate is read using a FLUOstar omega plate reader (BMG Labtech Ltd) with
a specilised illuminescence head. Absorbance was then converted to molar
concentration by linear regression of sample absorbance against the ATP
standard curve.
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Figure 2.10 ATP Concentration curve
A 6 point concentration curve (0-2pmol/ml). The ATP concentration curve is used to determine
the concentration of ATP in a given solution. Relative Luminesence units (RLU) values for a
solution are read across to the standard line to determine the concentration of ATP (e.g. If
RLU=1000, then protein concentrations=0.5pmol/ml)
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Figure 2.11 SH-SH5Y Cells Treated with 1mM Para-Aminobenzoic Acid
(PABA) incubated with 25µM tetramethylrhodamine methyl ester (TMRM)
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2.7. Confocal Microscopy
2.7.1. Preparation of Cells
SH-SY5Y cells were cultured in 6 well plates on 22 mm glass coverslips. Cells
were seeded at a density of 1 x 104 cells/cm2 and were treated over a 5 day
time-course (see Section 2.2.6).
2.7.2. Confocal microscopy method
A Zeiss 710 VIS confocal laser scanning microscope equipped with a META
detection system and a 63x oil immersion objective was used for all microscopy
experiments. Analysis was performed using Velocity software (Perkin Elmer,
Cambridge, UK). Analysis involved selecting 50-100 regions of interest using
the stamp tool function (e.g. TMRM: areas of red fluorescence, picogreen:
areas of green fluorescence that resembled mitochondria [not nuclear DNA]).
An average fluorescence (AU) of the regions of interest for each view was
taken. Results from each day of experimentation were expressed as a
percentage of the average control fluorescence (AU) to control for variation
between days. Averages were taken for views per day and subsequently taken
between days.
e.g.
Day 1
100%=average of control views fluorescence per day (AU)
Treatment 1 (1mM PABA):
Treatment view 1 (fluorescence of treatment view 1 (AU)/average control
fluorescence (AU) x 100), treatment view 2 (same as treatment view 1),
treatment view 3 (same as treatment view 1) etc.
An average was then taken for views per day.
Average of treatment 1, day 1 (n=1) = 120% of control fluorescence
Averages were subsequently taken between days.
2.7.3. Mitochondrial Membrane Potential
ΔΨm is a key indicator of mitochondrial function (Figure 2.11). The
characterization of ΔΨm in situ can also indicate mitochondrial bioenergetics
and cellular metabolism. ΔΨm can be monitored with monovalent cationic
fluorescent dyes such as tetramethylrhodamine methyl ester (TMRM). The
accumulation of TMRM in mitochondria is driven by their membrane potential.
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Due to the probes Nernstian nature (Figure 2.15a), mathematical analysis can
provide quantitative data for mitochondrial membrane potential (Ward et al.
2000; Abramov et al. 2010; Düssmann et al. 2003; Nicholls 2006).
The cells were initially loaded with 25nM TMRM for 20 min at +20°C. TMRM
and all other microscopy probes were reconstituted in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)-buffered salt solution composed of
(mM): 156 NaCl, 3 KCl, 2MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose and 10
HEPES, pH adjusted to 7.35 with NaOH. The dye was present at the same
concentration in all solutions throughout the experiment. Δψm was monitored in
single cells. TMRM was excited using the 565 nm laser line and fluorescence
measured above 580nm. A Zeiss 710 VIS confocal laser scanning microscope
equipped with a META detection system and a 63x oil immersion objective was
used for all microscopy experiments. Illumination intensity was kept to a
minimum to avoid phototoxicity and the pinhole set to give an optical slice of ~2
mm.All imaging data were collected and analysed using Volocity software
(Perkin Elmer, Cambridge, UK). Three Z-stack measurements per cover slip
were used to assess relative fluorescence intensity.
All conditions were compared to mean control intensity (100%) to control for
experimental differences. One time series measurement was taken per cover
slip. Data were acquired at intervals of 5–10 s. In these experiments TMRM is
used in the ‘redistribution mode’ (Abramov et al. 2010) to assess Δψm, and
therefore a reduction in mitochondrial localised TMRM fluorescence represents
mitochondrial depolarisation.
The rate of change before and after addition of oligomycin (2mg/ml; an
established Complex V inhibitor), was used to assess the functionality of
Complex V. Generally Δψm is maintained by the ETC (Complexes I-IV),
however when the functionality of the ETC is compromised Complex V may be
reversed to help maintain the Δψm. Depolarisation after addition of oligomycin (a
Complex V inhibitor) indicated a reversal of Complex V activity. Total
depolarisation was induced by the mitochondrial uncoupler FCCP (1µM;
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone). This method has been
used in previous studies to establish reversal of Complex V activity (Yao et al.
2012; Gandhi et al. 2009).
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2.7.4. Mitochondrial Superoxide
Mitosox™ Red is a mitochondrial superoxide indicator (Figure 2.15c). It is a
cationic derivative of dihydroethidum designed for selective detection of
superoxide in the mitochondria of live cells (Figure 2.12). This
triphenylphosphonium cation is driven across the mitochondrial membrane
depending on the membrane potential; oxidation by superoxide results in
hydroxylation at the 2-position (2-hydroxyethidium).
For measurements, cells were loaded with 1µM Mitosox for 20 min at +20˚C.
Slides were then washed once before being suspended in 1ml of HEPES buffer
for measurement. One timeseries measurement was taken per well. The rate of
probe oxidation was measured as increase in red fluorescence over a 5 min
time course. All readings were expressed as a percentage compared to mean
control rate of probe oxidation (100%) to control for experimental differences.
Fluorescence excitation was at 560 nm and emission detection was at ~590 nm.
2.7.5. Cytosolic Superoxide
Cytosolic dihydroethidium (DHE) exhibits blue fluorescence; however, once this
probe is oxidized to ethidium, it intercalates within DNA, staining the cell
nucleus a bright fluorescent red (Figure 2.13). It is widely used as an indicator
of cytosolic superoxide production (Abramov et al. 2010). Similar to MitoSOX™,
dihydroethidium is oxidized by superoxide to 2-hydroxyethidium (Figure 2.15b).
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Figure 2.12 SH-SY5Y Cells Incubated with 1µM Mitosox
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Figure 2.13 SH-SH5Y Cells Treated with 1mM Para-Aminobenzoic Acid
(PABA) incubated with 5 µM dihydroethidium (DHE)
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For measurements, cells were loaded with 5µM DHE for 10 min at +20˚C and
the dye was present at the same concentration in all solutions throughout the
experiment. Slides were then washed once before being suspended in 1ml of
HEPES buffer for measurement. One timeseries measurement was taken per
well. The rate of probe oxidation was measured as increase in red fluorescence
over a 5 min time course. All readings were expressed as a percentage
compared to mean control rate of probe oxidation (100%) to control for
experimental differences. Fluorescence excitation was at 560 nm and emission
detection was at ~590 nm.
2.7.6. Lipid Peroxidation
The BODIPY 581/591 C11 fatty acid is a sensitive fluorescent reporter for lipid
peroxidation (Figure 2.15e), undergoing a shift from red to green fluorescence
emission upon oxidation of the phenylbutadiene segment of the fluorophore
(Figure 2.2). This oxidation-dependent emission shift enables fluorescence ratio
imaging of lipid peroxidation in live cells.
For measurements, cells were loaded with 1µM DHE for 10 min at +25˚C.
Slides were then washed once before being suspended in 1ml of HEPES buffer
for measurement. One timeseries measurement was taken per well. The rate of
probe oxidation was measured as increase in the ratio of red to green over a 5
min time course. All readings were expressed as a percentage compared to
mean control ratio (100%) to control for experimental differences.
2.7.7. Mitochondrial DNA Quantification
Quant-iT™ Picogreen® (molecular probes, Invitrogen) is a fluorescent nucleic
acid stain used to quantify double stranded DNA (dsDNA). Picogreen® is an
asymmetrical cyanine dye (Figure 2.15d) that upon binding dsDNA emits
fluorescence at ~530nm. Here we use it estimate the degree of mitochondrial
DNA (mtDNA) depletion in the neuroblastoma cell model (Figure 2.14).
SH-SH5Y cells incubated with 3µg/ml of the Quant-iT™ Picogreen® stock
solution for 30 mins at +25˚C. Coverslips were washed once and resuspended
in 1ml of HEPES buffered salt solution. In this instance only mtDNA
fluorescence was analysed i.e. fluorescence external to the nucleus with
mitochondrial morphology; illustrated by the white arrows in Figure 2.14.
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Relative fluorescence intensity was used as a measure of mtDNA depletion;
compared to mean control intensity (100%). Fluorescence excitation was at
480nm and fluorescence emission was at 550nm.
2.8. Statistical Analysis
All results are expressed as mean ± standard error of the mean (SEM). One-
way ANOVA (analysis of variance) was used for comparison of groups >2, with
Bonferroni post-hoc analysis. In all cases p <0.05 was considered significant.
Expression of ratios (i.e. complex activities expressed as a ratio to citrate
synthase activity) required the data to be transformed using the following
equation: arcsin √enzyme activity/citrate synthase activity. This minimises the
negative skew of distribution produced when expressing proportions, thus
yielding a normal distribution prior to analysis (Gegg et al. 2004).
93
Figure 2.14 SH-SH5Y Cells Incubated with 3µg/ml of the Quant-iT™
Picogreen® Stock Solution
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Figure 2.15 Chemical Structures of Microscopy Dyes a) TMRM, b) DHE, c)
Mitosox, d) Picogreen, e) Bodipy 581/591
e)
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Chapter 3
Neuronal Cell Model of Coenzyme Q10
Deficiency
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3.1. Introduction
The first clinical case of CoQ10 deficiency was reported by Ogasahara in 1989 in
siblings with progressive muscle weakness, fatigability and central nervous
system dysfunction (Ogasahara et al. 1989). Primary CoQ10 deficiency is
usually inherited in an autosomal recessive manner, with recessive mutations
reported in 7 CoQ10 biosynthetic genes (6 biosynthetic enzymes) to date:
PDSS1 (Mollet et al. 2007) and PDSS2 (López et al. 2006), ADCK3 (Mollet et
al. 2008; Lagier-Tourenne et al. 2008), COQ9 (Duncan et al. 2009), COQ6
(Heeringa et al. 2011), COQ4 (Salviati et al. 2012) and COQ2 (Mollet et al.
2007; Figure 1.9). CoQ10 deficiency can be broadly divided into five major
phenotypes: 1) Recurrent rhabdomyolysis with encephalopathy; 2) infantile-
onset multisystem disease; 3) isolated cerebellar ataxia; 4) a pure myopathic
form; and 5) steroid resistant nephropathy ± sensorineural hearing loss. Leigh
syndrome can also be considered a separate phenotype (Rahman et al. 2012).
Neurological involvement is a common feature of CoQ10 deficiency. There have
been 3 reported cases of Leigh syndrome, a severe neurological disease as the
result of a CoQ10 deficiency caused by mutations in the PDSS2 gene (Van
Maldergem et al. 2002; CM Quinzii et al. 2006). Encephalopathy predominates
the multisystematic neonatal phenotype and sensorineural hearing loss is
variably present in the steroid resistant nephrotic syndrome (Rahman et al.
2012). The ataxic phenotype of CoQ10 deficiency is the most common clinical
presentation of the disorder with 94 known cases reported to date (Emmanuele
et al. 2012). The causative gene defect has been identified in 34 of these
patients. In 22 of these patients ataxia is caused by a mutation in the ADCK3
gene and in the remaining 12 patients ataxia is the result of a mutation in the
APTX gene.
One of the original publications of the ADCK3 gene mutation (Lagier-Tourenne
et al. 2008) suggested that patients with the ADCK3 gene defect can be
distinguished from other recessive ataxias by the presence of cerebellar atrophy
and childhood onset. However Horvath at al. discovered several patients with
an adult onset form of the disease with mild cerebellar ataxia (Horvath et al.
2012). The ADCK3 gene is a functional homolog of coq8 (yeast) and UbiB
(bacterial). ADCK3 encodes a putative kinase which appears to indirectly
modulate CoQ10 biosynthesis. Yeast studies have indicated that the ADCK3
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encoded protein stabilises the COQ3 enzyme that catalyses the O-methylation
steps in the terminal portion of CoQ biosynthesis (Tauche et al. 2008).
AOA1 is a recessive ataxia caused by a gene mutation in APTX. The APTX
gene encodes a ubiquitously expressed protein that is thought to play a role in
single stand DNA break repair (Moreira et al. 2001). The cause of CoQ10
deficiency in AOA1 as yet remains to be elucidated. Interestingly
hypercholesterolemia is a common clinical presentation of AOA1. Cholesterol
and CoQ10 share a common initial portion of their biosynthetic pathways;
suggesting a possible interaction of aprataxin with this pathway resulting in up
regulation of cholesterol biosynthesis and down-regulation of CoQ10
biosynthesis (Quinzii et al. 2005).
Patients with all phenotypes of CoQ10 deficiency have been reported to show
some form of clinical improvement following CoQ10 supplementation. While
muscle abnormalities improve clinically and biochemically, neurological
symptoms associated with CoQ10 deficiency appear to be particularly refractory
to treatment (Rahman et al. 2001; Auré et al. 2004). A recent literature review
stated that CoQ10 supplementation is only effective in 46% of patients with the
ataxic phenotype (Emmanuele et al. 2012). However when treatment was
instigated for the other clinical phenotypes of CoQ10 deficiency 79% of patients
were reported to show some clinical improvement upon CoQ10 supplementation
(Emmanuele et al. 2012). At present the reasons for this variation remain
unclear but possible explanations include: irreversible structural and/or
biochemical neuronal dysfunction; poor penetration of CoQ10 supplements
across the blood-brain barrier; and inability of neuronal cells with a CoQ10
deficiency to utilise exogenous CoQ10.
3.2. Aims
In order to investigate the pathogenesis of neuronal CoQ10 deficiency we have
established a pharmacologically induced SH-SY5Y neuroblastoma cellular
model of this disorder using PABA treatment. PABA has previously been
reported to competitively inhibit COQ2 activity (Alam, Nambudiri, et al. 1975;
Figure 1.7) inducing a CoQ10 deficiency in HL-60 cells (González-Aragón et al.
2005). This cellular model will allow the effects of CoQ10 deficiency on neuronal
ETC function and cellular oxidative stress to be evaluated.
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3.3. Methods
3.3.1. Cell Culture
SH-SY5Y cells were cultured as described in Section 2.2.4 and treated with
PABA and CoQ10 as described in Section 2.2.4 over a 5 day incubation period.
3.3.2. Quantification of CoQ10 Levels
CoQ10 content was analysed in SH-SY5Y cells by reverse phase HPLC as
described in Section 2.3
3.3.3. Mitochondrial Bioenergetics Analysis
Complexes I, II+III and IV of the ETC, CS and ATP were assayed in SH-SY5Y
cells as described in Section 2.6.
3.3.4. Blue Native in-Gel Complex V Assay
Complex V activity was determined in SH-SY5Y cell homogenates using blue
native gel electrophoresis as described in Section 2.6.5
3.3.5. Oxidative Stress Assessment
Reduced glutathione (GSH) content was also quantified in SH-SY5Y cells as
described in Section 2.5. Mitochondrial (Mitosox) and cytosolic (DHE)
superoxide production and lipid peroxidation (Bodipy 581/591) in SH-SY5Y cells
was determined by confocal microscopy as described in Section 2.7
3.3.6. Mitochondrial DNA Quantification
Quant-iT™ Picogreen® was used to quantify mitochondrial DNA (mtDNA)
content as described in Section 2.7.7.
3.3.7. Mitochondrial Membrane Potential
TMRM was used to determine Δψm in the SH-SY5Y cells as described in
Section 2.7.3.
3.3.8. Total Protein Determination
The protein content of the SH-SH5Y cells was determined by the Lowry method
as described in Section 2.3.
3.3.9. Statistical Analysis
Statistical analysis was performed as described in Section 2.8.
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3.4. Results
3.4.1. Optimisation of PABA Treatment
CoQ10 levels were significantly decreased (p <0.0001) compared to controls
(untreated cells) after 5 days of PABA treatment. The effect was progressive
and reproducible (0mM PABA =100%, 0.25mM=90%, 0.5mM=76%,
0.75mM=68% residual CoQ10 compared to control levels). Treatment of SH-
SY5Y cells with 1mM PABA induced a maximal 54% decrease (46% residual
CoQ10; Figure 3.1) in cellular CoQ10 status. Treatment of SH-SY5Y cells with
higher concentrations of PABA (2mM) did not induce a further decrease in
cellular CoQ10 status (53% decrease; 47% residual CoQ10); thus 1mM PABA
was selected as the maximum treatment condition.
Figure 3.1 Effect of Para-Aminobenzoic Acid (PABA) Treatment on CoQ10
Concentration
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using
one-way ANOVA with Bonferroni post hoc analysis; levels of significance: *:p<0.05, **:p<0.005,
***:p<0.0005; n=15.
In view of the reported half-life of rat brain ubiquinone status (CoQ9) of
approximately 90 hours (3.75 days; Turunen et al. 2004) an incubation period of
5 days was selected for the present study. Furthermore, the neuronal CoQ10
status following PABA treatment for 10 days was found to be comparable to that
of the 5 day treatment period (Figure 3.2) indicating that a longer period of
treatment would not be necessary.
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Figure 3.2 Effect of 5 day versus 10 day Treatment with 0 (control; no
treatment), 0.5 and 1mM PABA
Error bars represent standard error of the mean (SEM).
We also evaluated the effect of PABA treatment on cell growth. To do so we
used a trypan blue haemocytometer method to count the number of cells per
ml; as described in Section 2.2.2. There was no significant difference in cell
growth between conditions (Figure 3.3).
Figure 3.3 SH-SY5Y Cell Growth Curve
A cell count of control (no treatment) SH-SY5Y cells and SH-SY5Y cells treated with 0.5mM and
1mM PABA performed on a haemocytometer.
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3.4.2. Electron Transport Chain Activities
All ETC complex activities are expressed as a ratio of CS. CS is used as a
mitochondrial marker enzyme to allow differences in mitochondrial enrichment
between samples to be taken into account. CS activity was not affected by the
compromised CoQ10 status (Figure 3.4); however there is an insignificant trend
towards an increase in mitochondrial content at 76% residual CoQ10.
Figure 3.4 Effect of CoQ10 Deficiency on Citrate Synthase Activity
Error bars represent standard error of the mean (SEM); n=7
The effect of a decrease in neuronal CoQ10 status on ETC enzyme activity was
assessed in the PABA-treated SH-SY5Y cells. All ETC complexes displayed a
significant, progressive decrease in activity accompanying the diminution in
cellular CoQ10 status. The decrease in Complex IV activity was the most
pronounced following reduction of cellular CoQ10 levels, with a decrease of 69%
compared to control (Figure 3.5C). Complex I (Figure 3.5A) and Complex II/III
(Figure 3.5B) activities were decreased by 59%.
Figure 3.5 Effect of CoQ10 Deficiency on A) Complex I Activity (n=4), B) Complex II+III Activity (n=7), C) Complex IV Activity
(n=3), D) Total Cellular ATP Concentration (n=5)
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using one-way ANOVA with Bonferroni post hoc analysis; levels of
significance: *:p<0.05, **:p<0.005, ***:p<0.0005.
3.4.3. Cellular ATP Status
A decrease in cellular CoQ10 status resulted in a significant and progressive
decrease in the level of total cellular ATP (Figure 3.5D). A maximal 68%
decrease in total cellular ATP levels (compared to control) was observed at
46% residual CoQ10 levels. This decrease did not appear to affect cell growth,
since there was no difference in the growth curves between PABA treated and
control cells (Figure 3.3).
Figure 3.6 a) Blue native gel image of CoQ10 deficient neuroblastoma cells;
100%, 76% and 46% of control CoQ10 levels and b) Image of in-gel
Complex V assay; n=3.
3.4.4. Blue Native Complex V Assay
Blue native gel electrophoresis studies revealed that the protein level of
Complex V (holo-F1-F0) in CoQ10 deficient neuronal cells was comparable to
control levels (Figure 3.6A). Complex V activity was decreased by 14% of the
control level at 46% residual CoQ10 and the F1 band activity was decreased by
59% (Figure 3.6B).
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Figure 3.7 Effect of CoQ10 Deficiency on Oxidative Stress:
A) mitochondrial superoxide (n=4), B) cytosolic superoxide (n=3), C) lipid peroxidation (n=3), D) Glutathione (n=7)
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using one-way ANOVA with Bonferroni post hoc analysis; levels of
significance: *:p<0.05, **:p<0.005, ***:p<0.0005, ****:p<0.00005.
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3.4.5. Oxidative Stress Analysis
Mitochondrial and cytosolic superoxide levels were determined in order to
assess the distribution of oxidative stress. Results suggested a CoQ10-
dependent variable distribution of superoxide. At both 46% and 76% residual
CoQ10, the level of mitochondrial superoxide was significantly elevated
increasing by approximately 4 times that in control cells (Figure 3.7A). However,
mitochondrial superoxide production was marginally higher at 76% residual
CoQ10 compared to 46% residual CoQ10. There was no significant difference
between conditions for cytosolic superoxide (Figure 3.7B); however there was a
slightly lower level of cytosolic superoxide at 76% residual CoQ10.
Lipid peroxidation varied between the different treatment conditions (Figure
3.7C), although not significantly. At 46% residual CoQ10 levels there was a 15%
increase in lipid peroxidation. In contrast, a 10% decrease in lipid peroxidation
was detected at 76% residual CoQ10 levels. The status of cellular GSH was also
assessed. However following PABA induced CoQ10 deficiency no evidence of a
decrease in glutathione status was observed (Figure 3.7D). Interestingly,
glutathione levels appeared to increase although not significantly at 76%
residual CoQ10 levels, coinciding with the decrease in both cytosolic superoxide
and in lipid peroxidation.
Figure 3.8 Effect of CoQ10 Deficiency on Mitochondrial DNA (Picogreen)
Error bars represent standard error of the mean (SEM); n=3
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3.4.6. Mitochondrial DNA Quantification
In the CoQ10 deficient neuronal cell model a non-significant decrease in the
level of mtDNA was observed. This decrease was maximal at 46% residual
CoQ10 with a decrease in mtDNA levels of 26% compared to the control (Figure
3.8).
Figure 3.9 Effect of CoQ10 Deficiency on Mitochondrial Membrane
Potential
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using
student t-tests; levels of significance: *:p<0.05, n=7
3.4.7. Mitochondrial Membrane Potential
Complex V is the final enzyme in the oxidative phosphorylation pathway. The
preceding ETC complexes create a proton gradient across the inner
mitochondrial membrane. Complex V utilises the energy from this process to
convert ADP and Pi into ATP:
ADP + Pi + 4H+ ⇌ ATP + H2O + 4H+
This reaction is in equilibrium and can be shifted depending on the proton-
motive force. If the proton-motive force is decreased, for example if the ETC
complex activities are substantially reduced, then Complex V can run in reverse
mode (Gandhi et al. 2009). By running in the reverse mode Complex V is able
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to pump protons across the mitochondrial membrane, thus maintaining the
Δψm.
Assessment of Δψm revealed a 25% decrease at 76% residual CoQ10.
Conversely a significant 40% increase was observed at 46% residual CoQ10
(Figure 3.9).
Control cells (Figure 3.10A) and cells with 76% residual CoQ10 (Figure 3.10B)
demonstrated either no response or a slight hyperpolarisation in response to
Complex V inhibition by oligomycin (0.2 μg/ml). In these cells the Δψm is 
maintained by the activity of the ETC (100% = basal Δψm, 0 = FCCP Δψm at 
end). In contrast, oligomycin treatment caused a distinct and immediate
mitochondrial depolarisation in cells with 46% residual CoQ10 (Figure 3.10C)
indicating that at this level of CoQ10 deficiency  Δψm is largely maintained by 
the reversal of Complex V activity rather than by mitochondrial respiration.
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Figure 3.10 Representative Trace of a Time-Series Measurement of Mitochondrial Membrane Potential after the Addition of
Oligomycin and FCCP: A) Control (100% CoQ10), B) 76% of Control CoQ10 Level, C) 46% of Control CoQ10 Level;
Bars indicate the presence of oligomycin/FCCP; n=4
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3.4.8. Co-incubation of PABA and CoQ10
To ensure that the effect seen in the neuronal cell model is due to PABA
induced CoQ10 deficiency and not an indirect effect of PABA we co-incubated
cells with the maximal concentration of PABA (1mM) together with CoQ10 (5µM)
to determine whether CoQ 10 supplementation could reverse the CoQ10 defect .
This concentration of CoQ10 (5µM) was selected because it is the approximate
plasma concentration reached in patients undergoing oral CoQ10
supplementation (Miles 2007; Bhagavan & Chopra 2006; Shults et al. 2004) and
subsequently because this concentration effectively normalised the bioenergetic
status of CoQ10 deficient fibroblasts after a week time course (López et al.
2010).
Co-incubation of the SH-SY5Y cells with 1mM PABA together with 5µM CoQ10
effectively restores ETC enzyme activity. Co-incubation was most effective in
restoring Complex II/III activity (90% of no treatment/control level; Figure
3.10B). No significant loss of ETC activity was observed between the cells co-
incubated with PABA and CoQ10 and untreated cells (Figure 3.11A, B and C).
Mitochondrial oxidative stress was also evaluated (Figure 3.11D). Co-incubation
of PABA and CoQ10 gave a 4% lower Mitosox reading compared to no
treatment. Here both the co-incubation condition and the no treatment attained
the same level of significance (p<0.005) when compared to isolated PABA
treatment
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Figure 3.11 Effect of Co-incubation of PABA and 5 µM CoQ10 over a 5 day Time Course on: A) Complex I Activity (n=3), B)
Complex II+III Activity (n=3), C) Complex IV Activity (n=3), D) Mitochondrial Oxidative Stress (n=3)
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using one-way ANOVA with Bonferroni post hoc analysis; levels of
significance: *:p<0.05, **:p<0.005
A B
C D
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CoQ10 levels are means ± SEM. Δψm, mitochondrial membrane potential; -, no effect/control; ↑*↓*, significant increase/decrease; ↑↓ insignificant
increase/decrease.
Table 3.1 Summary of Results Obtained in Neuronal Cell Model of CoQ10 Deficiency induced by PABA Treatment: CoQ10 Defect,
Mitochondrial Bioenergetics Analysis, Oxidative Stress Assessment.
PABA
(mM)
CoQ10
(% of control)
RC
Activity
Mitochondrial
Superoxide
Cytosolic
Superoxide
Lipid
Peroxidation
GSH mt DNA Δψm
Oligomycin induced
depolarisation?
0 100 - - - - - - - -
0.5 76 ↓ ↑* ↓ ↓ ↑ ↓ ↓ -
1 46 ↓* ↑* ↑ ↑ - ↓ ↑* Yes
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3.5. Discussion
CoQ10 deficiency often results in neurological disease; however the lack of an
appropriate cellular model has so far prevented the elucidation of the underlying
pathogenic mechanisms. In this study we have established the first neuronal
cell model of CoQ10 deficiency.
Using PABA treatment in neuroblastoma-derived SHSY-5Y cells, we have been
able to induce a maximal 54% decrease (46% residual CoQ10) in the level of
cellular CoQ10, which has enabled an evaluation of the effect of a deficit in
CoQ10 status upon neuronal ETC function, oxidative stress, mtDNA and Δψm 
(Table 3.1). A decrease in neuronal CoQ10 status was found to result in a
progressive decrease in the activities of ETC Complexes I, II/III and IV, with a
concomitant decrease in the level of total cellular ATP. Mitochondrial oxidative
stress was found to be significantly increased following a deficit in neuronal
CoQ10; however no significant effect was found on cytosolic oxidative stress,
lipid peroxidation, GSH content or mtDNA. A variable effect was found on Δψm;
whereby an insignificant decrease in Δψm was found in the middle range CoQ10
deficiency and a significant increase maintained by a reversal of Complex V
(indicated by oligomycin induced depolarisation) was found with a more severe
deficiency of CoQ10.
Importantly we have also demonstrated that the observed aberrant
mitochondrial function observed in this neuronal cell model is a result of CoQ10
deficiency and not a result of PABA treatment. All complex activities were
restored to levels comparable to controls and a similar level of mitochondrial
oxidative stress to controls was observed (Figure 3.11).
The increase in mitochondrial oxidative stress may be a possible explanation for
the pattern of ETC dysfunction observed following a deficit in CoQ10 status.
Loss of ETC function may result from oxidative damage to the membrane
phospholipids, protein subunits and/or mtDNA (Kowaltowski 1999). In previous
studies it has been suggested that Complex IV is the most susceptible ETC
complex to oxidative stress-induced inactivation (Benzi et al. 1991; Heales,
Davies & Bates. 1995). This may explain why Complex IV showed the largest
decrease in activity compared to the other neuronal cell ETC complexes
following a diminution of CoQ10 status. Susceptibility of Complex IV to oxidative
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damage may in part arise from its dependence on cardiolipin for maximal
activity. Cardiolipin is a mitochondrial inner membrane polyunsaturated
phospholipid (Soussi et al. 1990), and due to its unusually high content of
unsaturated bonds cardiolipin is prone to lipid peroxidation (Soussi et al. 1990).
The non-significant decrease in the level of mtDNA detected in the neuronal
cells following a diminution in cellular CoQ10 status may contribute to the global
loss of ETC activity. MtDNA is particularly prone to oxidative damage due to the
lack of protective histones and limited repair mechanisms (Ullrich et al. 1999).
CoQ10 is a cofactor in the conversion of DHO to OA (Malmquist et al. 2008) and
so is essential for de novo pyrimidine synthesis. Defects in nucleotide
metabolism have been associated with mtDNA depletion (López-Martín et al.
2007). The decrease in the level of mtDNA observed in this study further
supports a link between CoQ10 deficiency and mtDNA depletion (Montero et al.
2007).
A neuronal cell CoQ10 deficiency was found to have a variable effect upon Δψm.  
The Δψm decreased in the middle range of CoQ10 deficiency (76% of control
level) but increased at the lowest residual CoQ10 level (46% of controls). The
increase in Δψm in the presence of a concomitant decrease in ETC Complex I,
II/III and IV activities indicates that a reversal of Complex V activity has
occurred to maintain Δψm (Gandhi et al. 2009; Yao et al. 2012). Reversal of
Complex V activity has been described in a limited number of mitochondrial
diseases (Abramov et al. 2010; McKenzie et al. 2007); however this is the first
study to report a reversal of Complex V activity in association with CoQ10
deficiency. When the ETC is fully functional, as is the case with the controls,
Δψm is maintained by Complexes I, III and IV pumping protons across the inner
mitochondrial membrane. A mild decrease in ETC function, as observed in the
neuronal cells with 76% residual CoQ10 level, induces a decrease in Δψm.
However, when ETC function is profoundly decreased, as in neurons with 46%
residual CoQ10 levels, Complex V activity appears to reverse. This is indicated
by the rapid decrease in Δψm on addition of the Complex V inhibitor oligomycin.
Here, the reversed activity of Complex V is maintaining the Δψm. By blocking
the translocation of protons across the inner mitochondrial membrane with
oligomycin Δψm can no longer be maintained and hence decreases. This
hypothesis is further supported by the significant decrease in cellular ATP
observed at 46% residual CoQ10 level. This phenomenon has not been reported
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in previous studies of CoQ10 deficient fibroblasts (Quinzii et al. 2008; Quinzii et
al. 2010), leading to the possibility that the reversal of Complex V activity may
be a unique characteristic of CoQ10 deficient neuronal cells.
Blue native gel electrophoresis assessment of Complex V revealed that a
decrease in neuronal CoQ10 status (76% and 46% residual CoQ10) did not result
in a concomitant reduction in the protein level of the complex. Furthermore, only
a minimal loss of Complex V activity (12% decrease compared to control) was
detected at 46% residual CoQ10. The detection of the F1 band on the blue native
gel is commonly observed with both muscle and cell samples. This results from
some dissociation of the holo-F0-F1 complex by anionic detergents used in the
blue native gel electrophoresis assay (Wittig et al. 2007). Once isolated from the
mitochondrial environment of neuronal cells with 46% residual CoQ10, evidence
of a reversal of Complex V activity may not be detectable under in vitro
conditions as observed in the blue native gel electrophoresis studies. This is
because the requirement to maintain Δψm will no longer be present.
The results of this study indicate that CoQ10 deficiency in neuronal cells may
have different biochemical consequences than those previously reported for
fibroblasts (Quinzii et al. 2010; Quinzii et al. 2008). One of the most profound
differences is the effect of CoQ10 deficiency upon ETC complex activities. In
general CoQ10 deficient patient fibroblasts only display a loss of Complex II/III
and I/III activity. Not the universal loss of ETC complex activities observed in
this neuronal cell model, even at cellular CoQ10 levels <20% of control levels.
The reason for this disparity is uncertain. However, since all the enzymes of the
ETC are susceptible to ROS induced oxidative damage (Zhang et al. 1990),
ETC dysfunction may result from an imbalance between mitochondrial oxidative
stress and antioxidant capacity. The higher degree of ETC dysfunction
observed in CoQ10 deficient neuronal cells may reflect a lower cellular
antioxidant status than observed in fibroblasts. However further studies are
needed to verify this.
In agreement with studies in fibroblasts, an increase in oxidative stress confined
to the mitochondrion was observed in the CoQ10 deficient neuronal cells. Quinzii
et al (2008) suggested a variable effect of CoQ10 deficiency on mitochondrial
oxidative stress; whereby severe (<20% of control CoQ10) and moderate (>60%
of control CoQ10) defects demonstrate low levels of oxidative stress. However
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an intermediate defect (30-40% of control CoQ10) in patient fibroblasts resulted
in an increase in the level of mitochondrial oxidative stress. However neuronal
cells display mitochondrial oxidative stress at slightly higher CoQ10 levels than
fibroblasts (76-46% of control levels). The reason for the disparity between the
two cell types is as yet unknown but may again reflect variations in cellular
antioxidant status.
The increase in mitochondrial oxidative stress following PABA-induced CoQ10
deficiency may result from inefficient transfer of electrons from ETC Complexes
I, II and III. This results in increased electron leak and enhanced production of
the unstable semiquinone isoform of CoQ10, a major site of ROS production
(Turrens et al. 1985). A decrease in CoQ10 status may also affect the
organisation and assembly of Complex III and its association with Complex IV
into respiratory supercomplexes, thus altering the composition and activity of
these complexes. These alterations may result in an enhancement of ROS
generation at these sites (Rodríguez-Hernández et al. 2009). Interestingly, the
degree of mitochondrial oxidative stress in the CoQ10 deficient neuronal cells
does not reflect the level of ETC deficiency. Complex I and III are the major
sites of ROS generation in the ETC (Sugioka et al. 1988; Turrens & Boveris
1980). However, although the degree of Complex I and II/III inhibition is more
pronounced at 46% residual CoQ10 level, mitochondrial oxidative stress is lower
than at 76% residual CoQ10. A possible reason for this discrepancy is the
existence of energy thresholds. This happens once ETC complex activities are
decreased beyond a certain threshold of inhibition. Then the rate of
mitochondrial respiration and consequently ETC electron flow decreases with a
concomitant fall in ATP synthesis (Davey et al. 1998). Therefore, the level of
ETC inhibition at 46% residual CoQ10 may be sufficient to reduce ETC electron
flow and consequently decrease mitochondrial ROS generation (Wallace 2000).
The decrease in ETC activity at 46% residual CoQ10 may also contribute to the
profound loss of cellular ATP occurring at this level of CoQ10 deficiency.
Here we have highlighted the vulnerability of neuronal mitochondrial metabolism
to a small deficit in CoQ10 status (76% residual CoQ10 levels). This small deficit
in CoQ10 status also resulted in a simultaneous loss of ETC function and
increased mitochondrial oxidative stress. This could explain the prominent
neurological dysfunction associated with CoQ10 deficiencies.
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Although no evidence of a decrease in cellular GSH status was observed in the
CoQ10 deficient neurons, a non-significant increase in the level of this tripeptide
was observed at 76% control CoQ10 status. This increase in GSH status
coincides with a decrease in lipid peroxidation and cytosolic superoxide at this
level of CoQ10 deficiency. In agreement with these results, Zhu et al (2007)
have also reported an up-regulation of GSH synthesis in response to an
increase in cellular oxidative stress. The cause of this increase in cellular GSH
status has yet to be elucidated but may result from an up-regulation in the
expression of the antioxidant binding transcription factor NRF2 (Zhu et al.
2005). Interestingly, a non-significant increase in the activity of glutathione
reductase has been reported in fibroblasts from a patient with the COQ2 gene
mutation which may explain the elevated and normal levels of GSH following a
deficit in neuronal cell CoQ10. However the activity of this enzyme has yet to be
assessed in this cell model (Quinzii et al. 2008).
3.6. Conclusion
In conclusion, the results of this study have shown evidence that both ETC
dysfunction and mitochondrial oxidative stress may be involved in the
pathogenesis of neuronal cell CoQ10 deficiency. Interestingly, a marginal
decrease in CoQ10 status (76% residual CoQ10) appears to be sufficient to
impair ETC function and increase mitochondrial oxidative stress, highlighting
the vulnerability of neurons to a small deficit in CoQ10 status. In contrast to
CoQ10 deficient fibroblasts, a CoQ10 deficiency (46% residual CoQ10) in
neuronal cells appears to result in reversal of Complex V activity. This
phenomenon has not been reported in previous studies of CoQ10 deficiency and
may be a unique characteristic of neuronal cells. This neuronal cell model
provides insights into the effects of CoQ10 deficiency on neuronal mitochondrial
function and oxidative stress, and will be an important tool to evaluate candidate
therapies for neurological conditions associated with CoQ10 deficiency as
discussed in the next chapter.
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Chapter 4
Investigation of Coenzyme Q10 and Methylene
Blue Treatment on the Neuronal Cell Model of
Coenzyme Q10 Deficiency
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4.1. Introduction
CoQ10 and its analogues have been used in the treatment of a number of
diseases and conditions. These include various neurodegenerative diseases
(FA, AD, PD, FA; Spindler et al. 2009), cardiovascular diseases (Greenberg &
Frishman 1990; Langsjoen & Langsjoen 1999); and more tentatively
dermatological (Inui et al. 2008) and fertility (Mancini et al. 2005) issues.
Clinical trials to assess the therapeutic potential of CoQ10 have been
undertaken for a number of neurodegenerative disorders with varied success.
Clinical improvement has been reported in the treatment of FA with CoQ10 in
conjunction with vitamin E; whereby 49% of patients demonstrated an
improvement in the ICARS score (Cooper et al. 2008). Interestingly despite the
initial success reported for CoQ10 in the treatment of PD (Shults et al. 2002) the
recent Phase III trial was terminated after it was deemed unlikely to yield
significant results (Beale et al. 2011).
CoQ10 is available in many different forms with variable bioavailablity, including
powder, suspension, oil solution, solubilised forms (All-Q and Q-Gel), as well as
creams, tablets, wafers, and hard-shell or softgel capsules. Most recently a self-
emulsifying drug delivery system (SEDDS) composed of oil and surfactant
(Onoue et al. 2012) and a lipid-based formulation that self-assembles on
contact with an aqueous phase into a colloid delivery system (VESIsorb,
colloidal-Q10) (Liu & Artmann 2009), have been developed in an effort to
increase bioavailability. Various formulations of ubiquinol are also available
(Hosoe et al. 2007).
In the context of this chapter we are interested in the treatment of primary
CoQ10 deficiency. A recent literature review assessed the efficacy of CoQ10
supplementation on the various phenotypes associated with primary CoQ10
deficiency (Emmanuele et al. 2012). 75% of patients with CoQ10 deficiency were
reported to show some form of clinical improvement following CoQ10
supplementation (excluding the ataxic phenotype). However, only 49% of
patients with the ataxic phenotype demonstrated improvement/stabilisation in
their ataxic symptoms following CoQ10 supplementation. The refractory nature
of neurological symptoms associated with CoQ10 deficiency to CoQ10
supplementation has also been reported for the encephalomyopathic phenotype
of this condition (Ogasahara et al. 1989; Sobreira et al. 1997; Giovanni et al.
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2001). The muscle symptoms associated with CoQ10 deficiency have been
reported to improve upon supplementation, however encephalopathy is only
resolved in 1 of 4 patients (Giovanni et al. 2001).
Furthermore although biochemical improvement was reported for the CoQ10
deficient patients with the COQ9 and PDSS2 mutation no improvement in their
neurological symptoms was observed. (Rahman et al. 2001; López et al. 2006)
At present the reasons for the refractory nature of the neurological symptoms
associated with CoQ10 deficiency to CoQ10 supplementation remain to be
elucidated. However they could include; poor transfer of CoQ10 across the
blood-brain barrier, irreversible structural and biochemical neuronal dysfunction
or an inability of CoQ10 deficient neurones to utilise exogenous CoQ10.
Methylene blue (MB) is a heterocyclic aromatic chemical compound with the
molecular formula C16H18N3SCl (Figure 4.1). MB is a potent cationic dye with
maximum absorption of light around 670 nm (Cenens & Schoonheydt 1988).
However in recent years the investigation of the therapeutic potential of MB has
been undertaken. MB has historically been used as an anti-malarial agent
(Mandi et al. 2005) and has been investigated experimentally for a number of
conditions including sepsis (Ramamoorthy et al. 2013), dermatological
conditions (Riddle et al. 2009; Salah et al. 2009), and various viruses (Floyd et
al. 2004). Interestingly MB has also been suggested as a potential treatment for
a number of neurodegenerative diseases such as AD and PD. The university of
Aberdeen and TauRx Therapeutics have been investigating the effects of MB,
or as it is known commercially Rember, or LMTX. They have suggested that MB
may inhibit Tau and - synlucin aggregation through increasing proteasome
activity. However, in vitro studies have indicated that MB may also have a
beneficial effect on mitochondrial function, which is likely to contribute to its
therapeutic potential (Oz et al. 2009). A placebo controlled phase IIB clinical
trial on patient with mild AD found that through taking a 60mg dose of MB per
day over a period of 50 weeks the progression of AD slowed down by 5.4
ADAS-Cog units (Galimberti & Scarpini 2011). A phase III trial of the drug in AD
is currently undergoing recruitment.
A study by Wen et al. (2011) found that MB directly improves ETC I/III activity
through the enhanced electron transfer from NADH to cyt c. They found that MB
can act as a direct substrate of NADH dehydrogenase in mitochondrial complex
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I and electrons gained in this reaction can then be delivered to cyt c. Allowing
MB to form an independant redox cycle between NADH and Cyt c that reroutes
electrons between Complex I and III.
MB may also delay senescence at nM levels; increase mitochondrial Complex
IV by 30%; enhance cellular oxygen consumption by 37-70%, increase heme
synthesis and induce phase-2 antioxidant enzymes in hepG2 cells (Atamna et
al. 2008).
CoQ10 deficiency is a mitochondrial disorder whereby ETC complex activities
and antioxidant status can be perturbed. MB is a unique compound that is not
only able to act as an antioxidant but is also able to shuttle electrons down the
ETC, bypassing the disrupted complexes allowing the Δѱm to be maintained (Lin
et al. 2012). Consequently MB may have a potential therapeutic benefit in the
treatment of CoQ10 deficiency.
Figure 4.1 The Chemical Structure of Methylene Blue (Methylthioninium
Chloride)
MB is a unique compound that is not only able to act as an antioxidant but is also able to shuttle
electrons down the ETC, bypassing the disrupted complexes allowing the Δѱm to be maintained
(Lin et al. 2012). The structure is stabilised by allowing the + charge to be distributed on the two
nitrogens attached to the ring system (to become partial "ammonium ions"). When reduced, it
forms leucomethylene blue which is colourless
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4.2. Aims
In order to investigate the effect of CoQ10 supplementation on mitochondrial
function in CoQ10 deficient neurones we administered varying amounts of
CoQ10 (2.5, 5 and 10µM) to the previously established SH-SY5Y neuronal cell
model of CoQ10 deficiency (see chapter 3). We also chose to investigate the
effect of Methylene Blue (MB), an electron carrier that is a possible candidate
therapy for mitochondrial disorders on mitochondrial function in CoQ10 deficient
neuronal cells. Varying amounts of MB were administered to the neuronal cell
model of CoQ10 deficiency (0.1 and 1µM). ETC Complex activities (I, II/III and
IV), mitochondrial oxidative stress and mitochondrial membrane potential were
evaluated in the CoQ10 supplementation experiments. ETC activities (I, II/III and
IV) were investigated in MB experiments.
4.3. Methods
4.3.1. Cell Culture
SH-SY5Y cells were cultured as described in Section 2.2.4 and treated with
PABA as described in Section 2.2.4 (1mM) over a 5 day incubation period.
Following the 5 day treatment of the SH-SY5Y cells with PABA the cells were
then treated with CoQ10 or MB (plus 1mM PABA) for a further 5 day period (see
Section 4.4.1 for details).
4.3.2. Quantification of CoQ10 Levels
CoQ10 content was analysed in SH-SY5Y cells by reverse phase HPLC as
described in Section 2.3
4.3.3. Mitochondrial Bioenergetics Analysis
Complexes I, II/III and IV of the ETC, CS and ATP were assayed in SH-SY5Y
cells as described in Section 2.6.
4.3.4. Oxidative Stress Assessment
Microscopy analysis of mitochondrial oxidative stress (Mitosox) was performed
on SH-SY5Y cells as described in Section 2.7.4.
4.3.5. Mitochondrial Membrane Potential
TMRM was used to determine Δψm in the SH-SY5Y cells as described in
Section 2.7.3.
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4.3.6. Total Protein Determination
The protein content of the SH-SH5Y cells was determined by the Lowry method
as described in Section 2.3.
4.3.7. Statistical Analysis
Statistical analysis was performed as described in Section 2.8.
4.4. Results
4.4.1. Treatment Optimisation
4.4.1.1. Coenzyme Q10
CoQ10 is a lipophilic molecule; thus solubilising this quinone in an aqueous
solution is challenging. The media used to culture the SH-SY5Y cells (DMEM/F-
12+10% FBS) is rich is lipids due to its high FBS content. Cells were passaged
as previously described in Section 2.2.2. The CoQ10 (ethanol) stock solution
was incubated in a water bath at +37°C for 10 minutes prior to use. A given
concentration of the CoQ10 stock solution was added to the media in a 15/50ml
falcon tube and incubated at +37°C for 20 minutes.
Figure 4.2 Concentration curve demonstrating the effect of CoQ10
supplementation on SH-SY5Y cell CoQ10 content; 0-50µM treatment.
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In human plasma the approximate concentration reached during CoQ10
supplementation is ~1-5µM (Miles 2007; Bhagavan & Chopra 2006; Shults et al.
2004). A concentration of 5 µM was also used in a fibroblast CoQ10
supplementation study that effectively normalised the bioenergetic status of
CoQ10 deficient fibroblasts following a treatment period of a week (López et al.
2010).
We subsequently constructed a dose response curve around this approximate
value (Figure 4.2). Control cells were treated with a given dose (2.5-200µM) of
CoQ10 for 5 days and then the CoQ10 status of the cells was assessed. A linear
relationship between CoQ10 supplementation and SH-SY5Y CoQ10 content was
established (0-50 µM CoQ10). Cells treated with 100 and 200 µM CoQ10 died
after 24 hours. Concentrations of 2.5, 5 and 10µM were selected for
investigation in this study.
Figure 4.3 Cell count using a haemocytometer of SH-SY5Y cells treated
with 0-5µM Methylene Blue (MB)
4.4.1.2. Methylene Blue
MB has been dubbed a “cerebral metabolic enhancer” (Lin et al. 2012). It is able
to shuttle electrons directly from Complex I to Complex IV thus bypassing the
other ETC complexes and the need for CoQ10 as an electron carrier; making it
an ideal candidate as an alternative to CoQ10 supplementation. In HT-22 cells
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(hippocampal cell line) 10 µM of MB was able to increase oxygen consumption
rate (OCR) through enhancing Complex I/III activity (Lin et al. 2012). Initial
attempts to use a concentration of 10 µM resulted in total cell death. Increased
cell death was also observed between 1-5 µM (Figure 4.3). Thus we selected a
concentration range between 0.1 and 1 µM for the present study.
4.4.2. Coenzyme Q10 Treated Cells
4.4.2.1. CoQ10 Content
1mM PABA treatment consistently resulted in a 54% decrease in cellular CoQ10
content (Figure 4.4A).
The CoQ10 intercellular content of the CoQ10 supplemented cells was assessed
in PABA treated SH-SY5Y cells. Significant increases in CoQ10 intercellular
content were noted in the PABA treated SH-SY5Y cells supplemented with 5
and 10µM CoQ10. A maximal increase in CoQ10 content of 79 times (10 µM
CoQ10 condition) was observed when compared to PABA treated SHSY-5Y
cells (Figure 4.4A)
4.4.2.2. Mitochondrial Electron Transport Chain Activities
All ETC complex activities are expressed as a ratio of CS activity a
mitochondrial marker enzyme (Hargreaves et al. 1999).
The effect of CoQ10 treatment on mitochondrial ETC complex activity was
assessed in PABA-treated SH-SY5Y cells. Following treatment with 5 µM
CoQ10 ETC Complex II/III activity was restored to 82% of control level (no PABA
treatment condition (Figure 4.4C). However, increasing the concentration to
10µM did not further restore Complex II/III activity. 5µM CoQ10 and 10µM CoQ10
treatments significantly (p<0.05) increased Complex III/III activity compared to
PABA treated cells (Figure 4.4C).
CoQ10 treatment resulted in a non-significant increase in Complex I activity
compared to PABA treated cells. Interestingly it was noted that Complex I
activity increased sequentially according to the dosage of CoQ10 administered
with Complex I activity being restored to 71% of control levels at 10µM CoQ10
(Figure 4.4B). A similar non-significant progressive increase was noted for
Complex IV activity following CoQ10 treatment. However, Complex IV activity
was restored to 78% of control level at 10µM CoQ10 (Figure 4.4D).
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Figure 4.4 Effect of 5 day treatment with Coenzyme Q10 (CoQ10) following PABA (1mM) induced CoQ10 deficiency in SH-SY5Y cells on a) CoQ10 (n=4), b)
Complex I (n=3), c) Complex II+III (n=3), d) Complex IV (n=3), e) mitochondrial superoxide (Mitosox; n=4), f) mitochondrial membrane potential (TMRM;
n=4)
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using one-way ANOVA with Bonferroni post hoc analysis; levels of
significance: *:p<0.05, **:p<0.005, ***:p<0.0005
A B
D E
C
F
126
4.4.2.3. Mitochondrial Oxidative Stress Analysis
Results suggest a significant decrease in the level of mitochondrial superoxide
in cells treated with CoQ10 and PABA compared to PABA only treated cells
(Figure 4.4E). There was no significant difference between treatments with 2.5
CoQ10, 5µM CoQ10 and controls.
4.4.2.4. Mitochondrial Membrane Potential
As stated in the previous chapter (Section 3.3.7) Δψm is differentially affected
by neuronal CoQ10 deficiency. At the highest PABA induced CoQ10 deficiency,
1mM PABA, the Δψm is increased in comparison to normal levels. The middle
range deficiency induced a decrease in Δψm (0.5mM PABA).
The results from the CoQ10 supplementation studies indicate that following
treatment with 5µM CoQ10 Δψm was restored to 90% of control (no PABA
treatment) levels (Figure 4.4F). Interestingly the Δψm observed in the 2.5µM
CoQ10 (+1mM PABA) treatment condition was similar to that observed in the
0.5mM PABA treated cells (Section 3.3.7; 35% decrease: 2.5µM CoQ10+1mM
PABA v. 25% decrease: 0.5mM PABA).
It is also interesting to note that the punctuate structure of the mitochondria
following PABA treatment (1mM) in the SH-SY5Y cells (Figure 4.5b). Increasing
supplementation with CoQ10 produces a less punctuate mitochondrial structure
and increases the fluorescence closer to control levels (Control: Figure 4.5a;
PABA+ 2.5µM CoQ10: Figure 4.5c, PABA + 5µM CoQ10: Figure 4.5d).
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b)
d)
a)
c)
Figure 4.5 SH-SH5Y cells incubated
with TMRM treated with a) no
treatment, b) PABA, c) PABA+ 2.5µM
CoQ10, d) PABA + 5µM CoQ10
Note the punctuate structure of the mitochondria
following PABA treatment (1mM) in the SH-
SY5Y cells (Figure 4.5b). Supplementation with
CoQ10 produces a less punctuate mitochondrial
structure and increases the fluorescence closer
to control levels (Control: Figure 4.5a; PABA+
2.5µM CoQ10: Figure 4.5c, PABA + 5µM CoQ10:
Figure 4.5d).
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4.4.3. Methylene Blue Treated Cells
4.4.3.1. CoQ10 Content
MB treatment did not appear to induce an increase in SH-SY5Y CoQ10 status.
In contrast, inclusion of MB with the PABA treatment induced a progressive
decrease in neuronal CoQ10 status compared to the PABA treated cells (Figure
4.6A). The addition of 0.5 and 1µM MB induced a significant decrease
(p<0.005) compared to the PABA treated and 0.1µM MB and PABA treatment
conditions (p<0.05).
4.4.3.2. Mitochondrial Electron Transport Chain Activities
The effect of MB treatment on mitochondrial ETC complex activity was
assessed in PABA-treated SH-SY5Y cells. MB was not able to restore any of
the ETC complex activities to control level (Figure 4.6). Complex II/III and IV
activities in the MB treated cells (+PABA) were comparable to that of cells
treated with PABA only (Figure 4.6 C and D; Complex II/III: ~54% decrease;
Complex IV: ~71% decrease [compared to no treatment condition]). MB
(+PABA) treated cells demonstrated a non-significant progressive increase in
Complex I activity compared to PABA treated cells (Figure 4.6B). However
there was still a significant difference in Complex I activity between the control
and MB treatment conditions (Figure 4.6D).
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Figure 4.6 Effect of 5 day treatment with Methylene Blue (MB) following PABA induced Coenzyme Q10 (CoQ10) deficiency in SH-SY5Y cells on a) CoQ10
(n=4), b) Complex I (n=3), c) Complex II+III (n=3), d) Complex IV (n=3)
Error bars represent standard error of the mean (SEM); statistical analysis was carried out using one-way ANOVA with Bonferroni post hoc analysis; levels of
significance: *:p<0.05, **:p<0.005, ***:p<0.0005
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Blank: not measured; -: no effect; ↑↓ insignificant increase/decrease; ↑*↓*, significant increase/decrease.
Table 4.1Summary of results obtained in neuronal cell model of CoQ10 deficiency induced by PABA treatment (1mM) treated
with 2.5 and 5µM CoQ10 and 0.5 and 1µM methylene blue (MB): CoQ10 content, mitochondrial ETC complex activities,
mitochondrial superoxide and Δψm.
Treatment Concentration
(µM)
CoQ10
content
Complex
I
Complex
II/III
Complex
IV
Mitochondrial
superoxide
Δψm
CoQ10 2.5 ↑ ↑ ↑ ↑ ↓*** ↓**
5 ↑* ↑ ↑* ↑ ↓*** ↓***
MB 0.5 ↓ - - -
1 ↓ ↑ - -
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4.5. Discussion
CoQ10 deficiency is a rare but often treatable disease. However the neurological
symptoms associated with the disease are frequently refractory to treatment, for
reasons as yet to be determined. In this chapter we have investigated the effect
of CoQ10 and MB treatment on mitochondrial function in CoQ10 deficient
neuronal cells.
Utilising our PABA induced neuronal cell model of CoQ10 deficiency we were
able to investigate the effect of CoQ10 supplementation on ETC complex
activities, mitochondrial superoxide and Δψm (Table 4.1). Following CoQ10
supplementation a significant increase in ETC Complex II/III activity was
observed (>5µM CoQ10) compared to the level of activity in the CoQ10 deficient
cells. In addition, a progressive increase in Complex I and IV activities was also
determined. However, CoQ10 treatment failed to restore ETC activity to control
levels. This suggests the possibility that insufficient CoQ10 was reaching the
inner mitochondrial membrane to restore ETC activity and therefore higher
doses of CoQ10 supplementation may be required to ameliorate the deficit in
ETC activity.
In addition, the significant decrease in mitochondrial oxidative stress (lower than
controls) following CoQ10 treatment (5µM) indicates that oxidative damage to
the ETC complexes may not be the primary mediator of this loss of ETC activity.
Therefore following supplementation insufficient CoQ10 may still be present in
the inner mitochondrial membrane to restore its electron carrier activity to
normal levels. Furthermore, the persistent generalised loss of ETC following
supplementation may be the result of an insufficient level of CoQ10 being
present in the cell to restore pyrimidine synthesis to controls levels (López-
Martín et al. 2007).
Following CoQ10 supplementation Δψm was restored to 90% of control levels
indicating that the reversal of ETC Complex V activity, which was determined in
the SH-SY5Y neuronal cells following 1mM PABA treatment (Chapter 3), had
been ameliorated, and Complex V activity was working in the forward direction.
Mitochondrial membrane potential has not previously been investigated at a
cellular level in relation to CoQ supplementation.
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The effect of MB treatment on ETC activity in CoQ10 deficient neuronal cells
was investigated in this chapter. MB has been dubbed as a metabolic enhancer
and thus would be a good candidate for restoring mitochondrial ETC activity in
mitochondrial diseases. MB treatment induced a non-significant increase in
Complex I activity, but was ineffective in restoring Complex II/III and Complex IV
activity to control levels. This result is in agreement with the study of Lin et al
(2012) which reported that Complex II/III activity was unaffected by MB
treatment, but Complex I/III activity was enhanced following MB treatment as a
possible consequence of increased electron donation from NADH to MB rat
brain mitochondria.
Another interesting finding relating the Δψm studies was the punctuate nature of
the mitochondria in the CoQ10 deficient neurones. Mitochondria are dynamic in
structure and are capable of adapting their structure according to the energy
demands of the cell; through fusion and division. The fused inter-mitochondrial
system can decompose into small roundish mitochondria (punctuate structure)
under some physiological conditions but also occurs in some pathology
(Skulachev 2001). It has been suggested that this is a protective mechanism
against oxidative stress (Skulachev 2001).
CoQ10 supplementation was effective in decreasing the level of mitochondrial
oxidative stress observed in the CoQ10 deficient neuronal cells. This is in
agreement with the result obtained in the fibroblast studies performed by Quinzii
and colleagues (López et al. 2010). Mitochondrial oxidative stress has been
implicated in contributing to the pathogenesis in a number of neurodegenerative
diseases including CoQ10 deficiency. Ubiquinol is a potent antioxidant; due to
CoQ10’s high concentration in the mitochondria we would expect a deficiency in
CoQ10 to increase mitochondrial oxidative stress which was observed in the
CoQ10 deficient neuronal cells. Intriguingly, CoQ10 supplementation was found
to reduce the level of mitochondrial oxidative stress below that of the control.
Although ROS has been frequently associated with cellular damage; ROS are
also important for cell signalling (Thannickal & Fanburg 2000). ROS generation
by plasma membrane oxidases have been implicated in normal physiological
signalling pathways involving growth factors and cytokines. Thus a decrease in
ROS below control levels may actually be detrimental to cellular function.
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Consequently decreased ROS signalling should be considered during CoQ10
supplementation.
CoQ10 supplementation was also partially effective at restoring mitochondrial
ETC activity. Complex II/III activity was significantly restored to 82.5% [10µM
CoQ10] of the no treatment condition. CoQ10 supplementation was less effective
at restoring Complex I and IV activity (Complex I: 71.1% restored [10µM
CoQ10]; Complex IV: 77.7% restored [10µM CoQ10]). In contrast Quinzii and
colleagues found a complete restoration of ETC activity in CoQ10 deficient
fibroblasts, demonstrated through ATP quantification (López et al. 2010). The
inability to restore ETC activity following CoQ10 treatment in the CoQ10 deficient
neuronal cells may be an indication of why neurological CoQ10 deficiency has
been reported to be refractory to treatment (Emmanuele et al. 2012). The ATP
quantification used in the fibroblast study is a measure of the physiological
output of the ETC. In the present study we have assessed the activity of the
ETC complexes. It is possible that the ETC complex enzymes are compromised
but are sufficient to perform oxidative phosphorylation at normal levels. Davey
et al. (1998) reported that a deficiency in neuronal ETC Complex I activity by
25% of normal level may be sufficient to perturb oxidation phosphorylation.
Therefore, a 29% decrease in ETC Complex I activity determined in the CoQ10
deficient neuronal cells following supplementation may indicate that oxidative
phosphorylation is still compromised in these cells. However, quantification of
cellular ATP levels would be required to confirm/refute this hypothesis.
MB is has demonstrated efficacy in treating a number of neurodegenerative
disorders; including PD and AD (Lin et al. 2012). However the efficacy of MB
has never been examined in CoQ10 deficiency. In this study we investigated the
effect of MB treatment on the ETC complex activities in CoQ10 deficient
neuronal cells. Following treatment with MB no significant increase in ETC
activity was observed compared to the CoQ10 deficient neuronal cells. This
suggests that MB was not effective at restoring the ETC deficiency associated
with the perturbation in neuronal cell CoQ10 status. However further studies
would be needed to investigate the effect on oxidative stress and physiological
ETC function. Interestingly MB decreased the level of CoQ10 (not significant);
implying that MB treatment of CoQ10 deficiency could further exacerbate the
deficit in CoQ10 status.
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Neurological CoQ10 deficiency is often refractory to treatment. Only 46% of
patients with the ataxic phenotype showed a clinical improvement/stabilisation
following CoQ10 supplementation; compared to 75% for other phenotypes
(Emmanuele et al. 2012). It has been suggested that this may be a result of
poor blood brain barrier penetration or irreversible structural brain alterations
(López et al. 2010). The work in this chapter has indicated that CoQ10
supplementation to CoQ10 deficient neuronal cells results in a decrease in
mitochondrial oxidative stress as well as an increase in Δψm, however it is
unable to fully restore ETC activity to normal levels. Longer incubation periods
and/or different formulations of CoQ10 may be required to improve ETC function.
Treatment regimens for CoQ10 are variable, between clinicians and for different
conditions. Current formulations of CoQ10 demonstrate a plasma CoQ10
concentration of 1-5µM (oral dose: 90-3000mg; Miles 2007). There are many
different formulations available and there is a great deal of variability in
bioavailability between formulations. Newer more sophisticated formulations
may be able to increase the plasma concentration in line with the 10µM target
highlighted in this study.
However to date no studies have investigated the effect of CoQ10
supplementation of CSF levels of CoQ10. The blood brain barrier may further
widen the gap between achieving a therapeutic dose suitable for treatment of
neuronal CoQ10 deficiency. A plasma CoQ10 concentration of 1-5µM may not
translate to a similar concentration in the CSF. Therefore, CSF studies will be
vital in developing treatment regimens for neurological CoQ10 deficiency.
4.6. Conclusion
In conclusion, the results in this chapter have indicated that CoQ10
supplementation has the ability to decrease mitochondrial oxidative stress and
increase Δψm in neuronal CoQ10 deficiency. However higher doses of CoQ10
may be required to fully restore ETC activities to control levels. Studies have
indicated that following CoQ10 supplementation a concentration of ~5µM is
reached in the plasma. Here we demonstrate that a concentration of 5µM is
capable for counteracting the reversal of Complex V activity and the increase in
mitochondrial oxidative stress observed in CoQ10 deficient neuronal cells.
However, the deficit in ETC activity could not be fully ameliorated by treatment
even at higher doses of CoQ10 supplementation (10µM). This study highlights
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the need for improved CoQ10 formulations to increase CoQ10 bioavailability in
the treatment of neuronal CoQ10 deficiency.
We can also conclude that further work is needed to assess if MB is suitable for
treatment of CoQ10 deficiency. Here we examine the effect on separate ETC
enzyme assays, however the effect of MB treatment on oxidative stress and
integrated ETC activity need to be investigated in relation to CoQ10 deficiency.
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Chapter 5
Tandem Mass Spectrometry Method for
Quantifying Coenzyme Q10 in CSF
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5.1. Background
Currently, the most common analytical techniques employed to determine
tissue levels of CoQ10 are high performance liquid chromatography (HPLC) with
either UV or EC detection. UV detection utilises the ability of the benzoquinone
core of CoQ10 to absorb UV light at 275 nm. This method has been widely used
and is highly reliable. However it is time consuming, takes more than 15
minutes to analyse each sample, and has a detection limit of 6nM making it
unsuitable for CSF CoQ10 assessment (Duncan et al. 2005). Similarly, HPLC
EC detection methods are also widely described, and have been previously
utilised for measurement of CoQ10 in CSF (Isobe et al. 2010; Isobe et al. 2009;
Murata et al. 2008). However, both UV and EC detection can potentially be
subject to interference, due to either electrical interference or mobile phase
contamination when measurements are made close to the detection limit. A
robust and sensitive tandem mass spectrometry (LC-MS/MS) method would
ensure a fast, selective and highly sensitive method of ubiquinone
quantification.
Various LC-MS/MS methods for measurement of CoQ10 have been described
(Ruiz-Jiménez et al. 2007; Takamiya et al. 1999; Li et al. 2008; Schaefer et al.
2004). However, CoQ10 forms Na+ and K+ adducts which can be difficult to
fragment, thus limiting sensitivity and utility of these methods. This has been
overcome by use of methylamine to produce a dominant ion ([M + CH3NH3]+)
which fragments easily and this significantly increases sensitivity (Teshima &
Kondo 2005).
A major problem with current mass spectrometric methods has been the
selection of a suitable internal standard (IS). IS’s currently used for CoQ10
analysis include ubiquinone analogues such as CoQ9, which will be influenced
by endogenous CoQ9 in human tissue, and chemically synthesised analogues
such as CoQ11, di-ethoxy-CoQ10 and di-propoxy-CoQ10. These are type 2 ISs,
structurally related to CoQ10 with similar chemical properties. Type 1 ISs are
preferred for MS. These compounds share the same chemical structure of the
analyte but differ in mass owing to the incorporation of stable isotopes. This
means the IS will fragment in an analogous way to the analyte to produce a
characteristic product ion. Although isotopically-labelled CoQ10 has previously
138
been synthesised (Hamamura, Yamagishi, et al. 2002; Hamamura, Yamatsu, et
al. 2002), the syntheses are difficult and none are commercially available.
5.2. Aims
The primary aim of this chapter is to develop a sensitive method capable of
quantifying CoQ10 in CSF; the low nanomolar range. The UV detection method
that is currently used to diagnose CoQ10 deficiency is not sensitive enough for
the analysis of CSF CoQ10 content. However a method utilising MS may prove
more sensitive. Hence we set out to establish a MS method suitable for the
analysis of CoQ10 in skeletal muscle homogenates, fibroblasts and CSF.
A secondary aim is to develop an IS suitable for a MS method, consequently we
synthesied a deuterated CoQ10 IS via an alcohol exchange method.
5.3. Synthesis of Deuterated CoQ10 (d6-CoQ10)
Here we describe a novel and simple method for the synthesis of d6-CoQ10
which is suitable for analysis of CoQ10 in skeletal muscle homogenates,
fibroblasts and CSF.
The two methoxy groups of CoQ10 can be exchanged with other alcohols in
alkaline solution. This has been exploited to synthesise other ISs such as
diethoxy-CoQ10 (Edlund 1988) or dipropoxy-CoQ10 (Duncan et al. 2005) for
HPLC. We used the same approach to replace the two CH3O- groups of CoQ10
with two CD3O- groups, yielding d6-CoQ10. Preliminary experiments attempting
exchange of CH3O- groups directly with a large excess of deuterated methanol
in alkaline solution yielded a mixture of d6-CoQ10 with a major contaminant of
unexchanged CoQ10 (results not shown). In view of this we opted for a two-step
synthesis, firstly synthesising and purifying diethoxy-CoQ10, exchanging the two
ethoxy groups with d3-methoxy groups and re-purifying to yield d6-CoQ10. The
d6-CoQ10 synthesised had undetectable levels of unlabelled CoQ10 and is
therefore suitable as an IS.
Initially a solution of di-ethoxy-CoQ10 was synthesised, as described by Edlund
(1988): 100mg CoQ10 was dissolved in 1ml hexane and diluted in 4ml dry
ethanol. 100µl sodium hydroxide in ethanol (40g/L) was added to the CoQ10
solution and was left for 30 mins. The reaction was then terminated by the
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addition of 100µl glacial acetic acid. 10ml of hexane was added and the solution
was centrifuged at 1000g for 5 mins at +25oC. The top organic phase was
removed and washed by adding 10ml H2O and centrifuging at 1000g for 5 mins
at +25oC. This procedure was repeated twice. The organic phase was then
dried down under nitrogen gas at 60oC and reconstituted in 1ml methanol.
Semi-preparative reverse phase HPLC was then used to purify the diethoxy-
CoQ10 from unexchanged CoQ10 and the partially exchanged monoethoxy-
CoQ10. A Hypersil 250 x 10mm HyperPrep HS C18 column (Thermo-Hypersil,
Runcorn, Cheshire, UK), plus a C18 guard column (Phenomenex, UK) were
used at a flow rate of 3.2 ml/min at +25oC. The mobile phase was isocratic and
was composed of methanol and ethanol (25:75, v/v), containing 50mM
ammonium acetate. The effluent was monitored at 275 nm and fractions were
collected using 5ml glass tubes.
D6-CoQ10 was then synthesised by utilising the backward version of this
reaction, converting di-ethoxy-CoQ10 to d6-CoQ10. 200µl of purified di-ethoxy-
CoQ10 was diluted in 800µl hexane. 4ml of d4-methanol (CD3OD) was then
added to the mixture. 100µl sodium hydroxide (40g/L) dissolved in d4-methanol
was added to the solution which was incubated for 5 hours at +25oC. The
reaction was stopped by the addition of 100µl deuterium chloride. 10ml of
hexane was added and the solution was centrifuged at 1000g for 5mins at
+25oC. The top organic phase was removed and washed by the addition of
10ml deuterium oxide and centrifuging at 1000g for 5 mins at +25oC. This was
repeated twice. The organic phase was then evaporated under nitrogen gas at
+60oC and reconstituted in 1ml methanol. The d6-CoQ10 was then purified by
semi-preparative HPLC as described above for di-ethoxy-CoQ10.
5.4. Tandem Mass Spectrometry Method Development
5.4.1. Preparation of Standard Solutions
2µM Stock solutions for CoQ10 and d6-CoQ10 were prepared in
ethanol/methanol 1:1 (v/v). Samples were quantified spectrophotometrically at
275 nm using the molar extinction coefficient of 14.6 x 103 M-1 cm-1 of CoQ10
(Crane & Barr 1967). The CoQ10 stock solution was serially diluted in 50:50 (v/v)
methanol:ethanol to construct a calibration curve. Samples were diluted to
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concentrations of 200, 100, 50, 20, 10, 5, 2, 1, 0.5, 0 nM. 20nM d6-CoQ10 was
then added to each sample.
5.4.2. Subjects
5.4.2.1. Skeletal Muscle and Fibroblasts
The `disease control` group consisted of patients assigned retrospectively after
no evidence of mitochondrial ETC deficiency was detected in their skeletal
muscle biopsies or fibroblast cultures (muscle: mean [SE] age, 24.5 [3.9] years;
range, 0.5–59 years; ratio of males to females, 7:6; fibroblasts: mean [SE] age,
11.33 [1.3] years; range, 0.03–55 years; ratio of males to females, 2:3)
5.4.2.2. CSF
The `disease control` group consisted of patients assigned retrospectively after
demonstrating no evidence of a monoamine metabolite disorder (mean [SE]
age, 6.15 [0.5] years; range, 0.1-22 years; ratio of males to females, 10:7).
Anonymised skeletal muscle homogenates and CSF samples were provided by
the Neurometabolic Unit, National Hospital. Anonymised fibroblast cultures
were provided by the Enzyme Laboratory, The Chemical Pathology Dept., Great
Ormond Street Children`s Hospital. These samples were redundant samples
retained by the lab for diagnostic test method development. Ethical consent
from the patients was obtained for this purpose.
5.4.3. Preparation of Patient Samples
Skeletal muscle samples were prepared according to the method of Duncan et
al (Duncan et al. 2005). Fibroblast samples were harvested in Hank’s balanced
salt solution ready for analysis. Protein content was analysed in skeletal muscle
and fibroblast samples according the method described by Lowry et al (Lowry et
al. 1951). Unfiltered CSF was used.
Due to its low level of protein it is often possible to analyse CSF by directly
injecting it into the mass spectrometer. However due to observed ion
suppression this was not possible. Ion suppression occurs when matrix
components compete with the analyte for charge in the electrospray process.
As a result the analyte of interest may not undergo complete ionisation and thus
is not detected in an accurate quantity. To overcome this phenomenon the
CoQ10 is extracted according to the method of Duncan et al (2005). This
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removes the majority of competing matrix components leaving just the analyte
of interest (plus other lipophilic components).
No. of Hexane/Methanol
Extractions (5:2, v/v, 700µl)
IS (nM)
Final volume
(µl)
Muscle 2 200 300
Fibroblasts 2 50 300
CSF 3 10 70
Table 5.1 Extraction Procedure and Internal Standard (IS) Concentration
IS was added to the muscle, fibroblast and CSF samples (Table 5.1). ~100µl of
each tissue, depending on the volume available, was extracted according to the
method previously described in Section 2.4.2. Due to the low CoQ10
concentration in CSF (Isobe et al. 2009), samples were extracted a third time to
increase recovery (Table 5.1). Samples were then evaporated to dryness using
a rotary concentrator and re-suspended in 50:50 methanol/ethanol (final volume
shown in Table 5.1).
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Figure 5.1 Schematic Diagram of the Electrospray Process
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Figure 5.2 Schematic Diagram of Instrumentation Used in the Tandem Mass Spectrometry Method for Quantifying CoQ10
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5.4.4. Electrospray Ionisation-MS/MS (ESI-MS/MS)
The electrospray process first developed by John Bennett Fenn in 1989 (Fenn
et al. 1989) is the interface between the HPLC and the MS; and importantly
underpins the transformation of the liquid analyte into a gas phase ion (Figure
5.1). Developing a method for LC-MS/MS means considering optimal conditions
for both chromatography and electrospray. ESI-MS/MS of CoQ10 and d6-CoQ10
was carried out using a Quattro micro triple quadrupole mass spectrometer with
a 2975 HPLC (Figure 5.2; Waters, Manchester, UK). To optimize analytical
conditions, initially standards were directly infused into the electrospray source
via a 25 m (i.d.) fused silica transfer line by means of a syringe pump at a flow
rate of 40 µl/ min. The instrument was operated in positive ionisation mode.
Since an extensive evaporation takes place in electrospray ionisation a volatile
mobile phase is vital. In this case we used a largely alcohol based mobile phase
(methanol/isopropanol) with an ammonium acetate additive. Formic acid was
also used to aid positive ion formation (conductivity). The analyte is introduced
into the MS from the HPLC system via a capillary. A voltage (3.38kV) is applied
between the capillary and cone (end of capillary) within the source of the MS.
Nitrogen is used as a nebulising gas to maintain a stable spray (flow rate of
950l/h [desolvation] and 50l/h [cone]). Heating aids solvent evaporation to
charged droplets depending on flow rate. The source temperature was held
constant at 150oC and the desolvation at 350oC. As solvent evaporation occurs
the droplets become progressively smaller until the surface tension can no
longer sustain the charge; the Rayleigh limit. Here, a process known as
Coombs fisson occurs (Kebarle & Verkerk 2009) resulting in gas phase ions
(Figure 5.1). The capillary voltage supplies excess charge to the analyte; as the
capillary voltage remains at a constant high voltage (3.38kV) it is the cone
voltage that is the important parameter in the electrospray process.
Thus the first parameter to be optimised was the cone voltage (V). A
hydrodynamic cone was first observed by William Gilbert in the late 16th century
(Gilbert, 1893; english translation). It wasn’t until 1964 that Sir Geoffrey Ingram
Taylor explained this phenomenon in relation to production of thunderstorms
(Taylor 1964). The theory stated that when a small volume of conductive liquid
is exposed to an electric field the surface tension of the liquid allows the
formation of a cone structure. Above a threshold voltage a jet is emitted from
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the apex of this cone structure allowing the beginning of the electrospray
process. This process is now utilised in MS as a means of converting liquid
samples into gaseous, highly charged molecules eligible for quantification.
A voltage of 30V was determined as the optimum voltage for CoQ10
electrospray (Figure 5.3a). At 60V the K+ and Na+ adducts predominated
(Figure 5.3b), suggesting that this voltage is too high for spray formation of the
methylamine adduct. Conversely at 5V the methylamine adduct was observed
but at substantially lower levels, ~15% of the output at 30V (Figure 5.3c).
The extractor voltage (V) is the accelerating voltage that focuses ions toward
the quadrapole. The optimal extractor voltage attained was 2V (Figure 5.4a). At
5V the methylamine adduct is ~65% of the output at 2V (Figure 5.4b); at 1V the
methylamine adduct is at ~85% (Figure 5.4c).
The highly charged ions now pass into the triple quadrupole mass analyser. The
first quadrupole mass analyser was developed by Prof James Douglas Morrison
in LaTrobe University, Australia (Morrison et al. 1979). A triple quadrupole mass
analyser consists of a linear series of three quadrupoles. The first (Q1) and third
(Q3) quadrupoles act as mass filters, and the middle (Q2) quadrupole is
employed as a collision cell. After parent ion selection in Q1 the collision cell
uses an inert gas, in this case argon, to fragment the parent ion into
characteristic daughter ion/s. The Q3 is then used to select the daughter ions. It
is the unique combination of parent and daughter ions that allow discrimination
between molecules.
Each quadrupole consists of 4 parallel cylindrical rods. Its purpose is to filter
sample ions according to their mass to charge ratio (m/z). Ions are separated
according to their trajectories under the oscillating electric current that is applied
to the rods. Each opposing rod pair is electrically connected. A radio frequency
(RF) voltage is applied to each rod pair. The RF lens voltage (V) can be
optimised to ensure accurate detection of a desired ion. In this case the optimal
RF lens voltage for the Q1 is 1.5V (Figure 5.5a). When a voltage of 3V was
applied, the methylamine adduct of CoQ10 was found but peaks were 80% of
1.5V peak intensity (Figure 5.5b). Predictably peak height at 0.1V was
substantially lower at 25% of optimal peak intensity (Figure 5.5c).
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The ion energy also plays an important role in determining the trajectory of the
ions. Here we selected a voltage of 1.5V as optimal (Figure 5.6a); a lesser
voltage of 0.5V gave a read out of 80% compared to 1.5V (Figure 5.6b).
The Q3 ion energy is optimal at 1.5V (Figure 5.7a); a higher voltage of 2V gave
a read out 70% of the 1.5V intensity (Figure 5.7b).
The collision voltage (V) is an important aspect of MS. The aim is to fragment
the parent ion into its characteristic daughter ion without causing further
fragmentation. The optimal voltage for the methylamine adduct of CoQ10 was
27V (Figure 5.8a). At 30V the intensity of the daughter peak (m/z 197) was
substantially less; ~35% compared to ~50% at 27V (Figure 5.8b). As the
collision voltage decreases the fragmentation of the parent ion decreases
leading to the appearance of the parent ion in the mass scan at 20V and a
considerable decrease in the daughter ion peak intensity (Figure 5.8c). At 10V
the daughter ion ceases and is replaced by the parent ion owing to a complete
lack of fragmentation.
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Figure 5.3 MS Scan for Optimisation of Cone Voltage (V)
a) 30V b) 60V, c) 5V (886m/z: Na+ CoQ10 adduct; 895m/z: Methylamine CoQ10 adduct; 902m/z: K+ CoQ10 adduct)
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Figure 5.4 MS Scan of Extractor Voltage (V)
a) 2V, b) 5V, c) 1V (886m/z: Na+ CoQ10 adduct; 895m/z: Methylamine CoQ10 adduct; 902m/z: K+ CoQ10 adduct)
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Figure 5.5 MS Scan of RF Lens Voltage (V)
a) 1.5V, b) 3V, c) 0.1V (885/6m/z: Na+ CoQ10 adduct; 894/5m/z: Methylamine CoQ10 adduct; 901m/z: K+ CoQ10 adduct)
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Figure 5.6 MS Scan of Ion Energy 1
a) 1.5V, b) 0.5V (885/6m/z: Na+ CoQ10 adduct; 894/5m/z: Methylamine CoQ10 adduct; 901m/z: K+ CoQ10 adduct)
a)
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Figure 5.7 MS Scan of Ion Energy 2
a) 1.5V, b) 2V (885/6m/z: Na+ CoQ10 adduct; 894/5m/z: Methylamine CoQ10 adduct; 901m/z: K+ CoQ10 adduct)
a)
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Figure 5.8 Daughter Scan of Collision Energy (V)
a) 27V, b) 30V, c) 20V, d) 10V (895m/z: Methylamine CoQ10 adduct parent ion; 197m/z: CoQ10 daughter
a)
b)
c)
d)
5.4.5. High Performance Liquid Chromatography (HPLC)
For quantitative analyses samples were separated using HPLC coupled to the
mass spectrometer (Figure 5.2). The mobile phases consisted of (A) methanol
(B) 4mM ammonium acetate 0.1% formic acid and (C)
methanol:isopropanol:formic acid (45:55:0.5, v/v/v) containing 5mM
methylamine as an ion pair reagent (Teshima & Kondo 2005). The column was
a 3M Hypersil Gold C4 (150mm x 3mm, 3µm) with a Gold C4 guard column
(3mm, 10mm length, 3µm) operated at 40ºC at a flow rate of 0.4ml/min. The
initial conditions were 50% A, 50% B for 2 minutes, followed by a switch to 50%
B, 50% C at 4 minutes and a gradient to 100% C for a further 8 minutes, after
which the column was re-equilibrated in the starting conditions for a further 5
minutes before the next injection.
50µl of sample was injected and CoQ10 and d6-CoQ10 eluted at approximately 8
minutes (Figure 5.9). MS/MS detection was performed by selection reaction
monitoring (SRM) from the methylammonium adduct molecule ([M + CH3NH3]+).
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Figure 5.9 Chromatography of a Control Fibroblast Sample
a) CoQ10 – daughter ion: 197 m/z, parent ion: 865 m/z, and b) Deuterated CoQ10 -daughter
ion: 203 m/z, parent ion: 901 m/z.
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5.5. Results
5.5.1. Deuterated Internal Standard
As described by Teshima and Kondo (2005), use of a methylamine adduct
yields a precursor ion of m/z 895 for CoQ10 (Figure 5.10a) and a product
benzoquinone ring ion of m/z 197 (Figure 5.10a). D6-CoQ10 gave similar ions
with the expected 6Da difference (precursor m/z 901; Figure 5.10b and product
m/z 203; Figure 5.10b), indicating that d6-CoQ10 is an appropriate IS for the
measurement of CoQ10. D6-CoQ10 was 99.5% isotopically pure, with only a
0.5% contamination with CoQ10, demonstrating the efficiency of the conversion
and suitability for use as an IS.
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Figure 5.10 a) CoQ10 and b) d6-CoQ10 Mass Spectra (895m/z: Methylamine
CoQ10 adduct parent ion; 197m/z: CoQ10 daughter ion; 901 m/z: Methylamine d6-CoQ10
adduct parent ion; 203 m/z: d6-CoQ10 daughter ion)
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5.5.2. Linearity, Precision, Recovery
Linearity is an important aspect of any analytical chemistry method and outlines
the correlational relationship between concentration and response (Harvey
2009). A concentration curve over the range 0-200 nM CoQ10 (with a d6-CoQ10
concentration of 20 nM) gave a linearity of R2 = 0.9995 (Figure 5.11a). At lower
concentrations (0-5 nM), linearity was less: R2 = 0.9886 (Figure 5.11b).
The limit of detection (LOD) is defined as the lowest concentration or amount of
an analyte that can be reliably identified as being qualitatively present in the
sample. The limit of quantification (LOQ) is defined as the lowest concentration
or amount of analyte that can be reproducibly quantified in a sample (Clinical
Chemistry 2012). Thus the LOD in this method is 0.5nM and the LOQ is 2 nM
(Figure 5.11b).
Figure 5.11 Concentration Curves for CoQ10 Standard
a) 0-200nM (R2=0.9995), b) 0-5nM (R2=0.9886)
a)
b)
The precision of an analytical method is a measure of variability. The closer the
agreement between individual analyses the more precise the method (Harvey
2009). The precision of the MS method was assessed by examining the inter
(between runs) and intra (within run) coefficient of variation (CV). CSF was
pooled from 64 disease controls. The inter assay CV was calculated by
comparing 10 pooled CSF repeats (1 run) over 5 separate days. The intra CV
was calculated by comparing 10 repeats in the same run; an average was then
calculated. The inter-assay CV was 3.6% when 10 nM CoQ10 was added to
pooled CSF and 4.3% with addition of 20 nM CoQ10 (Table 5.2). Intra-assay CV
was 3.4% (10 nM) and 3.6% (20 nM; Table 5.2).
Average Intra-assay
Coefficient of
Variation (CV; %)
Inter-assay
Coefficient of
Variation (CV; %)
Spike
recovery
Low Spike
(10nM)
3.43 3.55 0.995
High Spike
(20nM)
3.55 4.26 -
Table 5.2 Inter- and Intra-assay Coefficient of Variation (CV; %) and
spiking accuracy of CoQ10 Tandem MS/MS method on pooled control CSF
samples.
The accuracy of an analytical method is how closely the result of the experiment
agrees with the “true” or expected result. The MS method was tested by
measuring the concentration of a pooled CSF sample before and after addition
of 10 nM CoQ10. Pre-addition concentration was 4.09 nM +/- 0.03 (standard
deviation; SD), post-addition was 14.04 nM +/- 0.61 (SD), giving a recovery of
99.5%.
5.5.3. Muscle Analysis
The CoQ10 status determined in muscle homogenates by the tandem MS
method was compared with the results obtained from the analysis of the same
samples by the HPLC UV detection method. This method is currently used to
determine the CoQ10 status of clinical samples in the Neurometabolic unit,
National Hospital of Neurology and Neurosurgery and can therefore be
considered to be the gold standard method for CoQ10 quantification. This
method is described in Section 2.4.2 (Duncan et al. 2005). We compared 5
muscle biopsy samples previously analysed by the HPLC UV detection method
with the tandem MS/MS method described. Correlation analysis revealed a R2
value of 0.9914, indicating a strong positive correlation between methods.
We established a tentative reference range for skeletal muscle CoQ10 status of
187.3-430.1 pmol/mg (mean: 307.7pmol/mg; n = 15; Table 5.3; Figure 5.12A).
The reference range for skeletal muscle CoQ10 using the UV detection method
is 140-580 pmol/mg; thus the MS/MS method appears to have a tighter
reference range. However substantially less samples were analysed suggesting
this reference range will change upon analysing more samples.
Reference range Mean concentration
Muscle (pmol/mg; n=15) 187.3-430.1 307.7
Fibroblasts (pmol/mg;
n=50)
57.0-121.6 89.3
CSF (nM; n=17) 5.697-8.681 7.39
Table 5.3 Reference Intervals for Skeletal Muscle, Fibroblasts and CSF
5.5.4. Fibroblast and CSF Analysis
The tandem MS/MS method was also employed to establish a tentative
reference range for fibroblasts of 57.0-121.6 pmol/mg (Table 5.3; Figure 5.12B)
with a mean concentration of 89.3 pmol/mg.
This compares to a reported value in the literature of 67.2±11.6 pmol/mg protein
established from 5 control fibroblast lines, using HPLC with EC detection
(Quinzii et al. 2010). This disparity may be due to differences in tissue culture
media, fibroblast passage number and/or the protein assay used in
determination. We have confirmed the potential application of our method to
detect primary CoQ10 deficiency in fibroblasts by measurement of CoQ10 in
fibroblasts from a patient with established CoQ10 deficiency due to a mutation in
COQ9 (Rahman et al. 2001; Duncan et al. 2009). The CoQ10 level determined
for this patient was 13.17 pmol/mg; 12% of the mean control CoQ10
concentration for fibroblasts. This value is lower than that obtained by the UV
detection method (Duncan et al. 2009; 25.3 pmol/mg).
The LOD for the UV detection method is 6 nM (Duncan et al. 2005), making it
unsuitable for CSF analysis. The higher sensitivity seen with the tandem MS
method has enabled the detection of the low levels of CoQ10 in CSF, allowing
us to establish a tentative reference range of 5.70-8.68 nM (mean: 7.38 nM;
Table 5.3; Figure 5.12C). No age (R2=0.03; Spearman correlation: p=-0.17) or
gender (t-test: p=0.98) effects on CSF CoQ10 concentration were detected
Isobe et al. (2009, 2010) measured CoQ10 (as oxidised and reduced CoQ10) in
CSF (filtered with a 10,000 MW cut off) of adults using HPLC with EC detection,
a reference range was not reported. From the data reported in their papers the
total CoQ10 concentration of CSF appears to be approximately 2.8nM (oxidised
+reduced=total CoQ10). It is possible that the difference between their data and
our measured CSF CoQ10 concentration is due to their use of a 10,000 MW
cutoff filter. In a preliminary experiment we found that filtered CSF had
undetectable levels of CoQ10, suggesting that CSF CoQ10 may be associated
with lipoproteins or other CSF proteins, as in plasma (Eaton et al. 2000). In
addition, the possibility arises that the differences in the mean CSF CoQ10
status between the present study and that of Isobe et al may be due to the
differences in the mean age of the patients investigated. The average age of the
controls in Isobe et al’s study was 67 years whereas the subjects assessed in
present study had a mean age of 6.15 years. However it is yet to be established
whether age has an effect on CSF CoQ10 status and further work is required
before this can be confirmed or refuted.
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Figure 5.12 CoQ10 levels in a) skeletal muscle homogenate (n=15), b) fibroblasts (n=50), c) cerebrospinal fluid (CSF; n=17)
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5.6. Discussion
HPLC linked to UV or EC detection are methods currently employed for the
assessment of tissue CoQ10 status (Duncan et al. 2005; Isobe et al. 2010;
Isobe et al. 2009). Although useful in the quantification of CoQ10 in skeletal
muscle, mononuclear cells and plasma (Duncan et al. 2005), these methods are
insufficiently sensitive to accurately determine CoQ10 in CSF and therefore in
this study we utilised tandem MS/MS as a means to analyse CoQ10 status in
view of the high level of sensitivity reported for this method (Ruiz-Jiménez et al.
2007; Takamiya et al. 1999; Li et al. 2008; Schaefer et al. 2004). In this chapter
we have described the development of a highly sensitive method capable of
accurately quantifying CoQ10 to low nM levels (LOQ: 2nM).
During the development of this MS method we also attempted tandem
quantification of CoQ10 and CoQ9. Although it was possible to detect CoQ9 we
found that the sensitivity of the method was compromised with dual analysis,
possibly due to ion suppression. This loss of sensitivity meant that CoQ9
analysis was not viable during CSF quantification of CoQ10. However this MS
method could be employed to assess CoQ9 status in mouse/rat models and
also in other human tissue. It would be interesting to monitor CoQ10 and CoQ9
concentrations in CoQ10 deficient patient fibroblasts to investigate the effect of a
CoQ10 deficiency on CoQ9 status and whether this impacts upon the disease
phenotype. It is postulated that CoQ9 present in human tissue is mainly of
dietary origin; due to the high concentration found in plasma (Hargreaves &
Heales 2002). However the possibility arises that CoQ9 may have a functional
role in human tissue. In rat the predominant form of ubiquinone is CoQ9;
however in some tissues (brain, spleen, intestine) nearly a third of the total
ubiquinone is CoQ10; suggesting differential expression and potentially different
roles of the analogues (Aberg et al. 1992).
As part of this study we also attempted the analysis of the reduced form of
CoQ10, ubiquinol (CoQ10-H2). CoQ analogues are potent antioxidants and thus
an alteration in the ratio of oxidized to reduced CoQ10/9 maybe a potential
marker of oxidative stress (Isobe et al. 2010; Isobe et al. 2009). However due to
its propensity to oxidise it was not possible to determine ubiquinol using the MS
method employed in the present study. Other groups have successfully
analysed ubiquinol in mononuclear cells (Hahn et al. 2012) and serum (Ruiz-
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Jiménez et al. 2007). Therefore although it may be possible to measure
ubiquinol, the problems encountered maintaining it in its reduced state may
present difficulties as encountered in this work. This inability to assess ubiquinol
in the present work may be the result of; oxidation within the line, oxidation at
the source, or oxidation during extraction/waiting for analysis. This will require
further investigation to assess the viability of accurately measuring ubiquinol.
One of the most interesting applications of this method would be to investigate
the terminal portion of the CoQ10 biosynthetic pathway. The biosynthetic
pathway is best understood in several organisms; Escherichia coli,
Saccharomyces cerevisiae, and Schizosaccharomyces pombe (Meganathan
2001; Kawamukai 2002); however very little is known about the human
pathway. We currently know the function of two enzymes that are associated
with human primary CoQ10 deficiency; PDSS1/2 and COQ2. However there are
four other genes associated with the primary CoQ10 deficiency (ADCK3, COQ4,
COQ6, COQ9). We know that these genes are involved in the terminal portion
of the CoQ10 biosynthetic pathway but we have yet to elucidate their function. In
theory when CoQ10 biosynthesis is perturbed by the dysfunction of a particular
enzyme there may be an accumulation of the respective enzyme substrate.
There is evidence in yeast that the terminal enzymes involved in CoQ
biosynthesis are held together in a multi-subunit complex stabilised by COQ4
(Marbois et al. 2009). Thus dysfunction at any point in the pathway may result in
accumulation of the isoprenoid 3-hexaprenyl-4- hydroxy-benzoic acid (Marbois
et al. 1994). Therefore, it would be of interest to investigate whether this
phenomenon occurs in humans.
The ability to assess CoQ10 levels in CSF will be of potential clinical utility for the
diagnosis of patients with neurological CoQ10 deficiency, both primary and
secondary. A recent literature review revealed that only 60% of patients with the
cerebellar phenotype of CoQ10 deficiency have a decreased level in fibroblasts,
and decrease in muscle CoQ10 status may not always be significant
(Emmanuele et al. 2012). However with many of these cases a reliable
reference range for muscle and fibroblasts was not established. The ability to
assess CSF CoQ10 status will enable a direct evaluation of cerebral CoQ10
levels in patients with the cerebellar ataxic presentation of CoQ10 deficiency.
This may therefore improve the diagnostic yield of CoQ10 deficiency in this
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clinical phenotype since the possibility arises that the CoQ10 deficiency may not
be expressed or to a lesser degree in fibroblasts or skeletal muscle.
A similar story is observed with Complex II/III activity; only 53% of patients with
the cerebellar ataxic presentation of CoQ10 deficiency presented with a
decrease in Complex II/III activity in muscle (Emmanuele et al. 2012). A
personal communication with Dr. Iain Hargreaves suggested that this is a
common problem with diagnosis of CoQ10 deficiency. In the Neurometabolic unit
(NHNN) patients with a skeletal muscle CoQ10 level that is 30% of the lower
reference interval (~90 pmol/mg) may not present with a deficit in Complex II/III
activity. Therefore, a decrease in CoQ10 status may not always result in a loss
of Complex II/III activity. Furthermore, since it has been reported that
approximately 45% of cellular CoQ10 is of mitochondrial origin (Ericsson &
Dallner 1993) it is important to take into account the level of mitochondrial
enrichment of a tissue sample when determining CoQ10 status.
This MS method would also be useful for monitoring therapeutic CSF CoQ10
levels following supplementation in mitochondrial and other neurodegenerative
diseases. Currently CoQ10 supplementation is only effective in 46% of patients
with the ataxic phenotype (Emmanuele et al. 2012). However we have proved in
our model that CoQ10 supplementation is effective in recuperating CoQ10, the
ETC and also in reducing mitochondrial oxidative stress (see chapter 4). This
raises the question: Why is CoQ10 supplementation effective at a cellular level
but not in patients? (López et al. 2006; Rahman et al. 2001) A possibility is the
poor penetration of CoQ10 across the blood brain barrier. To investigate this
hypothesis CoQ10 levels could be monitored before and after treatment in the
plasma and the CSF. If the CSF concentration is unaltered it is possible that
CoQ10 is ineffective at crossing the blood-brain barrier. However time of lumbar
puncture would be vital in this experiment. Further investigation into the
pharmacokinetics of CoQ10 may need to be done before this experiment could
be undertaken. Furthermore, the MS method developed in this chapter may
also have utility in assessing the CSF levels of idebenone in the treatment of
Friedreich's ataxia (Meier et al. 2012)
5.7. Conclusion
Deuterated ISs are the “gold” standard of MS; we have devised a simple
synthesis of d6-CoQ10. Other deuterated ISs are available to purchase but this
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method offers a relatively inexpensive method using chemicals that are readily
available in most labs. This has enabled the establishment of a method suitable
for CoQ10 quantification by tandem MS/MS of muscle, fibroblasts and CSF. This
is advantageous over several published CoQ10 methods in which CoQ9, an
endogenous ubiquinone to human tissue, or non-endogenous chemically similar
compounds are used as ISs. D6-CoQ10 will fragment in the same way as CoQ10
and will prove to be a useful tool in CoQ10 analysis.
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Chapter 6
General Discussion
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CoQ10, the predominant form of ubiquinone in humans, serves as an electron
carrier in the ETC, a potent lipid soluble antioxidant and is involved in a number
of other cellular functions. Therefore, a deficit in CoQ10 status could be a
contributory factor to disease pathophysiology by causing a failure in oxidative
phosphorylation and a diminution of cellular antioxidant function. Deficiency in
CoQ10 status has been implicated in a number of diseases and conditions
(Rahman et al. 2012; Spindler et al. 2009). Since the first reported cases of
CoQ10 deficiency by Ogasahara and colleagues in 1989 of two sisters who
presented with recurrent rhabdomyolysis with associated seizures and mental
retardation a number of patients have been reported. Although the clinical
presentation of CoQ10 deficiency is extremely heterogeneous there does appear
to be five distinct clinical phenotypes (
Table 1.4). The most common clinical presentation of CoQ10 deficiency appears
to be the ataxic phenotype and to date, 100 patients have been reported
(Emmanuele et al. 2012). In addition, neurological dysfunction is also a
common feature of the other clinical phenotypes associated with CoQ10
deficiency (
Table 1.4). Patients with all clinical phenotypes of CoQ10 deficiency have been
reported to show some clinical improvement following supplementation
(Rahman et al. 2012). Whilst muscle abnormalities have been reported to
improve, neurological symptoms associated with CoQ10 deficiency appear
particularly refractory to CoQ10 supplementation (Emmanuele et al. 2012).
Furthermore, only 49% of patients with the ataxic phenotype of CoQ10
deficiency have been reported to respond to CoQ10 supplementation with
clinical improvement in contrast to 75% of patients with the other clinical
phenotypes of CoQ10 deficiency (Emmanuele et al. 2012).
At present, the reasons for the refractory nature of neurological dysfunction
associated with CoQ10 deficiency to treatment have yet to be elucidated. They
may result from irreversible structural and/or biochemical neuronal dysfunction
prior to diagnosis, poor penetration of CoQ10 across the blood brain barrier and
inability of CoQ10 deficient neurones to utilise supplemented exogenous CoQ10.
In view of the paucity of information about neuronal CoQ10 deficiency, the
primary objective of this research project was to investigate the effect of CoQ10
deficiency upon neuronal cell mitochondrial metabolism and cellular oxidative
166
stress. In addition, the effect of CoQ10 supplementation was investigated on
CoQ10 deficient neuronal cells to assess the ability of exogenous CoQ10 to
correct neuronal cell CoQ10 deficiency and ameliorate ETC dysfunction and
cellular oxidative stress.
In view of the refractory nature of neurological dysfunction associated with
CoQ10 deficiency to treatment, coupled with the absence of existing analytical
procedures to assess cerebral CoQ10 status, another aim of this project was to
establish a liquid chromatography tandem mass spectrometry (LC-MS/MS)
method to determine CSF CoQ10 status.
In order to assess the effect of a deficit in CoQ10 status on neuronal cell
mitochondrial metabolism and oxidative stress we established a neuronal cell
model of CoQ10 deficiency using pharmacological inhibition of CoQ10 synthesis.
Utilising the ability of PABA to competitively inhibit the CoQ10 biosynthetic
pathway enzyme, COQ2 we were able to induce up to a maximal 54% decrease
in SHSY-5Y neuroblastoma cell CoQ10 status compared to control levels (46%
residual CoQ10). By treating SHSY-5Y cells with different concentrations of
PABA (0.25 -1 mM) the neuronal cell CoQ10 status could be titrated to between
90% and 46% residual CoQ10, enabling an assessment of different levels of
neuronal CoQ10 deficiency on mitochondrial metabolism and oxidative stress.
Many studies have been undertaken in fibroblasts however there is a lack of
studies assessing the biochemical consequences of CoQ10 deficiency at a
neuronal level (Quinzii et al. 2012; Quinzii et al. 2013; Quinzii et al. 2010;
Quinzii et al. 2008). A study by Quinzii et al., 2013 reported a kidney specific
increase in oxidative stress and mitochondrial loss in Pdss2 kd/kd mice the
suggesting that the biochemical consequences of CoQ10 deficiency vary
between organs. Furthermore, it has been suggested that there may be tissue
specific isoenzymes in the CoQ10 biosynthetic pathway (Ogasahara et al. 1989).
Therefore, the effect on a CoQ10 deficiency on fibroblast mitochondrial function
and oxidative stress may not truly represent that of other cell types.
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Figure 6.1 Diagrammatic Representation of SH-SY5Y Cell Model of CoQ10
Deficiency
Figure 6.2 Diagrammatic Representation for the Results of CoQ10
Supplementation of the SH-SY5Y Cell Model of CoQ10 Deficiency
 Moderate ETC defect
 Decreased Δψm
 Increased mitochondrial
oxidative stress
PABA induced CoQ10 deficiency
46% residual
CoQ10
77% residual
CoQ10
 Severe ETC defect
 Increased Δψm
 Increased mitochondrial
oxidative stress
 Partially restored ETC defect
 Decreased Δψm
 Decreased mitochondrial
oxidative stress
Treatment of CoQ10 deficiency
46% residual CoQ10 +
exogenous CoQ10
supplementation
 Severe ETC defect
 Increased Δψm
 Increased mitochondrial
oxidative stress
46% residual CoQ10 +
NO CoQ10
supplementation
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A marginal decrease in neuronal cell CoQ10 status (76% residual CoQ10)
appears sufficient to impair ETC function and increase oxidative stress, as well
as decreasing Δψm to below normal levels (Figure 6.1). A more substantial
decrease in CoQ10 (46% residual CoQ10) resulted in further decreased ETC
activities, an increase in Δψm (suggesting a reversal in Complex V activity) and
an increase in oxidative stress (Figure 6.1).
The increase in Δψm observed in our CoQ10 deficient neuronal cell model is
unique to this CoQ10 deficient model. The increase in Δψm in the presence of a
concomitant decrease in ETC Complex I, II/III and IV activities indicates that a
reversal of Complex V activity has occurred to maintain Δψm (Gandhi et al.
2009; Yao et al. 2012). Reversal of Complex V activity has been described in a
limited number of mitochondrial diseases (Abramov et al. 2010; McKenzie et al.
2007); however this is the first study to report a reversal of Complex V activity
in association with CoQ10 deficiency.
Mitochondrial oxidative stress is a common finding in a number of mitochondrial
disorders including CoQ10 deficiency. Neuronal cells display mitochondrial
oxidative stress at slightly higher residual CoQ10 levels than fibroblasts
(neuronal cells: 76-46% of control CoQ10; fibroblasts: 30-40% of control CoQ10).
Furthermore the ETC defect seen in the neuronal cell model is more severe.
Inefficient transfer of electrons from ETC Complexes I, II and III, results in
increased electron leak and enhanced production of the unstable semiquinone
isoform of CoQ10, a major site of ROS production.
It is interesting to note that the increased level of mitochondrial oxidative stress
seen in our model is corrected after CoQ10 supplementation (Figure 6.2). This
suggests that CoQ10 may be a good candidate therapy for mitochondrial
disease, since secondary CoQ10 deficiency has been reported in MELAS and
mtDNA depletion syndromes. Intriguingly, CoQ10 supplementation was found to
reduce the level of mitochondrial oxidative stress below that of the control.
Although ROS has been frequently associated with cellular damage, ROS are
also important for cell signalling (Thannickal & Fanburg 2000). Thus a decrease
in ROS below control levels may actually be detrimental to cellular function.
Consequently decreased ROS signalling should be considered a potential
drawback during CoQ10 supplementation.
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However, CoQ10 supplementation was also partially effective at restoring
mitochondrial ETC activity (Figure 6.2). In contrast Quinzii and colleagues found
a complete restoration of ETC activity in CoQ10 deficient fibroblasts,
demonstrated by ATP quantification (López et al. 2010). The inability to
completely restore ETC activity following CoQ10 treatment in the CoQ10 deficient
neuronal cells may be an indication of why neurological CoQ10 deficiency has
been reported to be refractory to treatment (Emmanuele et al. 2012).
CoQ10 supplementation was also affective in restoring Δψm to 90% of control
levels (Figure 6.2), indicating that the reversal of ETC Complex V activity had
been ameliorated, and Complex V activity was working in the forward direction.
MB has demonstrated efficacy in treating a number of neurodegenerative
disorders including PD and AD (Lin et al. 2012). However MB was not effective
at restoring the ETC deficiency associated with the perturbation in neuronal cell
CoQ10 status. MB treatment induced a non-significant increase in Complex I
activity, but was ineffective in restoring Complex II/III and Complex IV activity to
control levels. Interestingly MB decreased the level of CoQ10 (not significant);
implying that MB treatment of CoQ10 deficiency could further exacerbate the
deficit in CoQ10 status.
CoQ10 supplementation in the treatment of neurodegenerative disease such as
PD has to date proved ineffective in large scale clinical trials (Beale et al. 2011).
In our study on supplementation we only see an adequate improvement of ETC
activity after supplementation of 10µM CoQ10. Previous studies have quoted
that serum/plasma levels of CoQ10 only reach ~1-5µM regardless of the dose of
CoQ10 prescribed (30-3000mg), highlighting issues of bioavailability in the
treatment of neurological CoQ10 deficiency. There are many different
formulations available and there is a great deal of variability in bioavailability
between formulations. Newer more sophisticated formulations may be able to
increase the plasma concentration in line with the 10µM target highlighted in
this study.
The development of the tandem MS method for quantification of CoQ10 in CSF
will allow us to monitor the CSF levels of CoQ10 following supplementation in
patients. Following the results of our cellular supplementation study a target
CSF level of 10µM could be aimed for successful CoQ10 therapy.
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One of the most interesting applications of this method would be to investigate
the terminal portion of the CoQ10 biosynthetic pathway. The biosynthetic
pathway is best understood in lower organisms (Escherichia coli,
Saccharomyces cerevisiae, and Schizosaccharomyces pombe) (Meganathan
2001; Kawamukai 2002). In contrast, very little is known about the human
CoQ10 biosynthetic pathway. We currently know the function of two enzymes
that are associated with human primary CoQ10 deficiency; COQ1 (PDSS1/2)
and COQ2. However there are four other genes associated with the primary
CoQ10 deficiency (ADCK3, COQ4, COQ6, COQ9). We know that these genes
are involved in the terminal portion of the CoQ10 biosynthetic pathway but we
have yet to elucidate their precise function.
The ability to assess CoQ10 levels in CSF will be of potential clinical utility for the
diagnosis of patients with neurological CoQ10 deficiency, both primary and
secondary. A recent literature review revealed that only 60% of patients with the
cerebellar phenotype of CoQ10 deficiency have a decreased level in fibroblasts,
and decrease in muscle CoQ10 status is not always significant (Emmanuele et
al. 2012). The ability to assess CSF CoQ10 status will enable a direct evaluation
of cerebral CoQ10 levels in patients with the cerebellar ataxic presentation of
CoQ10 deficiency. This may improve the diagnostic yield of CoQ10 deficiency in
this clinical phenotype since the possibility arises that the CoQ10 deficiency may
not be expressed or to a lesser degree in fibroblasts or skeletal muscle.
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6.1. Future Work
There are a number of further investigations that could be carried out to further
the work done in this thesis.
6.1.1. Neuronal Cell Model
The cell model that has been developed for this thesis is the first human cell
model of CoQ10 deficiency, however there is now the technology to develop a
more sophisticated neuronal cell model of CoQ10 deficiency. Induced
Pluripotency Stem (iPS) cell technology has allowed scientists to convert patient
fibroblasts into functional neurones that, in theory have the same characteristics
as those patients’ neurones. There are a number of patient fibroblasts available
for the various phenotypes and genotypes associated with CoQ10 deficiency. A
comparative study of a predominantly neurological phenotype (ADCK3 gene
mutation; Lagier-Tourenne et al. 2008; Horvath et al. 2012; Mollet et al. 2008)
and a phenotype that has no neurological presentation (COQ6 gene mutation;
Heeringa et al. 2011), would help us to understand more about the neurological
features of CoQ10 deficiency.
6.1.2. Treatments
We have established that CoQ10 supplementation is effective at preventing
mitochondrial superoxide production and restoring normal function of ETC
Complex V, but ETC Complex I, II/III and IV were still compromised. Although
the concentrations used are near to the level observed in plasma of treated
patients, it would be interesting to investigate higher concentrations of CoQ10 to
discover if ETC complex activities can be restored to normal levels.
To further strengthen this study oxygen electrode studies and ATP
quantification could be carried out to assess the physiological functionality of
the ETC. Additionally further investigation into the effect of CoQ10
supplementation on Complex V function would be of interest.
Regarding the MB treatment studies, we have established that MB treatment is
not capable of restoring ETC complex activities, but not if MB treatment could
prevent mitochondrial superoxide production and restore Δψm.
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6.1.3. MS Method
In relation to the treatment and MS method chapters, it would be of interest to
investigate the bioavailability of CoQ10 across the blood brain barrier. Previous
studies have investigated plasma CoQ10 concentration after a 28 day treatment
period with varying dosages (300 and 900mg; 2.27 and 6.62µg/ml above
baseline). A comparative study of plasma versus CSF concentration could be
done for different formulations of CoQ10 to determine which formulation crosses
the blood brain barrier most effectively. Together with the results obtained in the
treatment chapter, this will be extremely important in explaining why
neurological CoQ10 deficiency may be refractory to treatment.
Another important application of the MS method will be to complete a screen of
patients with ataxia of unknown cause. Following the discovery of several
patients with adult onset ataxia caused by CoQ10 deficiency secondary to a
mutation in the ADCK3 gene (Horvath et al. 2012), there is a consensus in the
scientific community that CoQ10 deficiency may be under diagnosed. Although a
screen for the ADCK3 gene mutation would potentially unearth new cases of
CoQ10 deficiency, screening CSF for a CoQ10 deficiency would initially
determine a deficiency, prompting a genetic screen in these patients. This
would potentially allow the discovery of a new gene mutations associated with
CoQ10 deficiency.
One of the most interesting adaptations of this method would be to look for
intermediates in the CoQ10 biosynthetic pathway. Yeast studies have
demonstrated the accumulation of a single product when any of the CoQ
biosynthetic enzymes are mutated (coq1-9) (Tauche et al. 2008). It would be
interesting to see if this phenomenon occurs in human CoQ deficiency.
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